CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of United States Provisional Application No.

62/245,956, filed on October 23, 2015, which is incorporated herein by reference in its entirety.

BACKGROUND

[0002] The present disclosure relates to novel compounds which exhibit inhibition of fibroblast growth factor receptor tyrosine kinases (FGFRs), in particular FGFR1, FGFR2, FGFR3 and/or FGFR4, pharmaceutical compositions comprising the compounds, to processes for making the compounds, and the use of the compounds in therapy. More particularly, it relates to 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds useful in the treatment or prevention of diseases which can be treated with an FGFR inhibitor, including diseases mediated by FGFR tyrosine kinases.

[0003] Fibroblast growth factors (FGFs) and their receptors (FGFRs) regulate a wide range of physiologic cellular processes, such as embryonic development, differentiation, proliferation, survival, migration, and angiogenesis.

[0004] The FGF family comprises 18 secreted ligands (FGFs) which are readily sequestered to the extracellular matrix by heparin sulfate proteoglycans (FIPSGs). For signal propagation, FGFs are released from the extracellular matrix by proteases or specific FGF -binding proteins, with the liberated FGFs subsequently binding to a cell surface FGF-receptor (FGFR) in a ternary complex consisting of FGF, FGFR and FIPSG (Beenken, A., Nat. Rev. Drug Discov. 2009; 8:235-253).

[0005] There are five FGFRs, of which four (FGFRs 1-4) are highly conserved single-pass transmembrane tyrosine kinase receptors (Eswarakumar, V.P., Cytokine Growth Factor Rev., 2005; 16: 139-149). The binding of an FGF to an FGFR leads to receptor dimerization and transphosphorylation of tyrosine kinase domains (Dieci, M.V., et al., Cancer Discov. 2013; 3 :264- 279; Korc, N., and Friesel, R.E., Curr. Cancer Drug Targets 2009; 5:639-651). Activation of downstream signaling occurs via the intracellular receptor substrate FGFR substrate 2 (FRS2) and phospholipase Cy (PLC-γ), leading to subsequent upregulation of RAS/mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT signaling pathways. Other pathways can be activated, including STAT-dependent signaling (Turner, N., Grose, R., Nat. Ref. Cancer 2010; 10: 116-129; Brooks, N.S., et al., Clin Cancer Res. 2012; 18: 1855-1862; Dienstmann, R., et al., Ann. Oncol. 2014; 25:552-563).

[0006] FGFR signaling components are frequently altered in human cancer, and several preclinical models have provided compelling evidence for the oncogenic potential of aberrant FGFR signaling in carcinogenesis, thereby validating FGFR signaling as an attractive target for cancer treatment.

[0007] The mechanisms by which FGFR signaling is dysregulated and drive cancer are better understood in recent years, and include activating mutations, FGFR gene amplification, chromosomal translocations, autocrine and paracrine signaling, and altered FGFR splicing.

SUMMARY OF THE INVENTION

[0008] It has now been found that 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)- one compounds are inhibitors of FGFRl, FGFR2, FGFR3 and/or FGFR4, which are useful in the treatment or prevention of diseases which can be treated with an inhibitor of FGFRl, FGFR2, FGFR3 and/or FGFR4, including diseases mediated by FGFRl, FGFR2, FGFR3 and/or FGFR4.

[0009] Accordingly, provided herein is a com ound of the general Formula I:

or pharmaceutically acceptable salt or solvate thereof, wherein X, Ring A, z, R ¹ , R ² and R ³ are as defined herein.

[0010] Also provided herein is a pharmaceutical composition comprising a compound of

Formula I or a pharmaceutically acceptable salt or solvate thereof, in admixture with a pharmaceutically acceptable diluent or carrier.

[0011] Also provided herein is a method of inhibiting cell proliferation, in vitro or in vivo, the method comprising contacting a cell with an effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof as defined herein. [0012] Also provided herein is a method of treating an FGFR-associated disease or disorder in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof as defined herein.

[0013] Also provided herein is a method of treating cancer and/or inhibiting metastasis associated with a particular cancer in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein.

[0014] Also provided herein is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof as defined herein for use in therapy.

[0015] Also provided herein is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein for use in the treatment of cancer and/or inhibiting metastasis associated with a particular cancer.

[0016] Also provided herein is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof for use in the inhibition of FGFR1, FGFR2, FGFR3 and/or FGFR4.

[0017] Also provided herein is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof as defined herein, for use in the treatment of an FGFR-associated disease or disorder.

[0018] Also provided herein is the use of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of cancer and/or inhibiting metastasis associated with a particular cancer.

[0019] Also provided herein is a use of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, as defined herein in the manufacture of a medicament for the inhibition of activity of FGFR1, FGFR2 FGFR3 and/or FGFR4.

[0020] Also provided herein is the use of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, as defined herein, in the manufacture of a medicament for the treatment of an FGFR-associated disease or disorder.

[0021] Also provided herein is a method for treating cancer in a patient in need thereof, the method comprising (a) determining if the cancer is associated with a dysregulation of an FGFR gene, a fibroblast growth factor receptor, or expression or activity or level of any of the same (e.g., an FGFR-associated cancer); and (b) if the cancer is determined to be associated with a dysregulation of an FGFR gene, a fibroblast growth factor receptor, or expression or activity or level of any of the same (e.g., an FGFR-associated cancer), administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition thereof.

[0022] Also provided herein is a method for reversing or preventing acquired resistance to an anticancer drug, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, to a patient at risk for developing or having acquired resistance to an anticancer drug. In some embodiments, the patient is administered a dose of the anticancer drug (e.g., at substantially the same time as a dose of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof is administered to the patient).

[0023] Also provided herein is a method of delaying and/or preventing development of cancer resistant to an anticancer drug in an individual, comprising concomitantly administering to the individual (a) an effective amount of a compound of Formula I and (b) an effective amount of the anticancer drug.

[0024] Also provided herein is a method of treating an individual with cancer who has increased likelihood of developing resistance to an anticancer drug, comprising concomitantly administering to the individual (a) an effective amount of a compound of Formula I and (b) an effective amount of the anticancer drug.

[0025] Also provided herein is a method for treating a disease involving angiogenesis and/or neovascularization, comprising administering to a subject in need thereof, a therapeutically effective amount of a compound of Formula I.

[0026] Also provided herein is a method for inhibiting angiogenesis in a tumor, which comprises contacting the tumor with a compound of Formula I.

[0027] Also provided herein is a pharmaceutical combination for treating cancer in a patient in need thereof, which comprises (a) a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, (b) an additional therapeutic agent, and (c) optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use for the treatment of cancer, wherein the amounts of the compound of Formula I or pharmaceutically acceptable salt or solvate thereof and of the additional therapeutic agent are together effective in treating the cancer. Also provided herein is a pharmaceutical composition comprising such a combination. Also provided herein is the use of such a combination for the preparation of a medicament for the treatment of cancer. Also provided herein is a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of cancer a patient in need thereof.

[0028] Also provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof.

[0029] Also provided herein is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof obtained by a process of preparing the compound as defined herein.

[0030] In some embodiments, a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof exhibits potent and selective FGFR inhibition. In some embodiments, said inhibition occurs with relative sparing of FGFRl inhibition. In certain embodiments, a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof exhibits a relatively high potency for FGFR2 and FGFR3 (e.g., FGFR3, e.g., FGFR3-TACC3 fusion). In certain embodiments, a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof provides dose-dependent inhibition of tumor growth in RTl 12/84 FGFR3-TACC3 xenografts. In certain embodiments, a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof exhibits (independently) greater selectivity for FGFR2 and/or FGFR3 (e.g., FGFR3) as compared to FGFRl (e.g., exhibits greater selectivity for FGFR3 over FGFRl in enzyme and cell- based assays e.g., exhibit greater cytotoxicity for FGFR2/3 than FGFRl mutant cells). See Lewin, et al, Journal of Clinical Oncolgy, 2015, 22, 3372.

[0031] In some embodiments, administration of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof results in less hyperphosphatemia than administration of a pan-FGFR inhibitor (e.g., a pan-FGFR inhibitor, which when compared with the Formula I compounds described herein, exhibits less selectivity for FGFR2 and/or FGFR3 (e.g., FGFR3) as compared to FGFRl ; e.g., a pan-FGFR inhibitor that is less sparing of FGFRl inhibition than the Formula I compounds described herein). In view of the foregoing and while not wishing to be bound by theory, it is believed that a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof can provide greater dosing/regimen flexibility and/or efficacy than, for example, a pan-FGFR inhibitor (e.g., a pan-FGFR inhibitor, which when compared with the Formula I compounds described herein, exhibits less selectivity for FGFR2 and/or FGFR3 (e.g., FGFR3) as compared to FGFR1 ; e.g., a pan-FGFR inhibitor that is less sparing of FGFR1 inhibition than the Formula I compounds described herein). By way of example, and as the skilled person will appreciate, the compounds described herein can be administered at higher doses and/or with increased frequencies, thereby providing higher drug exposure/target coverage, and done so with reduced risk of causing unwanted (e.g., abnormal) increases in blood phosphate levels, which in some instances can necessitate administration of phosphate binders and/or temporary (e.g., drug holidays) or permanent cessation of therapy to allow phosphate levels to return to normal.

[0032] Accordingly, also provided are methods of treating a FGFR-associated cancer in a patient, which include: (a) administering to a patient identified or diagnosed as having an FGFR- associated cancer one or more doses of a first FGFR inhibitor over a treatment period; (b) determining the level of phosphate in a biological sample comprising blood, serum, or plasma obtained from the patient after the treatment period; (c) selecting a patient having an elevated level of phosphate in the biological sample as compared to a reference level of phosphate; and (d) ceasing administration of the first FGFR inhibitor and initiating administration of a therapeutically effective amount of a compound as described herein or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing the same, to the selected patient. In certain embodiments, the treatment period is at least 7 days. In other embodiments, the treatment period is at least 21 days. In certain embodiments, the first FGFR inhibitor is JNJ-42756493 or BGJ398. By way of example, the first FGFR inhibitor can be JNJ-42756493 and a daily dose of 6 mg to 12 mg of the first FGFR inhibitor is administered to the patient over the treatment period (e.g., 7 days). As another example, the first FGFR inhibitor can be BGJ398 and a daily dose of 50 mg to 125 mg of the first FGFR inhibitor is administered to the patient over the treatment period (e.g., 21 days). In certain embodiments, the patient is administered a therapeutically effective amount of a phosphate binder over the treatment period. In certain embodiments, step (d) further comprises ceasing administration of the phosphate binder to the selected patient. In certain embodiments, step (d) further includes administering a decreased dose of the phosphate binder to the selected patient relative to the dose of the phosphate binder administered to the patient over the treatment period. JNJ-42756493 (erdafitinib) is also known as JNJ-493 and has the following systematic name, Nl-(3,5-dimethoxyphenyl)-N2-isopropyl-Nl-(3-(l-methyl-lH-pyr azol-4- yl)quinoxalin-6-yl)ethane-l,2-diamine, and the following structure:

[0034] BGJ398 (infigratinib) has the following systematic name, 3-(2,6-dichloro-3,5- dimethoxyphenyl)-l-(6-((4-(4-ethylpiperazin-l-yl)phenyl)amin o)pyrimidin-4-yl)-l -methyl and the following chemical structure:

[0036] Also provided herein are methods of treating a FGFR-associated cancer in a patient, the method comprising administering a therapeutically effective dose of a compound as described herein or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing the same to a patient identified or diagnosed as having an FGFR-associated cancer over a treatment period of at least 8 days, wherein the patient is determined to have about the same or a decreased level of phosphate in one or more biological sample(s) comprising blood, serum, or plasma obtained from the patient over the treatment period as compared to a reference level of phosphate.

[0037] Also provided herein are methods of treating a FGFR-associated cancer in a patient, the method comprising administering a therapeutically effective dose of a compound as described herein or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing the same to a patient identified or diagnosed as having an FGFR-associated cancer over a treatment period, wherein the patient is not administered a phosphate binder over the treatment period.

[0038] Also provided herein are methods of treating a FGFR-associated cancer in a patient, the method comprising administering a therapeutically effective dose of a compound as described herein or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing the same to a patient identified or diagnosed as having an FGFR-associated cancer over a treatment period, wherein the patient is further administered a low dose of a phosphate binder over the treatment period.

[0039] Also provided herein are methods of treating a patient having a FGFR-associated cancer, the method comprising administering a therapeutically effective dose of a compound as described herein or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition containing the same to a patient identified or diagnosed as having an FGFR-associated cancer over a treatment period, wherein the patient does not experience or is less likely to experience one or more of soft tissue calcification, stomatitis, dry mouth, nail changes, fatigue, asthenia, anorexia, malaise, and muscle aches over the treatment period.

[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

[0041] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

DETAILED DESCRIPTION OF THE INVENTION

[0042] Provided herein is a com ound of the general Formula I:

I

[0043] or a pharmaceutically acceptable salt or solvate thereof, wherein:

[0044] X is N or CH;

[0045] Ring A is a 5-membered heteroaryl ring having 1-2 ring nitrogen atoms;

[0046] z is 1, 2 or 3;

[0047] each R ¹ is independently selected from the group consisting of: [0048] (a) hydrogen,

[0049] (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros),

[0050] (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros),

[0051] (d) dihydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros),

[0052] (e) cyano(Cl-C6 alkyl)-,

[0053] (f) R ^a R N(Cl-C6 alkyl)-,

[0054] (g) (C1-C3 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros),

[0055] (h) (C3-C6 cycloalkyl)(CH2)n- where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy,

[0056] (i) hetCyc ¹ (CH2)m- where m is 0-3,

[0057] (j) hetCyc ² (CH2) _p - where p is 0 or 1,

[0058] (k) hetAr ¹ (CH ₂ ) _q - where q is 1 or 2,

[0059] (1) halogen, and

[0060] (m) hetCyc ¹ C(=0)CH ₂ -;

[0061] hetCyc ¹ is a 4-7 membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, HO, C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl )C(=0)-;

[0062] hetCyc ² is a 7-10 membered heterospirocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterospirocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl )C(=0)-;

[0063] hetAr ¹ is a 6-membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said ring is optionally substituted with one or more substituents independently selected from Cl- C6 alkyl and halogen;

[0064] R ² is Ar ¹ or hetAr ² ;

[0065] Ar ¹ is phenyl substituted with one or more groups independently selected from halogen, cyano, C 1-C3 alkyl, C 1-C3 alkoxy, (C 1-C3 alkyl) HC(=0)-, (C 1-C3 alkyl)C(=0) H-, (cyclopropyl)C(=0)NH- and (cyclopropyl) HC(=0)-, wherein each of said C 1-C3 alkyl and Cl- C3 alkoxy portions is optionally substituted with 1 -3 fluoros;

[0066] hetAr ² is a 6-10 membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said heteroaryl ring is optionally substituted with one or more groups independently selected from halogen, C 1-C3 alkyl, C 1 -C3 alkoxy, (C1-C3 alkyl) HC(=0)-, (C 1-C3 alkyl)C(=0) H-, (C3-C4 cycloalkyl)C(=0) H- and (C3-C4 cycloalkyl) HC(=0)-, wherein each of said C 1-C3 alkyl and C 1-C3 alkoxy portions is optionally substituted with 1 -3 fluoros;

[0067] R ³ is hydrogen, C1-C4 alkyl or (C3-C4)cycloalkyl; and

[0068] R ^a , R , R ^c and R ^d are independently hydrogen or C 1 -C6 alkyl optionally substituted with F, OH or C1-C6 alkoxy.

[0069] In some embodiments of general formula (I):

[0070] X is N or CH;

[0071] Ring A is a 5-membered heteroaryl ring having 1 -2 ring nitrogen atoms;

[0072] z is 1, 2 or 3;

[0073] each R ¹ is independently selected from the group consisting of:

[0074] (a) hydrogen,

[0075] (b) C 1-C6 alkyl (optionally substituted with 1-3 fluoros),

[0076] (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros),

[0077] (d) dihydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros),

[0078] (e) cyano(Cl-C6 alkyl)-,

[0079] (f) R ^a R N(Cl-C6 alkyl)-,

[0080] (g) (C 1-C3 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros),

[0081] (h) (C3-C6 cycloalkyl)(CH2)n- where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy,

[0082] (i) hetCyc ¹ (CH2)m- where m is 0-3,

[0083] (j) hetCyc ² (CH2) _p - where p is 0 or 1,

[0084] (k) hetAr ¹ (CH ₂ ) _q - where q is 1 or 2, and

[0085] (1) halogen;

[0086] hetCyc ¹ is a 4-7 membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, HO, C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl )C(=0)-;

[0087] hetCyc ² is a 7-10 membered heterospirocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterospirocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl )C(=0)-;

[0088] hetAr ¹ is a 6-membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said ring is optionally substituted with one or more substituents independently selected from Cl- C6 alkyl and halogen;

[0089] R ² is Ar ¹ or hetAr ² ;

[0090] Ar ¹ is phenyl substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, (C1-C3 alkyl) HC(=0)-, (C1-C3 alkyl)C(=0) H-, (cyclopropyl)C(=0)NH- and (cyclopropyl) HC(=0)-, wherein each of said C1-C3 alkyl and Cl- C3 alkoxy portions is optionally substituted with 1-3 fluoros;

[0091] hetAr ² is a 6 membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said heteroaryl ring is optionally substituted with one or more groups independently selected from halogen, C1-C3 alkyl, C1-C3 alkoxy, (C1-C3 alkyl) HC(=0)-, (C1-C3 alkyl)C(=0) H-, (C3-C4 cycloalkyl)C(=0) H- and (C3-C4 cycloalkyl) HC(=0)-, wherein each of said C1-C3 alkyl and C1-C3 alkoxy portions is optionally substituted with 1-3 fluoros;

[0092] R ³ is hydrogen, C1-C4 alkyl or (C3-C4)cycloalkyl; and

[0093] R ^a , R , R ^c and R ^d are independently hydrogen or C 1 -C6 alkyl optionally substituted with F, OH or C1-C6 alkoxy.

[0094] For complex chemical names employed herein, the substituent group is named before the group to which it attaches. For example, methoxyethyl comprises an ethyl backbone with a methoxy substituent.

[0095] The term "halogen" as used herein means -F (sometimes referred to herein as

"fluoro" or fluoros"), -CI, -Br and -I. [0096] The terms "C1-C3 alkyl" and "C1-C6 alkyl" as used herein refer to a monovalent, saturated linear or branched hydrocarbon chains having from one to three and one to six carbon atoms, respectively. Examples include, but are not limited to, methyl, ethyl, 1 -propyl, isopropyl, 1-butyl, isobutyl, sec-butyl, tert-butyl, 2-methyl-2-propyl, pentyl, pentan-3-yl and hexyl.

[0097] The term "hydroxy(C 1 -C6 alkyl)-" as used herein refers to a monovalent, saturated linear or branched hydrocarbon chain having from one to six carbon atoms, wherein any one of the carbon atoms is substituted with a hydroxy (-OH) group.

[0098] The terms "dihydroxy(Cl-C6 alkyl)-" and "dihydroxy(C3-C6 alkyl)-" as used herein refers to a monovalent, saturated linear or branched hydrocarbon chain having from one to six carbon atoms or three to six carbon atoms, respectively, wherein any two of the carbon atoms are each substituted with a hydroxy group, provided that both hydroxy groups are not attached to the same carbon atom.

[0099] The term "cyano(Cl-C6 alkyl)-" as used herein refers to a monovalent, saturated linear or branched hydrocarbon chain having from one to six carbon atoms, wherein any one of the carbon atoms is substituted with a cyano (-CN) group.

[00100] The terms "C1-C3 alkoxy" and "C1-C6 alkoxy" as used herein refer to groups that have the formula, -OR, wherein R is "C1-C3 alkyl" and "C1-C6 alkyl", respectively, as defined herein. Illustrative examples include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.

[00101] The term "(C1-C6 alkoxy)(Cl-C6 alkyl)-" as used herein refers to a monovalent, saturated linear or branched hydrocarbon chain having from one to six carbon atoms, wherein any one of the carbon atoms is substituted with a C1-C6 alkoxy group as defined herein.

[00102] The term "C3-C6 cycloalkyl" refers to a monovalent, monocyclic, saturated hydrocarbon ring having from three to six ring atoms. Illustrative examples include, but are not limited to, cyclopropyl and cyclobutyl.

[00103] The term "C3-C6 cycloalkoxy" as used herein refers to a group having the formula,

-OR', wherein R' is "C3-C6 cycloalkyl" as defined herein.

[00104] The term "(C3-C6 cycloalkoxy)Cl-C6 alkyl-" as used herein refers to a monovalent, saturated linear or branched hydrocarbon chain having from one to six carbon atoms, wherein any one of the carbon atoms is substituted with a C3-C6 cycloalkoxy group as defined herein. [00105] The term "heterocyclic" refers to a saturated, monovalent, monocyclic ring having the indicated number of total ring atoms, in which at least one of the ring atoms is a heteroatom (e.g., N or O).

[00106] The term "heterospirocyclic ring" as used herein refers to a bicyclic, saturated, spiro-C-fused (i.e., the two rings share a common carbon atom) heterocyclic ring system having from seven to ten total ring atoms, wherein from one to two of the ring atoms is a heteroatom independently selected from the group consisting of N and O, provided that the heteroatoms are not adjacent to one another. Each ring independently contains from 3 to 7 ring atoms, and when two of the ring atoms are heteroatoms, each of the heteroatoms can be present in the same ring, or each can be present in a different ring. Examples include 7-oxa-4-azaspiro[2.5]octane, 2- azaspiro[3.3]heptane, 2,6-diazaspiro[3.3]heptane, 2,5-diazaspiro[3.4]octane, 2,6- diazaspiro[3.4]octane, l,6-diazaspiro[3.4]octane, l,7-diazaspiro[4.4]nonane, 2,7- diazaspiro[4.4]nonane, 2,7-diazaspiro[3.5]nonane, 2,6-diazaspiro[3.5]nonane, 2,5- diazaspiro[3.5]nonane, 1 ,7-diazaspiro[3.5]nonane, l,6-diazaspiro[3.5]nonane, 2,8- diazaspiro[4.5]decane, l,8-diazaspiro[4.5]decane, 1 , 7-diazaspiro[4.5 ] decane, 2,7- diazaspiro[4.5]decane, 2,6-diazaspiro[4.5]decane, 3,9-diazaspiro[5.5]undecane, 2,9- diazaspiro[5.5]undecane, 7-azaspiro[3.5]nonane, 6-oxa-2-azaspiro[3.4]octane, 2-oxa-7- azaspiro[4.4]nonane, 7-oxa-2-azaspiro[3.5]nonane and 7-oxa-2-azaspiro[4.5]decane. For purposes of clarification the chemical structures of two exemplary heterospirocyclic rings are

provided:

[00107] The term "(C3-C4)cycloalkyl" as used herein refers collectively to the cyclopropyl and cyclobutyl rings.

[00108] The term "heteroaryl" refers to an aromatic, monovalent or divalent, monocyclic or bicyclic ring having the indicated number of total ring atoms, in which at least one of the ring atoms is a heteroatom (e.g., N or O).

[00109] The term "compound," as used herein is meant to include all stereoisomers, geometric isomers, tautomers, and isotopically enriched variants of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified. [00110] The term "tautomer" as used herein refers to compounds whose structures differ markedly in arrangement of atoms, but which exist in easy and rapid equilibrium, and it is to be understood that compounds of the present invention may be depicted as different tautomers, and when compounds have tautomeric forms, all tautomeric forms are intended to be within the scope of the invention, and the naming of the compounds does not exclude any tautomer.

[00111] In certain embodiments of Formula I, X is N.

[00112] In certain embodiments of Formula I, X is CH.

[00113] In certain embodiments of Formula I, Ring A is pyrazolyl optionally substituted with one to three R ¹ groups, wherein each R ¹ group is independently selected from the group consisting of (a) hydrogen, (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (d) dihydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (f) R ^a R N(Cl-C6 alkyl)-, (g) (C1-C3 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (h) (C3-C6 cycloalkyl)(CH2)n- where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, (i) where m is 0-3, (j) hetCyc ² (CH ₂ ) _P - where p is 0 or 1, (k) hetAr ¹ (CH ₂ ) _q - where q is 1 or 2, (1) halogen and (m) hetCyc ¹ C(=0)CH ₂ -. In certain embodiments, z is 1.

[00114] In certain embodiments of Formula I, Ring A is pyrazolyl optionally substituted with one to three R ¹ groups, wherein each R ¹ group is independently selected from the group consisting of (a) hydrogen, (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (g) (C1-C3 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (h) (C3-C6 cycloalkyl)(CH ₂ ) _n - where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, (i) hetCyc ¹ (CH ₂ ) _m - where m is 0-3, (j) hetCyc ² (CH ₂ ) _P where p is 0 or 1, (1) halogen and (m) hetCyc ¹ C(=0)CH ₂ -. In certain embodiments, z is 1.

[00115] In certain embodiments of Formula I, R ¹ is hydrogen. In one embodiment of

Formula I, R ¹ is hydrogen and z is 1, 2 or 3.

[00116] In certain embodiments of Formula I, R ¹ is C1-C6 alkyl optionally substituted with

1-3 fluoros. Non-limiting examples of R ¹ include methyl, isopropyl, isobutyl, pentan-3-yl, 2,2- difluoroethyl, and 3,3,3-trifluoroethyl.

[00117] In certain embodiments of Formula I, R ¹ is C1-C6 alkyl optionally substituted with 1-3 fluoros and z is 1, 2 or 3. In certain embodiments, z is 1. In certain embodiments of Formula I, Ring A is substituted with one to two R ¹ groups independently selected from C1-C6 alkyl optionally substituted with 1-3 fluoros. In certain embodiments of Formula I, Ring A is substituted with one or two methyl groups. In certain embodiments of Formula I, Ring A is substituted with two or three groups independently selected from methyl and trifluorom ethyl.

[00118] In certain embodiments of Formula I, R ¹ is hydroxy(Cl-C6 alkyl)- optionally substituted with 1-3 fluoros, and z is 1, 2 or 3. In certain embodiments of Formula I, R ¹ is hydroxy(C3-C6 alkyl)- optionally substituted with 1-3 fluoros. In certain embodiments of Formula I, R ¹ is hydroxy(Cl-C6 alkyl) optionally substituted with 1-3 fluoros and z is 1. Non-limiting examples of R ¹ include the structures:

[00119] In certain embodiments of Formula I, R ¹ is dihydroxy(Cl-C6 alkyl)- optionally substituted with 1-3 fluoros, and z is 1, 2 or 3. In certain embodiments of Formula I, R ¹ is dihydroxy(Cl-C6 alkyl)- optionally substituted with 1-3 fluoros and z is 1. In certain embodiments, R ¹ is dihydroxy(C3-C6 alkyl)-. Non-limiting examples of R ¹ include the structures:

[00120] In certain embodiments of Formula I, R ¹ is cyano(Cl-C6 alkyl)-, and z is 1, 2 or 3.

In certain embodiments of Formula I, R ¹ is cyano(Cl-C6 alkyl)- and z is 1. A non-limiting example of R ¹ includes the structure:

CN

[00121] In certain embodiments of Formula I, R ¹ is R ^a R N(C 1 -C6 alkyl)-, where R ^a and R are independently hydrogen or C1-C6 alkyl optionally substituted with F, OH or C1-C6 alkoxy, and z is 1, 2 or 3. In certain embodiments of Formula I, R ¹ is R ^a R N(Cl-C6 alkyl)- and z is 1. Non-limiting examples of R ¹ include the structures:

[00122] In certain embodiments of Formula I, R ¹ is (C1-C3 alkoxy)Cl-C6 alkyl- optionally substituted with 1-3 fluoros, and z is 1, 2 or 3. In certain embodiments of Formula I, R ¹ is (C1-C3 alkoxy)Cl-C6 alkyl- optionally substituted with 1-3 fluoros and z is 1. Non-limiting examples of R ¹ include the

[00123] In certain embodiments of Formula I, R ¹ is (C3-C6 cycloalkyl)(CH2) _n - where n is

0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl, or (1- 3C)alkoxy, and z is 1, 2 or 3. In certain embodiments of Formula I, R ¹ is (C3-C6 cycloalkyl)(CH2)n- where n is 0-3 and said cycloalkyl is optionally substituted with CN. In certain embodiments, n is 0 or 1. In certain embodiments of Formula I, R ¹ is (C3-C6 cycloalkyl)(CH2) _n - and z is 1. No -limitin exam les of R ¹ include the structures:

[00124] In certain embodiments of Formula I, R ¹ is hetCyc ¹ (CH2) _m -, and z is 1, 2 or 3, where m is 0-3, and hetCyc ¹ is a 4-7 membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, HO, C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl - (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl)C(=0)-. [00125] In certain embodiments of Formula I, R ¹ is hetCyc ¹ (CH2) _m and z is 1, 2 or 3, where m is 0-3, and hetCyc ¹ is azetidinyl, piperidinyl or morpholinyl optionally substituted with one or more substituents independently selected from the group consisting of fluoro, HO, C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl), R ^c R ^d N- and (C1-C6 alkyl)C(=0)-.

[00126] In certain embodiments of Formula I, R ¹ is where m is 0-3, and hetCyc ¹ is azetidinyl, piperidinyl or morpholinyl optionally substituted with one or more substituents independently selected from the group consisting of C1-C6 alkyl (optionally substituted with 1-3 fluoros) and (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros). In certain embodiments, z is 1.

[00127] In certain embodiments of Formula I, R ¹ is hetCyc ¹ (CH2) _m and z is 1. In one embodiment, m is 0, 1 or 2. In one embodiment, m is 0. In one embodiment, m is 1. In one embodiment, m is 2.

[00128] Non-limiting examples of R ¹ when represented by hetCyc ¹ (CH ₂ ) _m - include the structures:

[00129] In certain embodiments of Formula I, R ¹ is hetCyc ² (CH2) _p - where p is 0 or 1, and hetCyc ² is a 7-10 membered heterospirocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterospirocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl)C(=0)-, and z is 1, 2 or 3.

[00130] In certain embodiments of Formula I, R ¹ is hetCyc ² (CH2) _p - where p is 0 or 1, and hetCyc ² is a 7-10 membered heterospirocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterospirocyclic ring is unsubstituted.

[00131] In certain embodiments of Formula I, R ¹ is hetCyc ² (CH2) _p - and z is 1.

[00132] Non-limiting examples when R ¹ is represented by hetCyc ² (CH2) _p - include the structures:

[00133] In certain embodiments of Formula I, R ¹ is hetAr ¹ (CH2) _q - where q is 1 or 2 and hetAr ¹ is a 6-membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said ring is optionally substituted with one or more substituents independently selected from C1-C6 alkyl and halogen, and z is 1, 2 or 3.

[00134] In certain embodiments of Formula I, R ¹ is hetAr ¹ (CH2) _q - and z is 1.

[00135] Non-limiting examples when R ¹ is represented by hetAr ¹ (CH2) _q - include the structures:

[00136] In certain embodiments of Formula I, R ¹ is halogen. In certain embodiments when

R ¹ is halogen, z is 1, 2 or 3. Non-limiting examples of R ¹ include F, CI and Br. In one embodiment of Formula I, R ¹ is F and z is 1 or 2. In one embodiment, z is 1.

[00137] In certain embodiments of Formula I, R ¹ is hetCyc ¹ C(=0)CH2-, and z is 1, 2 or 3, where m is 0-3, and hetCyc ¹ is a 4-7 membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, HO, C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl - (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl)C(=0)-. In one embodiment, hetCyc ¹ is piperidinyl or morpholinyl optionally substituted with one or more substituents independently selected from the group consisting of fluoro, HO, C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl), R ^c R ^d N- and (C1-C6 alkyl)C(=0)-. In certain embodiments, hetCyc ¹ is piperidinyl or morpholinyl optionally substituted with one or more substituents independently selected from the group consisting of C1-C6 alkyl (optionally substituted with 1-3 fluoros) and (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros). In certain embodiments, z is 1. A non-limiting example of hetCyc ¹ C(=0)CH2- is the structure:

[00138] In certain embodiments of Formula I, Ring A is pyrazolyl optionally substituted with one to three R ¹ groups (that is, z is 1, 2 or 3), wherein R ¹ is selected from the group consisting of (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (f) R ^a R N(Cl-C6 alkyl)-, (h) (C3-C6 cycloalkyl)(CH2)n- where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, (i) where m is 0-3, (j) hetCyc ² (CH2) _p - where p is 0 or 1, and (m) hetCyc ¹ C(=0)CH2-. In certain embodiments, z is 1

[00139] In certain embodiments of Formula I, Ring A is pyrazolyl optionally substituted with two or three R ¹ groups (that is, z is 2 or 3), wherein each R ¹ is independently selected from hydrogen and C1-C6 alkyl (optionally substituted with 1-3 fluoros).

[00140] In certain embodiments of Formula I, z is 1 and Ring A is pyrazolyl, which may be represented by the structure:

*

[00141] wherein the wavy line indicates the point of attachment to the 6-membered ring comprising X and the asterisk indicates the point of attachment to R ¹ , wherein R ¹ is selected from (a) hydrogen, (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl), (g) (C1-C3 alkoxy)Cl- C6 alkyl- (optionally substituted with 1-3 fluoros), (h) (C3-C6 cycloalkyl)(CH2) _n - where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, (i) hetCyc ¹ (CH2)m- where m is 0-3, (j) hetCyc ² (CH2) _p where p is 0 or 1, (1) halogen and (m) hetCyc ¹ C(=0)CH2-. In one embodiment, R ¹ is selected from (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (f) R ^a R N(Cl-C6 alkyl)-, (h) (C3-C6 cycloalkyl)(CH ₂ )n- where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (1- 3C)alkoxy, (i) hetCyc ¹ (CH2) _m - where m is 0-3, (j) hetCyc ² (CH2) _p - where p is 0 or 1, and (m) hetCyc ¹ C(=0)CH ₂ -.

[00142] In certain embodiments of Formula I, Ring A is pyrazolyl and z is 1, wherein Ring

A and R ¹ together may be represented by the structure:

[00143] wherein the wavy line indicates the point of attachment to the 6-membered ring comprising X, wherein z is 1 and R ¹ is selected from (a) hydrogen, (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (g) (C1-C3 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (h) (C3-C6 cycloalkyl)(CH2) _n - where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, (i) where m is 0-3, (j) hetCyc ² (CH2) _p - where p is 0 or 1, (1) halogen and (m) hetCyc ¹ C(=0)CH2-. In one embodiment, R ¹ is selected from (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (f) R ^a R N(Cl-C6 alkyl)-, (h) (C3-C6 cycloalkyl)(CH2) _n - where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, (i) hetCyc ¹ (CH ₂ ) _m - where m is 0-3, and (m) hetCyc ¹ C(=0)CH ₂ -.

[00144] In certain embodiments of Formula I, R ² is Ar ¹ , where Ar ¹ is phenyl substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, (C1-C3 alkyl)NHC(=0)-, (C1-C3 alkyl)C(=0)NH-, (cyclopropyl)C(=0)NH- and (cyclopropyl)NHC(=0)-, wherein each of said C1-C3 alkyl and C1-C3 alkoxy portions are optionally substituted with 1-3 fluoros.

[00145] In certain embodiments of Formula I, R ² is Ar ¹ , where Ar ¹ is phenyl substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy and (C1-C3 alkyl)NHC(=0)-, wherein each of said C1-C3 alkyl and C1-C3 alkoxy portions is optionally substituted with 1-3 fluoros.

[00146] Non-limiting examples of R ² when represented by Ar ¹ include the structures:

[00147] In certain embodiments of Formula I, R ² is hetAr ² , where hetAr ² is a 6-10 membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said ring is optionally substituted with one or more groups independently selected from halogen, C1-C3 alkyl, C1-C3 alkoxy, (C1-C3 alkyl)NHC(=0)-, (C1-C3 alkyl)C(=0) H-, (C3-C4 cycloalkyl)C(=0)NH- and (C3-C4 cycloalkyl) HC(=0)-, wherein each of said C1-C3 alkyl and C1-C3 alkoxy portions is optionally substituted with 1-3 fluoros.

[00148] In certain embodiments of Formula I, R ² is hetAr ² , where hetAr ² is a 6-10 membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said ring is optionally substituted with one or more groups independently selected from C1-C3 alkyl, C1-C3 alkoxy and (C1-C3 alkyl) HC(=0)-, wherein each of said C1-C3 alkyl and C1-C3 alkoxy portions is optionally substituted with 1-3 fluoros. [00149] Non-limiting examples of hetAr ² include:

[00150] In certain embodiments of Formula I, R ³ is H.

[00151] In certain embodiments of Formula I, R ³ is C1-C4 alkyl. Non-limiting examples include methyl, ethyl, propyl, isopropyl and isobutyl.

[00152] In certain embodiments of Formula I, R ³ is (C3-C4)cycloalkyl. In certain embodiments of Formula I, R ³ is cyclopropyl. In certain embodiments of Formula I, R ³ is cyclobutyl.

[00153] Compounds of Formula I include compounds of Formula I-A, wherein:

[00154] X is N;

[00155] z is l;

[00156] Ring A

[00157] wherein the wavy line indicates the point of attachment to the 6-membered ring comprising X and the asterisk indicates the point of attachment to R ¹ ;

[00158] each R ¹ is independently selected from the group consisting of (a) hydrogen, (b)

C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (d) dihydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (f) R ^a R N(Cl-C6 alkyl)-, (g) (C1-C3 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (h) (C3-C6 cycloalkyl)(CH2) _n - where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, (i) hetCyc ¹ (CH2)m- where m is 0-3, (j) hetCyc ² (CH2) _p - where p is 0 or 1, (k) hetAr ¹ (CH2) _q - where q is 1 or 2, (1) halogen and (m) hetCyc ¹ C(=0)CH ₂ -;

[00159] hetCyc ¹ is a 4-7 membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, HO, C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl )C(=0)-;

[00160] hetCyc ² is a 7-10 membered heterospirocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterospirocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl )C(=0)-;

[00161] hetAr ¹ is a 6-membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said ring is optionally substituted with one or more substituents independently selected from Cl- C6 alkyl and halogen;

[00162] R ² is Ar ¹ or hetAr ² ;

[00163] Ar ¹ is phenyl substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, (C1-C3 alkyl) HC(=0)-, (C1-C3 alkyl)C(=0) H-, (cyclopropyl)C(=0)NH- and (cyclopropyl) HC(=0)-, wherein each of said C1-C3 alkyl and Cl- C3 alkoxy portions is optionally substituted with 1-3 fluoros;

[00164] hetAr ² is a 6-10 membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said heteroaryl ring is optionally substituted with one or more groups independently selected from halogen, C1-C3 alkyl, C1-C3 alkoxy, (C1-C3 alkyl) HC(=0)-, (C1-C3 alkyl)C(=0) H-, (C3-C4 cycloalkyl)C(=0) H- and (C3-C4 cycloalkyl) HC(=0)-, wherein each of said C1-C3 alkyl and C1-C3 alkoxy portions is optionally substituted with 1-3 fluoros;

[00165] R ³ is hydrogen, C1-C4 alkyl or (C3-C4)cycloalkyl; and

[00166] R ^a , R , R ^c and R ^d are independently hydrogen or C 1 -C6 alkyl optionally substituted with F, OH or C1-C6 alkoxy.

[00167] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is as defined for Formula

I-A

[00168] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-.

[00169] In one embodiment of Formula I- A, R ³ is hydrogen.

[00170] In one embodiment of Formula I-A, R ³ is C1-C4 alkyl.

[00171] In one embodiment of Formula I-A, R ³ is (C3-C4)cycloalkyl.

[00172] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl

(optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-, and R ³ is hydrogen.

[00173] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-, and R ³ is C1-C4 alkyl.

[00174] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-, and R ³ is (C3-C4)cycloalkyl.

[00175] In one embodiment of Formula I-A, R ¹ is selected from (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (f) R ^a R N(Cl-C6 alkyl)-, (h) (C3-C6 cycloalkyl)(CH ₂ )n- where n is 0- 3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, (i) where m is 0-3, (j) hetCyc ² (CH ₂ ) _p - where p is 0 or 1, and (m) hetCyc ¹ C(=0)CH ₂ -; and hetCyc ¹ , R ^a , and R are as defined for Formula I-A.

[00176] In one embodiment of Formula I-A, R ¹ is C1-C6 alkyl (optionally substituted with

1-3 fluoros).

[00177] In one embodiment of Formula I-A, R ¹ is hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros).

[00178] In one embodiment of Formula I-A, R ¹ is cyano(Cl-C6 alkyl)-.

[00179] In one embodiment of Formula I-A, R ¹ is R ^a R N(Cl-C6 alkyl)-.

[00180] In one embodiment of Formula I-A, R ¹ is (C3-C6 cycloalkyl)(CH ₂ ) _n - where n is 0-

3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, [00181] In one embodiment of Formula I- A, R ¹ is where m is 0-3. In one embodiment, m is 0, 1 or 2. In one embodiment, m is 0. In one embodiment, m is 1. In one embodiment, m is 2.

[00182] In one embodiment of Formula I-A, R ¹ is hetCyc ² (CH2) _p - where p is 0 or 1.

[00183] In one embodiment of Formula I-A, R ¹ is hetCyc ¹ C(=0)CH ₂ -.

[00184] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl)NHC(=0)-; R ³ is hydrogen; R ¹ is selected from (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (f) R ^a R N(Cl-C6 alkyl)-, (h) (C3-C6 cycloalkyl)(CH ₂ )n- where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (1- 3C)alkoxy, (i) hetCyc ¹ (CH ₂ ) _m - where m is 0-3, (j) hetCyc ² (CH ₂ ) _p - where p is 0 or 1, and (m) hetCyc ¹ C(=0)CH ₂ -; and hetCyc ¹ , R ^a , and R are as defined for Formula I-A. In one embodiment, m is 0, 1 or 2. In one embodiment, m is 0. In one embodiment, m is 1. In one embodiment, m is 2.

[00185] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; R ³ is C1-C4 alkyl; R ¹ is selected from (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (f) R ^a R N(Cl-C6 alkyl)-, (h) (C3-C6 cycloalkyl)(CH ₂ )n- where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (1- 3C)alkoxy, (i) hetCyc ¹ (CH ₂ ) _m - where m is 0-3, (j) hetCyc ² (CH ₂ ) _p - where p is 0 or 1, and (m) hetCyc ¹ C(=0)CH ₂ -; and hetCyc ¹ , R ^a , and R are as defined for Formula I-A. In one embodiment, m is 0, 1 or 2. In one embodiment, m is 0. In one embodiment, m is 1. In one embodiment, m is 2.

[00186] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl)NHC(=0)-; R ³ is (C3-C4)cycloalkyl; R ¹ is selected from (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl-C6 alkyl)-, (f) R ^a R N(Cl-C6 alkyl)-, (h) (C3-C6 cycloalkyl)(CH ₂ )„- where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, (i) where m is 0-3, (j) hetCyc ² (CH ₂ ) _p - where p is 0 or 1, and (m) hetCyc ¹ C(=0)CH ₂ -; and hetCyc ¹ , R ^a , and R are as defined for Formula I-A. In one embodiment, m is 0, 1 or 2. In one embodiment, m is 0. In one embodiment, m is 1. In one embodiment, m is 2.

[00187] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; R ³ is hydrogen; and R ¹ is C1-C6 alkyl (optionally substituted with 1-3 fluoros).

[00188] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, C1-C3 alkyl (optionally substituted with 1-3 fluoros), and C1-C3 alkoxy (optionally substituted with 1-3 fluoros); R ³ is hydrogen; and R ¹ is hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros).

[00189] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, C1-C3 alkyl (optionally substituted with 1-3 fluoros), and C1-C3 alkoxy (optionally substituted with 1-3 fluoros); R ³ is hydrogen; and R ¹ is cyano(Cl-C6 alkyl)-.

[00190] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; R ³ is hydrogen; and R ¹ is R ^a R N(Cl-C6 alkyl)- where R ^a , and R are as defined for Formula I-A.

[00191] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; R ³ is hydrogen; and R ¹ is (C3-C6 cycloalkyl)(CH ₂ ) _n - where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (1- 3C)alkoxy. In one embodiment said cycloalkyl is unsubstituted. In one embodiment, said cycloalkyl is substituted with CN. In one embodiment, n is 0. In one embodiment n is 1.

[00192] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 where m is 0-3; and hetCyc ¹ is as defined for Formula I-A. In one embodiment, m is 0, 1 or 2. In one embodiment, m is 0. In one embodiment, m is 1. In one embodiment, m is 2.

[00193] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl)NHC(=0)-; R ³ is hydrogen; and R ¹ is hetCyc ² (CH ₂ ) _P - where p is 0 or 1, and hetCyc ² is as defined for Formula I-A. In one embodiment, p is 1. On one embodiment, hetCyc ² (CH ₂ ) _p - is

[00194] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; R ³ is hydrogen; and R ¹ is hetCyc ¹ C(=0)CH ₂ - where hetCyc ¹ is as defined for Formula I-A. In one embodiment, hetCyc ¹ is piperidinyl. In one embodiment, hetCyc ¹ C(=0)CH ₂ - is

[00195] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; R ³ is C1-C4 alkyl; and R ¹ is C1-C6 alkyl (optionally substituted with 1-3 fluoros).

[00196] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; R ³ is C1-C4 alkyl; and R ¹ is R ^a R N(Cl-C6 alkyl)-, wherein R ^a and R are as defined for Formula I-A. In one embodiment, R ^a and R are independently selected from C1-C6 alkyl.

[00197] In one embodiment of Formula I-A, R ² is Ar ¹ , where Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl)NHC(=0)-; R ³ is C1-C4 alkyl; and R ¹ is where m is 0-3, and hetCyc ¹ is as defined for Formula I-A.

[00198] In one embodiment of Formula I-A, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl (optionally substituted with 1-3 fluoros), C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl)NHC(=0)-; R ³ is C3-C4 cycloalkyl; and R ¹ is C1-C6 alkyl (optionally substituted with 1-3 fluoros).

[00199] Compounds of Formula I include compounds of Formula I-B, wherein:

[00200] X is N;

[00201] z is 2 or 3;

[00202] Ring A i s pyrazolyl ;

[00203] each R ¹ is independently selected from the group consisting of (a) hydrogen and

(b) C1-C6 alkyl (optionally substituted with 1-3 fluoros);

[00204] R ² is Ar ¹ ;

[00205] Ar ¹ is phenyl substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, (C1-C3 alkyl) HC(=0)-, (C1-C3 alkyl)C(=0) H-, (cyclopropyl)C(=0)NH- and (cyclopropyl) HC(=0)-, wherein each of said C1-C3 alkyl and Cl- C3 alkoxy portions is optionally substituted with 1-3 fluoros; and

[00206] R ³ is hydrogen, C1-C4 alkyl or (C3-C4)cycloalkyl.

[00207] In one embodiment of Formula I-B, Ar ¹ is phenyl substituted with one or more groups independently selected from halogen and C1-C3 alkoxy. [00208] In one embodiment of Formula I-B, R ³ is hydrogen.

[00209] In one embodiment of Formula I-B, Ar ¹ is phenyl substituted with one groups independently selected from halogen and C1-C3 alkoxy, and R ³ is hydrogen.

[00210] Compounds of Formula I include compounds of Formula I-C, wherein:

[00211] X is CH;

[00212] z is l;

[00213] Ring A

[00214] wherein the wavy line indicates the point of attachment to the 6-membered ring comprising X and the asterisk indicates the point of attachment to R ¹ ;

[00215] R ¹ is selected from the group consisting of (a) hydrogen, (b) C1-C6 alkyl

(optionally substituted with 1-3 fluoros), (c) hydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (d) dihydroxy(Cl-C6 alkyl)- (optionally substituted with 1-3 fluoros), (e) cyano(Cl- C6 alkyl)-, (f) R ^a R N(Cl-C6 alkyl)-, (g) (C1-C3 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (h) (C3-C6 cycloalkyl)(CH2) _n - where n is 0-3 and said cycloalkyl is optionally substituted with CN, OH, R ^a R N-, (l-3C)alkyl or (l-3C)alkoxy, (i) hetCyc^CHzV where m is

0- 3, (j) hetCyc ² (CH ₂ ) _P - where p is 0 or 1, (k) hetAr ¹ (CH ₂ ) _q - where q is 1 or 2, (1) halogen and (m) hetCyc ¹ C(=0)CH ₂ -;

[00216] hetCyc ¹ is a 4-7 membered saturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of fluoro, HO, C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with 1-3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl )C(=0)-;

[00217] hetCyc ² is a 7-10 membered heterospirocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein said heterospirocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C6 alkoxy)Cl-C6 alkyl- (optionally substituted with

1- 3 fluoros), (C3-C6 cycloalkoxy)Cl-C6 alkyl-, hydroxy(Cl-C6 alkyl)-, R ^c R ^d N- and (C1-C6 alkyl )C(=0)-;

[00218] hetAr ¹ is a 6-membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said ring is optionally substituted with one or more substituents independently selected from Cl- C6 alkyl and halogen;

[00219] R ² is Ar ¹ or hetAr ² ;

[00220] Ar ¹ is phenyl substituted with one or more groups independently selected from halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, (C1-C3 alkyl) HC(=0)-, (C1-C3 alkyl)C(=0) H-, (cyclopropyl)C(=0)NH- and (cyclopropyl) HC(=0)-, wherein each of said C1-C3 alkyl and Cl- C3 alkoxy portions is optionally substituted with 1-3 fluoros;

[00221] hetAr ² is a 6-membered heteroaryl ring having 1-2 ring nitrogen atoms, wherein said heteroaryl ring is optionally substituted with one or more groups independently selected from halogen, C1-C3 alkyl, C1-C3 alkoxy, (C1-C3 alkyl) HC(=0)-, (C1-C3 alkyl)C(=0) H-, (C3-C4 cycloalkyl)C(=0) H- and (C3-C4 cycloalkyl) HC(=0)-, wherein each of said C1-C3 alkyl and C1-C3 alkoxy portions is optionally substituted with 1-3 fluoros;

[00222] R ³ is hydrogen, C1-C4 alkyl or (C3-C4)cycloalkyl; and

[00223] R ^a , R , R ^c and R ^d are independently hydrogen or C 1 -C6 alkyl optionally substituted with F, OH or C1-C6 alkoxy.

[00224] In one embodiment of Formula I-C, R ² is Ar ¹ , wherein Ar ¹ is as defined for Formula

I-B

[00225] In one embodiment of Formula I-C, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, C1-C3 alkyl (optionally substituted with 1-3 fluoros), and C1-C3 alkoxy (optionally substituted with 1-3 fluoros).

[00226] In one embodiment of Formula I-C, R ³ is hydrogen.

[00227] In one embodiment of Formula I-C, R ³ is C1-C4 alkyl.

[00228] In one embodiment of Formula I-C, R ³ is (C3-C4)cycloalkyl.

[00229] In one embodiment of Formula I-C, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; and R ³ is hydrogen.

[00230] In one embodiment of Formula I-C, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; and R ³ is C1-C4 alkyl. [00231] In one embodiment of Formula I-C, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; and R ³ is (C3- C4)cycloalkyl.

[00232] In one embodiment of Formula I-C, R ¹ is independently selected from (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros) and (i) hetCyc ^C h - where m is 0-3; and hetCyc ¹ is defined for Formula I-C.

[00233] In one embodiment of Formula I-C, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; R ³ is hydrogen; R ¹ is independently selected from (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros) and (i) hetCyc ¹ (CH2)m- where m is 0-3; and hetCyc ¹ is defined for Formula I-C.

[00234] In one embodiment of Formula I-C, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl) HC(=0)-; R ³ is C1-C4 alkyl; R ¹ is independently selected from (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros) and (i) hetCyc ¹ (CH2)m- where m is 0-3; and hetCyc ¹ is defined for Formula I-C.

[00235] In one embodiment of Formula I-C, R ² is Ar ¹ , wherein Ar ¹ is phenyl optionally substituted with one or more groups independently selected from halogen, C1-C3 alkoxy (optionally substituted with 1-3 fluoros) and (C1-C3 alkyl)NHC(=0)-; R ³ is (C3-C4)cycloalkyl; R ¹ is independently selected from (b) C1-C6 alkyl (optionally substituted with 1-3 fluoros) and (i) hetCyc ¹ (CH2)m- where m is 0-3; and hetCyc ¹ is defined for Formula I-C.

[00236] It will be appreciated that certain compounds provided herein may contain one or more centers of asymmetry and may therefore be prepared and isolated in a mixture of isomers such as a racemic mixture, or in an enantiomerically pure form.

[00237] It will further be appreciated that the compounds of Formula I or their salts may be isolated in the form of solvates, and accordingly that any such solvate is included within the scope of the present invention. For example, compounds of Formula I and salts thereof can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.

[00238] The compounds of Formula I include pharmaceutically acceptable salts thereof. In addition, the compounds of Formula I also include other salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula I and/or for separating enantiomers of compounds of Formula I. Non-limiting examples of salts include monochloride, dichloride, trifluoroacetic acid, and di-trifluoroacetic acid salts of compounds of Formula I.

[00239] In one embodiment, the compounds of Formula I include the compounds of

Examples 1- 62 and stereoisomers and pharmaceutically acceptable salts and solvates thereof. In one embodiment, the compounds of Examples 1-83 are in the free base form. In one embodiment, the compounds of Examples 1-83 are monochloride, dichloride, trifluoroacetic acid, or di- trifluoroacetic acid salts.

[00240] The term "pharmaceutically acceptable" indicates that the substance or composition is compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the patient being treated therewith.

[00241] Compounds provided herein may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. That is, an atom, in particular when mentioned in relation to a compound according to Formula I, comprises all isotopes and isotopic mixtures of that atom, either naturally occurring or synthetically produced, either with natural abundance or in an isotopically enriched form. For example, when hydrogen is mentioned, it is understood to refer to ¾, ² H, ³ H or mixtures thereof; when carbon is mentioned, it is understood to refer to ^U C, ¹² C, ¹³ C, ¹⁴ C or mixtures thereof; when nitrogen is mentioned, it is understood to refer to ¹³ N, ¹⁴ N, ¹⁵ N or mixtures thereof; when oxygen is mentioned, it is understood to refer to ¹⁴ 0, ¹⁵ 0, ¹⁶ 0, ¹⁷ 0, ¹⁸ 0 or mixtures thereof; and when fluoro is mentioned, it is understood to refer to ¹⁸ F, ¹⁹ F or mixtures thereof. The compounds provided herein therefore also comprise compounds with one or more isotopes of one or more atom, and mixtures thereof, including radioactive compounds, wherein one or more non-radioactive atoms has been replaced by one of its radioactive enriched isotopes. Radiolabeled compounds are useful as therapeutic agents, e.g., cancer therapeutic agents, research reagents, e.g., assay reagents, and diagnostic agents, e.g., in vivo imaging agents. All isotopic variations of the compounds provided herein, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

[00242] For illustrative purposes, Schemes 1 and 1A show general methods for preparing the compounds provided herein as well as key intermediates. For a more detailed description of the individual reaction steps, see the Examples section below. Those skilled in the art will appreciate that other synthetic routes may be used to synthesize the inventive compounds. Although specific starting materials and reagents are depicted in the Schemes and discussed below, other starting materials and reagents can be easily substituted to provide a variety of derivatives and/or reaction conditions. In addition, many of the compounds prepared by the methods described below can be further modified in light of this disclosure using conventional chemistry well known to those skilled in the art.

[00243] Scheme 1 shows a general scheme for the synthesis of compound 9 where X, R ¹ ,

R ² , R ³ , Ring A and z are as defined for Formula I. Compound 3, where R ³ is as defined for Formula I, may be obtained by treating compound 1 (commercially available or prepared according to Scheme 2) with boronic acid 2, where R ² is as defined for Formula I, in the presence of Cu(II) catalyst such as cupric acetate and a ligand such as pyridine. Compound 3 may be reacted with a dioxoborinane, such as bis(pinacolato)diboron, using appropriate Suzuki coupling reaction conditions (e.g., in the presence of a palladium (II) catalyst such as Pd(OAc) ₂ , Pd ₂ (dba) ₃ , Pd(PPh ₃ ) ₄ or Pd(Dppf)2 and optionally in the presence of a suitable ligand such as XPhos and in the presence of an inorganic base such as potassium acetate or sodium carbonate), to provide compound 4 where R ² and R ³ are as defined for Formula I. Compound 4 may be reacted with compound 5 (prepared as described below) where X, Ring A, R ¹ and z are as defined for Formula I, using appropriate Suzuki coupling reaction conditions (e.g., in the presence of a palladium (II) catalyst such as Pd(PPh ₃ )4, Pd(Dppf)2, Pd(OAc) ₂ , or Pd ₂ (dba) ₃ , and an inorganic base such as potassium carbonate or sodium carbonate) to provide compound 9. Compound 5 may be prepared by reacting compound 6 (where R ¹ , Ring A and z are as defined for Formula I) with compound 7 (where X is as defined for Formula I) to provide compound 8, which may subsequently be brominated using standard conditions to provide compound 5. The syntheses of intermediates 3 and 6 which are not commercially available are described in the Examples.

[00244] Scheme 1A shows a general scheme for the synthesis of compound 9B where X,

R ² and R ³ are as defined for Formula I, z is 1 and R ¹ is a piperidine substituted with C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C3 alkoxy)Cl-C6 alkyl (optionally substituted with 1-3 fluoros) or hydroxy(Cl-C6 alkyl). Compound 9A, where X, R ² and R ³ are as defined for Formula I, z is 1 and R ¹ is a piperidine substituted with C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C3 alkoxy)Cl-C6 alkyl (optionally substituted with 1-3 fluoros) or hydroxy(Cl- C6 alkyl), prepared as described in Scheme 1, may be reacted with a compound having the formula R ^x -Y, where R ^x is C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C3 alkoxy)Cl-C6 alkyl (optionally substituted with 1-3 fluoros) or hydroxy(Cl-C6 alkyl), and Y is a leaving group such as a halogen or a tosylate, under standard alkylation reaction conditions, for example in the presence of an inorganic base such as potassium carbonate, to provide compound 9B. [00245] The compound of formulas 1, 3, 4, 5, 6, 8 and 9A as shown and described above for Schemes 1 and 1A are useful as intermediates for preparing compounds of Formula I and are provided as further aspects of the invention.

[00246] Further provided herein is a process for preparing of a compound of Formula I or a pharmaceutically acceptable salt thereof as defined herein which comprises:

[00247] (a) reacting a compound havin the formula 5:

where X, Ring A, R ¹ and z are as defined for Formula I, with a compound having

4

[00249] where R ² is as defined for Formula I, in the presence of a palladium (II) catalyst and an inorganic base; or

[00250] (b) for a compound of Formula I where X, R ² and R ³ are as defined for Formula I, z is 1 and R ¹ is a piperidine substituted with C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C3 alkoxy)Cl-C6 alkyl (optionally substituted with 1-3 fluoros) or hydroxy(Cl-C6 alkyl), reacting a compound having the formula 9A:

9A [00251] where X, R ² and Ring A are as defined for Formula I, with a compound having the formula R ^x -Y, where R ^x is C1-C6 alkyl (optionally substituted with 1-3 fluoros), (C1-C3 alkoxy)Cl-C6 alkyl (optionally substituted with 1-3 fluoros) or hydroxy(Cl-C6 alkyl), and Y is a leaving group such as a halogen or a tosylate, under standard alkylation reaction conditions; and

[00252] removing any protecting groups if present and optionally forming a pharmaceutically acceptable salt.

[00253] The ability of test compounds to act as inhibitors of FGFRl, FGFR2 and/or FGFR3 may be demonstrated by the assay described in Example A. IC50S are shown in Table F.

[00254] Compounds of Formula I have been found to inhibit FGFRl, FGFR2 and/or

FGFR3, and are therefore believed to be useful for treating diseases and disorders which can be treated with an inhibitor of FGFRl, FGFR2, FGFR3 and/or FGFR4, such as FGFR-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors.

[00255] In certain embodiments, compounds of Formula I are useful for preventing diseases and disorders as defined herein (for example cancer).

[00256] The term "preventing" as used herein means the prevention of the recurrence or spread, in whole or in part, of the disease or condition as described herein, or a symptom thereof.

[00257] As used herein, the word "a" before a noun represents one or more of the particular noun. For example, the phrase "a cell" represents "one or more cells."

[00258] As used herein, terms "treat" or "treatment" refer to therapeutic or palliative measures. Beneficial or desired clinical results include, but are not limited to, alleviation, in whole or in part, of symptoms associated with a disease or disorder or condition, diminishment of the extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state (e.g., one or more symptoms of the disease), and remission (whether partial or total). "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment.

[00259] The term "FGFR-associated disease or disorder" as used herein refers to diseases or disorders associated with or having a dysregulation of a FGFR gene, a FGFR protein, or the expression or activity, or level of the same (e.g., one or more of the same) (e.g., any of the types of dysregulation of an FGFR gene, a FGFR protein, or expression or activity, or level of the same, described herein). A non-limiting example of an FGFR-associated disease or disorder is an FGFR- associated cancer.

[00260] As used herein, the term "FGFR-associated cancer" shall be defined to include cancers associated with or having dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same (e.g., any of types of dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, described herein). Non-limiting examples of a FGFR-associated cancer are described herein.

[00261] As used herein, the term "subject," "individual," or "patient," used interchangeably, refers to any animal, including mammals such as mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, primates, and humans. In some embodiments, the patient is a human. In some embodiments, the subject has experienced and/or exhibited at least one symptom of the disease or disorder to be treated and/or prevented. In some embodiments, the subject has been identified or diagnosed as having a cancer with dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same (a FGFR-associated cancer) (e.g., as determined using a regulatory agency-approved, e.g., FDA-approved, assay or kit). In some embodiments, the subject has a tumor that is positive for dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same (e.g., as determined using a regulatory agency-approved assay or kit). The subject can be a subject with a tumor(s) that is positive for dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same (e.g., identified as positive using a regulatory agency-approved, e.g., FDA-approved, assay or kit). The subject can be a subject whose tumors have dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or a level of the same (e.g., where the tumor is identified as such using a regulatory agency-approved, e.g., FDA-approved, kit or assay). In some embodiments, the subject is suspected of having a FGFR-associated cancer. In some embodiments, the subject has a clinical record indicating that the subject has a tumor that has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same (and optionally the clinical record indicates that the subject should be treated with any of the compositions provided herein).

[00262] The term "FGFR" or "FGFR protein" includes any of the FGFR proteins described herein (e.g., a FGFR1, a FGFR2, a FGFR3 or a FGFR4 protein, or isoforms thereof).

[00263] The term "FGFR gene" includes any of the FGFR genes described herein (e.g., a

FGFR1, a FGFR2, a FGFR3 gene, or a FGFR4 gene).

[00264] The term "wildtype" or "wild-type" describes a nucleic acid (e.g., a FGFR gene or a FGFR mRNA) or protein (e.g., a FGFR protein) that is found in a subject that does not have a FGFR-associated disease, e.g., a FGFR-associated cancer (and optionally also does not have an increased risk of developing a FGFR-associated disease and/or is not suspected of having a FGFR- associated disease), or is found in a cell or tissue from a subject that does not have a FGFR- associated disease, e.g., a FGFR-associated cancer (and optionally also does not have an increased risk of developing a FGFR-associated disease and/or is not suspected of having a FGFR-associated disease).

[00265] The term "regulatory agency" is a country's agency for the approval of the medical use of pharmaceutical agents with the country. For example, a non-limiting example of a regulatory agency is the U.S. Food and Drug Administration (FDA).

[00266] The phrase "dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same" is a genetic mutation (e.g., a FGFR gene translocation that results in the expression of a fusion protein, a deletion in a FGFR gene that results in the expression of a FGFR protein that includes a deletion of at least one amino acid as compared to the wild-type FGFR protein, or a mutation in a FGFR gene that results in the expression of a FGFR protein with one or more point mutations, an alternative spliced version of a FGFR mRNA that results in a FGFR protein that results in the deletion of at least one amino acid in the FGFR protein as compared to the wild-type FGFR protein), or a FGFR gene amplification that results in overexpression of a FGFR protein) or an autocrine activity resulting from the overexpression of a FGFR gene a cell, that results in a pathogenic increase in the activity of a kinase domain of a FGFR protein (e.g., a constitutively active kinase domain of a FGFR protein) in a cell. For example, a dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, can be a mutation in a FGFR1, FGFR2, FGFR3, or FGFR4 gene that encodes a FGFR protein that is constitutively active or has increased activity as compared to a protein encoded by a FGFR1, FGFR2, FGFR3, or FGFR4 gene that does not include the mutation. For example, a dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, can be the result of a gene or chromosome translocation which results in the expression of a fusion protein that contains a first portion of FGFR1, FGFR2, FGFR3, or FGFR4 that includes a functional kinase domain, and a second portion of a partner protein (i.e., that is not FGFR1, FGFR2, FGFR3, or FGFR4). In some examples, dysregulation of a FGFR gene, a FGFR protein, or expression or activity, can be a result of a gene translation of one FGFR1 gene with another FGFR1 gene. Non- limiting examples of fusion proteins that are a result of a FGFR gene translocation are described in Table 3.

[00267] A dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, can, e.g., include a mutation(s) in a FGFR1, FGFR2, FGFR3, or FGFR4 gene that results in a FGFR1, FGFR2, FGFR3, or FGFR4 protein containing at least one (e.g., two, three, four, or five) point mutations (e.g., one of more of the point mutations listed in Table 1).

[00268] A dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, can be a mutation in a FGFR1, FGFR2, FGFR3, or FGFR4 gene that results in a deletion of one or more contiguous amino acids (e.g., at least two, at least three, at least four, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220, at least 230, at least 240, at least 250, at least 260, at least 270, at least 280, at least 290, at least 300, at least 310, at least 320, at least 330, at least 340, at least 350, at least 360, at least 370, at least 380, at least 390, or at least 400 amino acids) in the FGFR1, FGFR2, FGFR3, or FGFR4 protein (except for the deletion of amino acids in the kinase domain of FGFR1, FGFR2, FGFR3, or FGFR4 that would result in inactivation of the kinase domain).

[00269] In some examples, a dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, can include an alternate spliced form of a FGFR mRNA. In some examples, a dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, includes an amplification of a FGFR gene (e.g., one, two, three, or four additional copies of a FGFR1, FGFR2, FGFR3, and/or FGFR4 gene) that can result, e.g., in an autocrine expression of a FGFR gene in a cell.

[00270] The term "mammal" as used herein, refers to a warm-blooded animal that has or is at risk of developing a disease described herein and includes, but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters, and primates, including humans.

[00271] The phrase "time of survival" means the length of time between the identification or diagnosis of cancer (e.g., any of the cancers described herein) in a subject or patient by a medical professional and the time of death of the subject or patient (caused by the cancer). Methods of increasing the time of survival in a subject or patient having a cancer are described herein.

[00272] The term "metastasis" is an art known term and means the formation of an additional tumor (e.g., a solid tumor) at a site distant from a primary tumor in a subject or patient, where the additional tumor includes the same or similar cancer cells as the primary tumor.

[00273] The phrase "risk of developing a metastasis" means the risk that a subject or patient having a primary tumor will develop an additional tumor (e.g., a solid tumor) at a site distant from a primary tumor in a subject or patient over a set period of time, where the additional tumor includes the same or similar cancer cells as the primary tumor. Methods for reducing the risk of developing a metastasis in a subject or patient having a cancer are described herein.

[00274] The phrase "risk of developing additional metastases" means the risk that a subject or patient having a primary tumor and one or more additional tumors at sites distant from the primary tumor (where the one or more additional tumors include the same or similar cancer cells as the primary tumor) will develop one or more further tumors distant from the primary tumor, where the further tumors include the same or similar cancer cells as the primary tumor. Methods for reducing the risk of developing additional metastasis are described herein.

[00275] The term "angiogenesis-related disorder" means a disease characterized in part by an increased number or size of blood vessels in a tissue in a subject or patient, as compared to a similar tissue from a subject not having the disease. Non-limiting examples of angiogenesis- related disorders include: cancer (e.g., any of the exemplary cancers described herein, such as prostate cancer, lung cancer, breast cancer, bladder cancer, renal cancer, colon cancer, gastric cancer, pancreatic cancer, ovarian cancer, melanoma, hepatoma, sarcoma, and lymphoma), exudative macular degeneration, proliferative diabetic diabetic retinopathy, ischemic retinopathy, retinopathy of prematurity, neovascular glaucoma, iritis rubeosis, corneal neovascularization, cyclitis, sickle cell retinopathy, and pterygium.

[00276] The term "resistant cancer cell to an anti -cancer drug" means a cancer cell that demonstrates an increased rate of growth and/or proliferation in the presence of an anti-cancer drug as compared to the rate of growth and/or proliferation of a similar cancer cell (or an average rate of growth and/or proliferation of a population of a similar cancer cells). For example, a cancer cell that demonstrates an increased rate of growth and/or proliferation in the presence of an anticancer drug (as compared to the rate of growth and/or proliferation of a similar cancer cell) can be present in a patient or a subject (e.g., a patient or a subject having a FGFR-associated cancer).

[00277] The term "increasing sensitivity to an anti -cancer drug" means a decrease in the rate of growth and/or proliferation of a resistant cancer cell (to an anti -cancer drug) when contacted with the anti-cancer drug and at least one of the compounds described herein, as compared to the rate of growth and/or proliferation of a resistant cancer cell when contacted with the anti-cancer drug alone.

[00278] The FGFR receptors (FGFR1, FGFR2, FGFR3, and FGFR4) share several structural features in common, including three extracellular immunoglobulin-like (Ig) domains, a hydrophobic transmembrane domain, and an intracellular split tyrosine kinase domain with a 14- amino acid insertion (Johnson et al., Adv. Cancer Res. 60: 1-40, 1993; and Wilkie et al., Curr. Biol. 5:500-507, 1995). Several isoforms of each FGFR have been identified and are the result of alternative splicing of their mRNAs (Johnson et al., Mol. Cell. Biol. 11 :4627-4634, 1995; and Chellaiah et al., J. Biol. Chem. 269: 11620-11627, 1994). A few of the receptor variants that result from this alternative splicing have different ligand binding specificities and affinities (Zimmer et al., J. Biol. Chem. 268:7899-7903, 1993; Cheon et al., Proc. Natl. Acad. Sci. U.S.A. 91 :989-993, 1994; and Miki et al., Proc. Natl. Acad. Sci. U.S.A. 89:246-250, 1992). Protein sequences for FGFR proteins and nucleic acids encoding FGFR proteins are known in the art. Exemplary amino acid sequences for exemplary wildtype isoforms of FGFR1 are SEQ ID NO: 1 and SEQ ID NO: 2. Exemplary amino acid sequences for exemplary wildtype isoforms of FGFR2 are SEQ ID NO: 2 and SEQ ID NO: 3. Exemplary amino acid sequences for exemplary wildtype isoforms of FGFR3 are SEQ ID NO: 5 and SEQ ID NO: 6. Exemplary amino acid sequences for exemplary wildypte isoforms of FGFR4 are SEQ ID NO: 7 and SEQ ID NO: 8.

[00279] Signaling by FGFRs regulates key biological processes including cell proliferation, survival, migration, and differentiation. Dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, has been associated with many types of cancer. For example, dysregulation of FGFRs can occur by multiple mechanisms, such as FGFR gene overexpression, FGFR gene amplification, activating mutations (e.g., point mutations or truncations), and chromosomal rearrangements that lead to FGFR fusion proteins. Dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, can result in (or cause in part) the development of a variety of different FGFR-associated cancers. Non-limiting examples of the types of FGFR-associated cancers and the dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, that causes (or causes in part) the development of the FGFR-associated cancers are listed in Tables A-D.

[00280] For example, dysregulation of a FGFR1 gene, a FGFR1 protein, or expression or activity, or level of the same, can include FGFR1 gene amplification, a FGFR1 gene fusion from those listed in Table C, and/or one or more point mutations selected from those listed in Table A (e.g., one of more of T141R, R445W, N546K, K656E, and G818R). Dysregulation of a FGFR2 gene, a FGFR2 protein, or expression or activity, or level of the same, can, e.g., include FGFR2 gene amplification, a FGFR2 gene fusion from those listed in Table C, and/or one or more point mutations selected from those listed in Table A (e.g., one or more of S252W, P253R, A315T, D336N, Y375C, C382R, V395D, D471N, I547V, N549K, N549K, N549Y, and K659E). Dysregulation of a FGFR3 gene, a FGFR3 protein, or expression or activity, or level of the same can, e.g., include FGFR3 gene amplification, a FGFR3 gene fusion from those listed in Table C, and/or one or more point mutations selected from those listed in Table A (e.g., one or more of S131L, R248C, S249C, G370C, S371C, Y373C, G380R, R399C, E627K, K650E, K650M, V677I, and D785 Y). Dysregulation of a FGFR4 gene, a FGFR4 protein, or expression or activity, or level of the same can, e.g., include FGFR4 gene amplification and/or one or more point mutations selected from those listed in Table A (e.g., one or more of R183S, R394Q, D425N, V510L, and R610H).

[00281] Additional examples of FGFR fusion proteins, FGFR point mutations, FGFR gene overexpression, or FGFR gene amplification that cause (or cause in part) the development of a FGFR-associated cancer are described in: Wu et al., Cancer Discovery 3 :636, 2013; Wesche et al., Biochem. J. 437: 199-213, 2011; Gallo et al., Cytokine Growth Factor Rev. 26:425-449, 2015; Parker et al., J. Pathol. 232:4-15, 2014; Katoh et al., Expert Rev. Anticancer Res. 10: 1375-1379, 2010; Chang et al., PLoS One 9:el05524, 2014; Kelleher et al., Carcinogenesis 34:2198-2205, 2013; Katoh et al., Med. Res. Rev. 34:280-300, 2014; Knights et al., Pharmacol. Therapeutics 125: 105-117, 2010; Turner et al., Sci. Transl. Med. 2:62ps56, 2010; Dutt et al., PLoS One 6(6):e20351, 2011; Weiss et al., Sci. Transl. Med. 2:62ra93, 2010; Becker et al., J. Neurophatol. Exp. Neurol. 74:743-754, 2015; Byron et al., PLoS One 7(2):e30801, 2012; van Rhihn et al., Eur. J. Human Genetics 10:819-824, 2002; Hart et al., Oncogene 19(29):3309-3320, 2000; Lin et al., Cancer Res. 68:664-673, 2008; and Helsten et al., Clin. Cancer Res., e-publication dated September 15, 2015 (each of which is incorporated herein by reference). Additional non-limiting aspects and examples of FGFR fusion proteins, FGFR point mutations, FGFR gene overexpression, or FGFR gene amplification are described below. [00282] Point Mutations

[00283] FGFR mutations that confer constitutive activation have been described in a number of congenital skeletal disorders (Turner N, Grose R., Nat Rev Cancer 2010; 10: 116-129). FGFRs have been identified as among the most commonly mutated kinase genes in human cancers, with mutations in FGFR2 and FGFR3 being most prevalent (Turner N., Grose R., Nat Rev Cancer 2010; 10: 116-129). For example, approximately 50% to 60% of non-muscle invasive and 17% of high-grade bladder cancers possess FGFR3 mutations that cause constitutive FGFR dimerization and activation (Cappellen D. et al., Nat Genet 1999; 23 : 18-20). Activating and oncogenic FGFR2 mutations located in the extracellular and kinase domains of the receptor have been described in 12% of endometrial carcinomas (Dutt A. et al., Proc Natl Acad Sci USA 2008; 105:8713-8717). Importantly, the FGFR2 mutations found in endometrial cancer confer sensitivity to FGFR inhibition (Dutt A. et al., Proc Natl Acad Sci USA 2008; 105:8713-8717). More recently, FGFR2 mutations have been described in 5% of squamous non-small cell lung cancers (NSCLC; Hammerman P. et al., Genomic characterization and targeted therapeutics in squamous cell lung cancer [abstract]. In: Proceedings of the 14th World Conference on Lung Cancer; 2011 3-7 July; Aurora (CO): International Association for the Study of Lung Cancer; 2011). FGFR3 mutations in bladder cancer and FGFR2 mutations in endometrial cancer are mutually exclusive with mutations in HRAS and KRAS, respectively. In addition, mutations in the FGFR4 kinase domain have been found in the childhood soft tissue sarcoma rhabdomyosarcoma, causing autophosphorylation and constitutive signaling (Taylor JG, et al., J Clin Invest 2009; 119:3395— 407). FGFR1, FGFR2, FGFR3, and/or FGFR4 can include one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty different point mutations (as compared to an appropriate corresponding wildtype FGFR1, FGFR2, FGFR3, or FGFR4 amino acid sequence, respectively). Non-limiting examples of point mutations in FGFR1, FGFR2, FGFR3, or FGFR4 that are thought to cause (or cause in- part) a FGFR-associated cancer are listed in Table A.

Table A. FGFR Point Mutations

FGFR Point Mutation Cancer FGFR1 N546K Glioma

K656E

FGFR1 N546K Neuroblastoma

FGFR1 N546K Malignant peripheral nerve sheath tumor

FGFR1 N546K Paraganglioma

FGFR1 N544K or N546K Glioblastoma

R574W or R576W

K654E or K656E

FGFR1 N544K or N546K Pilocytic astrocytoma

K653I or K655I

K654D or K656D

K654E or K656E

K654M or K656M

K654N or K656N

T656P or T658P

FGFR1 N544K or N546K Rosette forming glioneural tumor

K654E or K656E

FGFR1 N546K Pineal tumor

FGFR1 S125L Breast cancer

FGFR1 P126S ² Neuroendocrine carcinoma of the breast

FGFR1 P150S Colorectal cancer

A268S

S428F or S430F

A429S or A431 S

G608D or G610D

FGFR1 S125L Skin cancer

P252S

FGFR1 P252S Melanoma

FGFR1 R445W Cutaneous squamous cell carcinoma

FGFR1 R78H Prostate cancer

FGFR1 P25Q Lung cancer

G70R

T141R

P252T

W445W

W471L

V664L

FGFR1 T141R Non-small cell lung carcinoma

FGFR1 P252T Lung adenocarcinoma

FGFR1 V662L or V664L Lung large cell carcinoma

FGFR1 G70R Lung squamous cell carcinoma

T141R

FGFR1 A268S Stomach cancer

FGFR1 K596N or K598N Esophageal adenocarcinoma

FGFR1 S125L Gallbladder cancer

FGFR1 E334Q Head and neck squamous cell carcinoma FGFR1 P252R Spermatocyte seminoma

P252T

N330I

Y374C

C381R

R574W or R576W

FGFR1 P253R Oral squamous cell carcinoma

V392A or V393A

FGFR1 N546K Sarcoma

FGFR1 T141R Endometrial adenocarcinoma

FGFR1 T141R Urothelial carcinoma

G818R

FGFR1 R661P Dysembryoplastic neuroepithelial tumor ¹⁹

N546K

K656E

FGFR1 S125L Dedifferentiated liposarcoma ²⁴

FGFR1 V561M ²⁵ In vitro study

FGFR1 N546K ²⁶ In vitro study

V561M ²⁶

FGFR1 V561M ³⁰ In vitro study

FGFR1 N546K ³¹ In vitro study

V561M ³¹

FGFR1 V561M ³² In vitro study

Y563C ³²

FGFR2 V395D Salivary gland carcinoma

K659E

FGFR2 (A266 S267i Carcinoma of unknown primary

nsSTVV66D)

D336N

FGFR2 N549D or N550D Head and neck squamous cell carcinoma

N549K or N550K

FGFR2 C382R or C383R Esophageal cancer

FGFR2 Y375C or Y376C Adenoid cystic carcinoma

N549K

K641R or K642R

FGFR2 R203H Colorectal cancer (e.g., colorectal

R210Q adenocarcinoma)

A315T

D334N or D336N

Q361R

L551I or L552I

P582L or P583L

R664W or R665W

E777K or E778K

FGFR2 M71T ³ Lymphoma M186T

FGFR2 M71T ³ Bladder cancer

M186T

FGFR2 S24F Skin cancer

V77M

El 60 A

H213Y

E219K

G227E

V248D

R251Q

G271E

G305R

W474X

E475K

D530N

E574K

E636K

M640I

I642V

A648T

S688F

G701 S

P708S

R759X

R759Q

L770V

FGFR2 S24F Melanoma

V77M

W156*

El 60 A

H213Y

E219K

G227E

V248D

R251Q

G271E

G305R

T370R or T371R

W474X

E476K or E475K

D530N or D531N

E574K or E575K

E636K or E637K

M640I or M641I

I642V or 1643 V A648T or A649T

S688F or S689F

G701 S or G702S

P708S or P709S

R759X

R759Q or R760Q

L770V or L771V

FGFR2 N549Y Basal cell carcinoma

FGFR2 S252W Ovarian cancer or ovarian serous cancer

G272V

Y375C

FGFR2 Q212K Brain cancer

G462E

K659E or K660E

FGFR2 K659E or K660E Medulloblastoma

FGFR2 K659E or K660E Pilocytic astrocytoma

FGFR2 I547V Anaplastic astrocytoma

FGFR2 R203C Breast cancer

S252W

N549K or N550K

S587C or S588C

K659N or K660N

FGFR2 S252W Ovarian cancer, Fallopian tube carcinoma

FGFR2 A97T Cervical cancer or cervical squamous cell

S252L carcinoma

P256S

K405E or K406E

M584V or M585V

Y588D or Y589D

K659M or K660M

FGFR2 E116K Lung cancer

D138N

R190G

N211I

D247Y

P253L

P253R

D283N

W290C

G302W ⁴

A315T

S320C

I380V or I381V

C382R or C383R

K420I or K421I

E470Q or E471Q D479N or D480N

R496T ⁴

M537I or M538I

H544Q or H545Q

G583W or G584W ⁴

I590M or I591M

D602E or D603E

R612T

Q620K or Q621K

R625T or R626T

K659E or K660E

K659N or K660N

K660E

K660N

L772F or L773F

T786K or T787K

G847A ⁵

G870C ⁵

G1487C ⁵

FGFR2 E116K Lung adenocarcinoma

P253L

I380V or I381V

K420I or K421I

D479N or D480N

H544Q or H545Q

G583V or G584V

I590M or I591M

Q620K or Q621K

R625T or R626T

FGFR2 D138N Squamous cell lung cancer

N211I

D247Y

S252W

P253R

D283N

W290C

G302W ⁴

S320C ⁴

C382R or C383R

E470Q or E471Q

M537I or M538I

G583W or G584W

D602E or D603E

K659E or K660E

K659N or K660N

L772F or L773F

A315S

G336R or G338R

Y338C or Y340C

Y338H or Y340H

T341P

C340F or C342F

C340R or C342R

C340S or C342S

C340W or C342W

C340Y or C342Y

A344G

A344P

S347C

S352C or S354C

Y375C or Y376C

K526E or K527E

N549K or N550K

K641R or K642R

G462E or G463E

K659E or K660E

FGFR2 S167P ¹³ Gastric cancer

Splice site mutation

940-2A-G ¹³

FGFR2 M536I ¹⁴ Endometrial cancer

M538I ¹⁴

I548V ¹⁴

N550H ¹⁴

N550K ¹⁴

N550S ¹⁴

V565I ¹⁴

E566G ¹⁴

L618M ¹⁴

E719G ¹⁴

Y770IfsX14 ¹⁴

FGFR2 K660M ¹⁷ Uterine cancer

FGFR2 K659E ²¹ Head and neck adenoid cystic carcinoma

FGFR2 K659E ²³ Breast cancer

FGFR2 M536I ²⁷ Endometrial cancer

M538I ²⁷

I548V ²⁷

N550H ²⁷

N550K ²⁷

N550S ²⁷

V565I ²⁷

E566G ²⁷

L618M ²⁷ K642N ¹

K660E ¹

E719G ²⁷

Y770IfsX14 ²⁷

FGFR2 N550H ²⁸ Uterine cancer (K660M)

V565I ²⁸

E566G ²⁸

K660M ²⁸

FGFR2 V562L ²⁹ In vitro study

V564F ²⁹

FGFR2 M536I ³³ In vitro study

M538I ³³

I548V ³³

N550H ³³

N550K ³³

N550S ³³

V565I ³³

E566G ³³

L618M ³³

E719G ³³

Y770IfsX14 ³³

FGFR2 N550H ³⁴ In vitro study

V565I ³⁴

E566G ³⁴

K660M ³⁴

K660N ³⁴

FGFR2 V562L ³⁵ In vitro study

V564F ³⁵

FGFR3 R399C Gastric cancer, gastroesophageal junction adenocarcinoma

FGFR3 V677I Endometrial adenocarcinoma

FGFR3 R248C Carcinoma of unknown primary

S249C

R399C

D785Y

FGFR3 S249C Anal squamous cell carcinoma

G380R

FGFR3 R248C Gallbladder cancer

S249C

G370C or G372C

Y373C or Y375C

G380R or G382R

K650M or K652M

G697C or G699C

FGFR3 A341T Esophageal cancer or esophageal adenocarcinoma

FGFR3 R248C Cervical cancer

S249C

G372C

K652E

FGFR3 K650E Testicular cancer

K650Q

K650M

K650N

K650T

FGFR3 E466K Brain cancer

FGFR3 E466K or E468K Glioblastoma

R603Q or R605Q

FGFR3 K650E Glioma

FGFR3 Q209H Head and neck cancer

R248C

S249C

F386L or F388L

K413N or K415N

D617G

V630M

K650N or K652N

E686K

G697C

FGFR3 C228R Colorectal cancer

E322K

R399C or R401C

V677I or V679I

FGFR3 D646Y or D648Y Mesothelioma

FGFR3 T79S Lung cancer

R248C

S249C

R248H

S249C

G370C

S433C or S435C

K650E

K715M or K717M

T787K

FGFR3 R248C Non-small cell lung carcinoma

S249C

G370C

K650E

FGFR3 T79S Lung adenocarcinoma

FGFR3 R248C Squamous cell lung cancer

R248H S249C

G370C

S433C or S435C

K650E

K715M or K717M

T787K ¹¹

FGFR3 S131L Urothelial carcinoma

R248C

S249C

G370C

G372C

Y373C

Y375C

A393E

R399C

K650E

K650M

K652E

K652M

K652T

C742T ⁶

C746G ⁷

G1114T ¹²

A1124G ⁸

G1144A

C1178A

A1954C

A1954G ¹²

FGFR3 S249C Cervical cancer

K650E

FGFR3 R248C Lymphoepitheli oma

FGFR3 G197S Multiple myeloma

Y241C

R248C

S249C

P250R

G370C

S371C

Y373C or Y375C

G380R

G382D or G384D

F384L or F386L

S433C or S435C

A441T

A452S

K650E or K652E

S371C or S373C

Y373C or Y375C

G375C or G377C

G380R or G382R

A391E or A393E

N540K or N542K

N540S or N542S

N540T or N542T

N540V or N542V

K650E or K652E

K650M or K652M

K650N or K652N

K650Q or K652Q

K650T or K652T

G697C or G699C

807C or 809C

807G or 809G

807R or 809R ¹⁰

807T or 809T

FGFR3 Y373C Thymic cancer

FGFR3 G697C or G699C Oral squamous cell cancer

FGFR3 G370C Cutaneous squamous cell carcinoma

S371C

FGFR3 S249C Renal cell carcinoma

FGFR3 S249C Pancreatic exocrine carcinoma

FGFR3 R248C Sarcoma

E627K

FGFR3 R248C Seborrheic keratosis

S249C

G370C or G372C

S371C or S373C

A391E or A393E

K650E or K652E

K650M or K652M

FGFR3 S249C ¹⁶ Breast cancer

FGFR3-IIIb S248C ¹⁸ Bladder cancer

FGFR3-IIIC S248C ¹⁸ Bladder cancer

FGFR3 K650M ²⁴ Dedifferentiated liposarcoma

FGFR3 V555M ³⁷ KMS-11 myeloma cell line derivative

FGFR4 D425N Carcinoid

FGFR4 G388R Bladder cancer

FGFR4 G388R Stomach cancer

FGFR4 G388R Skin cancer

P716R

FGFR4 Q144E Brain cancer G388R

R394Q or R434Q

FGFR4 Q144E Glioblastoma

R394Q or R434Q

FGFR4 G388R Prostate cancer

R610H

FGFR4 G388R Head and neck squamous cell carcinoma

D631N or D671N

FGFR4 G388R Liver cancer

R394Q

FGFR4 G388R Colorectal cancer (e.g., colorectal

P543Q or P583Q adenocarcinoma)

A574S or A614S

FGFR4 E326K Breast cancer

Y367C

G388R

A444T or A484T

V510M or V550M

V510L

V550E

V550L

FGFR4 V550M Neuroendocrine carcinoma of the breast

FGFR4 G388R Mammary carcinoma

FGFR4 Q144E Lung cancer

R183S

S232I

G388R

R434Q

R616G

E681K

P712T

A729G

S732N or S772N

Q738K

FGFR4 R183S Non-small cell lung carcinoma

FGFR4 S732N or S772N Lung neuroendocrine carcinoma

FGFR4 Q144E Lung squamous cell carcinoma

R394Q or R434Q

FGFR4 R183S Lung adenocarcinoma

S232I

R576G or R616G

E641K or E681K

P672T or P712T

A689G or A729G

FGFR4 G388R Sarcoma (e.g., soft tissue sarcoma)

K535 E550

FGFR4 C56S Rhabdomyosarcoma

R72L

T112A

T122A

A175T

R234H

G388R

N495D or N535D

N495K or N535K

V510E or V550E

V510L or V550L

V510M or V550M

A514V or A554V

G536D or G576D

FGFR4 G183C of tyrosine Stomach cancer

kinase domain ¹⁵

G596C ¹⁵

G636C ¹⁵

FGFR4 P568Q ²² Lung cancer

R59W ²²

FGFR4 G388R ³⁶ Breast cancer

¹ Each isoform of FGFRl, FGFR2, FGFR3, and FGFR4 has a different length, and thus, the corresponding amino acid position in one isoform of FGFRl, FGFR2, FGFR3, and FGFR4 may be different in another isoform of FGFRl, FGFR2, FGFR3, and FGFR4. The position of each point mutation listed above in each isoform of FGFRl, FGFR2, FGFR3, and FGFR4 can be identified by first identifying the isoform(s) of FGFRl, FGFR2, FGFR3, or FGFR4 which correspond to the specific point mutation listed above (by amino acid position and starting amino acid), and then aligning the amino acid sequence of identified isoform(s) of FGFRl, FGFR2, FGFR3, or FGFR4 with the amino acid sequences of the other isoforms of FGFRl, FGFR2, FGFR3, or FGFR4.

² Ang et al., Diagn. Mol. Pathol. Feb 24, 2014 (Epub ahead of print).

³ U.S. Patent Application Publication No. 2011/0008347.

⁴ Gallo et al., Cytokine Growth Factor Rev. 26:425-449, 2015.

⁵ Davies et al., J. Cancer Res. 65:7591, 2005.

6 Kelleher et al., Carcinogenesis 34:2198, 2013.

⁷ Cazier et al., Nat. Commun. 5:3756, 2014.

⁸ Liu et al., Genet. Mol. Res. 13 : 1109, 2014.

⁹ Trudel et al., Blood 107:4039, 2006.

¹⁰ Gallo et al., Cytokine Growth Factor Rev. 26:425, 2015.

¹¹ Liao et al., Cancer Res. 73 :5195-5205, 2013.

¹² Martincorena et al., Science 348:880 (2015).

¹³ U.S. Patent Application Publication No. US2016/0235744A1.

¹⁴ U.S. Patent No. 9254288B2.

¹⁵ U.S. Patent No. 9267176B2. ¹⁶ U.S. Patent Application Publication No. S2016/0215350A1.

¹⁷ European Patent Application Publication No. EP3023101 Al .

¹⁸ PCT Patent Application Publication No. WO2016105503A1.

¹⁹ Rivera et al., Acta. Neuropathol., U \(6):Ml-63, 2016.

²⁰ Lo Iacono et al., Oncotarget, 7(12): 14394-404, 2016.

²¹ Deeken et al., Journal of Clinical Oncology, 34:Supp. Supplement 15, pp. iii93. Abstract Number: el 7520, 2016 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

²² Sullivan et al., Journal of Clinical Oncology, 34:Supp. Supplement 15, pp. iii93. Abstract Number: 11596, 2016 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

²³ Nguyen et al., Molecular Cancer Therapeutics, Vol. 14, No. 12, Supp.2, Abstract Number: CI 99, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2015.

²⁴ Li et al., Hum. Pathol, 55: 143-50, 2016.

²⁵ European Patent No. EP2203449B1.

²⁶ Yoza et al., Genes Cells., (10): 1049-1058, 2016.

²⁷ U.S. Patent No. 9,254,288B2.

²⁸ European Patent Application Publication No. 3023101 Al .

²⁹ PCT Application Publication No. WO 2015/099127A1.

³⁰ European Patent No. EP2203449B1.

3 ¹ Yoza et al., Genes Cells., (10): 1049-1058, 2016.

3 ² Bunney et al., EbioMedicine, 2(3): 194-204, 2015.

³³ Byron et al., Neoplasia, 15(8):975-88, 2013.

³⁴ European Patent Application Publication No. EP3023101 Al .

³⁵ PCT Application Publication No. WO 2015/099127A1.

3 ⁶ Thussbas et al., J. Clin. Oncol, 24(23):3747-55, 2006.

3 ⁷ Chell et al., Oncogene, 32(25):3059-70, 2013.

FGFR Gene Amplification

[00284] FGFR. gene amplification often leads to FGFR overexpression, which can provoke ligand-independent signaling. In breast cancer, amplification of the genomic locus of FGFRl (8 I I -12) occurs in approximately 10% of predominantly estrogen receptor (ER)-positive patients (Taylor JG, et al., J Clin Invest 2009; 119:3395-4307). In vitro studies support the potential oncogenic nature of FGFRl amplification (Welm BE, et al., J Cell Biol 2002; 157:703- 14); however, due to the gene-dense nature of the 8pl 1-12 amplicon in breast cancer, there is continuing debate about the identity of the driving oncogene. More recently, FGFRl has been found to be amplified in 22% of squamous NSCLC (Weiss J, et al., Sci Transl Med 2010; 2:62ra93), and these amplifications seem to confer dependence upon FGFR signaling. Unlike the broad amplicon containing FGFRl found in breast cancers, the amplicon in lung is more focal; it remains to be seen if these differences influence the degree of oncogenic addiction to FGFR1. FGFR2 amplifications have been reported in up to 10% of gastric cancers, most of which are diffuse-type with relatively poor prognosis (Kunii K, et al., Cancer Res 2008; 68:2340-2348). Further, in an G Ri-amplified gastric cancer cell line, Snu-16, FGFR2 downregulation led to significant inhibition of cell growth and survival that further translated into tumor growth regression in vivo (Xie L, et al., AZD4547, a potent and selective inhibitor of FGF-receptor tyrosine kinases 1, 2 and 3, inhibits the growth of FGF-receptor 2 driven gastric cancer models in vitro and in vivo. In: Proceedings of the American Association of Cancer Research Annual Meeting; 2011 April 2-6; Orlando (FL). Philadelphia (PA): AACR; 2011. Abstract nr 1643). In some gastric cancer cell lines, FGFR2 amplification is accompanied by deletion of the coding exon located proximal to the C-terminus (Ueda T, et al., Cancer Res 1999; 59:6080-6086). This deletion impedes receptor internalization, thereby contributing to constitutive activation of the receptor. The presence of FGFR2 gene amplifications in gastric cancer is associated with sensitivity to inhibition of FGFR signaling by tyrosine kinase inhibitors and monoclonal antibodies in preclinical models (Zhao G, et al., Mol Cancer Ther 2011; 10:2200-2210; Zhao WM, et al., Clin Cancer Res 2010; 16:5750-5758). Non-limiting examples of FGFR-associated cancers that are caused (or caused in-part) by the amplification and/or overexpression of the FGFR1 gene, the FGFR2 gene, the FGFR3 gene, or the FGFR4 gene are listed in Table B. rerespression or Amplification of FGFR Genes smd FGFR-Associated Cancer Type of Dysregulaiion FGFR- Associated Cancer

FGFR1 Amplification or Breast cancer or carcinoma (e.g.,

Overexpression hormone receptor-positive breast

cancer, ductal carcinoma in situ

(breast)), pancreatic ductal

adenocarcinoma, pancreatic

exocrine carcinoma, smoking- associated lung cancer, small cell lung cancer, lung

adenocarcinoma, non-small cell lung cancer, squamous cell lung cancer or carcinoma, prostate

cancer or carcinoma, ovarian

cancer, fallopian tube carcinoma, bladder cancer,

rhabdomyosarcoma, head and neck carcinoma (e.g., head and neck squamous cell carcinoma), esophageal cancer (e.g., esophageal squamous cell carcinoma), sarcoma (e.g., osteosarcoma), hepatocellular carcinoma, renal cell carcinoma, colorectal cancer (e.g., colorectal adenocarcinoma), prostate cancer, salivary gland tumors, glioblastoma multiforme, urinary bladder cancer, urothelial carcinoma, carcinoma of unknown primary, squamous non- lung tumors, gastric cancer, gastroesophageal junction carcinoma, adenoid cystic carcinoma, anal squamous cell carcinoma, oral squamous cell carcinoma, cholangiocarcinoma, hemangioendothelioma, leiomyosarcoma, melanoma, neuroendocrine carcinoma, squamous cell carcinoma, uterine carcinosarcoma

FGFR2 Amplification Gastric cancer, gastroesophageal junction adenocarcinoma, breast cancer (e.g., triple-negative breast cancer), colon cancer, colorectal cancer (e.g., colorectal adenocarcinoma), urothelial cancer, bladder adenocarcinoma, carcinoma of unknown primary, cholangiocarcinoma, endometrial adenocarcinoma, esophageal adenocarcinoma, gallbladder carcinoma, ovarian cancer, fallopian tube carcinoma, pancreatic exocrine carcinoma, sarcoma, squamous cell carcinoma

FGFR2 Overexpression Myxoid lipocarcinoma, rectal cancer, renal cell carcinoma, breast cancer

FGFR3 Upregulation of Activity Colorectal cancer, hepatocellular carcinoma, pancreatic exocrine carcinoma

FGFR3 Overexpression Multiple myeloma, thyroid

carcinoma,

FGFR3 Amplification Bladder cancer and salivary

adenoid cystic cancer, urothelial cancer, breast cancer, carcinoid, carcinoma of unknown primary, colorectal cancer (e.g., colorectal adenocarcinoma), gallbladder

carcinoma, gastric cancer,

gastroesophageal junction

adenocarcinoma, glioma,

mesothelioma, non-small cell

lung carcinoma, small cell lung cancer, ovarian cancer, fallopian tube carcinoma, pancreatic

exocrine carcinoma

FGFR4 Amplification Rhabdomyosarcoma, prostate

cancer or carcinoma, breast

cancer, urothelial cancer,

carcinoid, carcinoma of unknown primary, esophageal

adenocarcinoma, head and neck carcinoma, hepatocellular

carcinoma, non-small cell lung

carcinoma, ovarian cancer,

fallopian tube carcinoma,

peritoneal carcinoma, renal cell carcinoma

FGFR4 Upregulation of Activity Colorectal cancer, hepatocellular

carcinoma, adrenal carcinoma,

breast cancer

FGFR4 Overexpression Pancreatic intraepithelial

neoplasia, and pancreatic ductal adenocarcinoma

[00285] Fusion Proteins

[00286] Several FGFR translocations have been identified to play a role in defects in development and in a wide range of malignancies, whereby chromosomal rearrangement results in a nucleic acid sequence encoding a fusion protein that includes a kinase domain of an FGFR protein and an amino acid sequence from a partner protein. In some examples, fusion proteins are located in the cytosol, do not undergo lysosomal degradation, are not susceptible to feedback inhibition, and are permanently dimerized in the absence of ligand. Such translocations can lead to FGFR overexpression, permanent dimerization of the fusion protein-FGFR complex, and continuous signaling. The mechanism of proliferation is dependent on the type of fusion protein and seems to be disease specific (Jackson CC, et al., Hum Pathol 2010;41 :461-476). For example, a t(4; 14) intergenic translocation, bringing FGFR3 and the adjacent Multiple Myeloma SET domain {MMSET) gene under the control of the Ig heavy chain (IGH) promoter, has been identified in 10% to 20% of multiple myelomas and is associated with poor prognosis and dependence upon FGFR signaling (Chesi M, et al., Nat Genet 1997; 16:260-264; Qing J, et al., J Clin Invest 2009; 119: 1216-1229). FGFR3 translocations are rarely found in prodromal conditions of multiple myeloma, implicating these translocations in the conversion to full multiple myeloma. Additional examples of FGFR fusion proteins and the specific FGFR-associated cancers that they cause (or cause in part) are listed in Table C. The expression of FGFR fusion proteins can, e.g., cause (or cause in part) cholangiocarcinoma, bladder cancer, lung cancer, and breast cancer. Additional examples of FGFR fusion proteins are known in the art.

Table C. FGFR Fusion Proteins

syndrome

FGFR1 FOP/FGFR10P1 Myeloproliferative disorder stem cell leukemia/lymphoma syndrome and lung cancer, myeloid and lymphoid neoplasms

FGFR1 ZNF 198/ZMYM2 Myeloid and lymphoid

neoplasms, 8pl l

myeloproliferative disorder

FGFR1 CEPl lO/CEPl/centriolin Myeloid and lymphoid

neoplasms; 8pl l

myeloproliferative disorder

FGFR1 CEPl lO/CEPl/centriolin Myeloproliferative disorder stem cell leukemia/lymphoma syndrome; 8pl l

myeloproliferative disorder

FGFR1 BCR Myeloproliferative disorder stem cell leukemia/lymphoma syndrome, 8pl l

myeloproliferative disorder, AML, CML, ALL (e.g., B-ALL)

FGFR1 LRRFIP1 Myeloproliferative disorder stem cell leukemia/lymphoma syndrome, 8pl l

myeloproliferative disorder, ALL, CMD, AML

FGFR1 CPSF6 Hematological Malignancies;

8pl l myeloproliferative disorder, CMD, MPN, AML

FGFR1 BAG4 Lung squamous cell carcinoma, non-small cell lung cancer

FGFR1 ERLIN2 Breast cancer

FGFR1 TREVI24/TIF 1 Myeloproliferative disorder stem cell leukemia/lymphoma syndrome, 8pl l

myeloproliferative disorder, AML, MPN

FGFR1 MY018A Myeloproliferative disorder stem cell leukemia/lymphoma syndrome, 8pl l

myeloproliferative disorder, MPN, AML

FGFR1 CPSF6 Myeloproliferative disorder stem cell leukemia/lymphoma syndrome

FGFR1 HERV-K Myeloproliferative disorder stem cell leukemia/lymphoma syndrome, 8pl l

myeloproliferative disorder, CMD, MPD, A ML

FGFR1 PLAG1 Head and neck cancer,

pleomorphic salivary gland adenocarcinoma

FGFR1 CUX1 Leukemia, lymphoma, 8pl l

myeloproliferative disorder, AML, MPN

FGFR1 FOXOl Rhabdomyosarcoma, alveolar rhabdomyosarcoma

FGFR1 SQSTM1 Leukemia

FGFR1 FN1 Phosphatunc mesenchymal tumor

FGFR1 NUP98 8pl l myeloproliferative disorder

FGFR1 RA BP2/NUP358 8pl l myeloproliferative disorder,

MPN, AML

FGFR1 TPR 8pl l myeloproliferative disorder,

MPN, T-lymphoblastic lymphoma, MPN T- lymphoblastic lymphoma

FGFR1 ZNF703 Breast cancer

FGFR1 NTM Bladder cancer, bladder urothelial

(transition cell) carcinoma

FGFR1 ¹ ZNF343 Osteosarcoma

FGFR1 ³ FOP2 AML

FGFR1 ⁷ OP2 AML

FGFR1 ¹¹ TKD Glioma

FGFR1 ¹³ TACC1 Gastrointestinal stromal tumors

FGFR1 ¹⁵ ADAM32 Embryonal Rhabdomyosarcoma

FGFR2 CCAR2 Lung squamous cell carcinoma

FGFR2 CD44 Gastric cancer

FGFR2 BICC1 Metastatic cholangiocarcinoma, cholangiocarcinoma, colorectal cancer, hepatocellular carcinoma, carcinoma of unknown primary

FGFR2 SLC45A3 Prostate cancer

FGFR2 AFF3 Breast cancer

FGFR2 CASP7 Breast cancer

FGFR2 CCDC6 Breast cancer,

cholangiocarcinoma

FGFR2 KIAA1598/SHOOTIN1 Cholangiocarcinoma, intrahepatic cholangiocarcinoma

FGFR2 KIAA1967 Lung squamous cell cancer

FGFR2 OFD1 Thyroid cancer FGFR2 CIT Lung adenocarcinoma

FGFR2 AHCYL1 Cholangiocarcinoma

FGFR2 PPHLN1 Cholangiocarcinoma

FGFR2 TACC3 Cholangiocarcinoma, intrahepatic cholangiocarcinoma

FGFR2 MGEA5 Cholangiocarcinoma, intrahepatic cholangiocarcinoma

FGFR2 FAM76A Ovarian cancer

FGFR2 FRAG1 Osteosarcoma

FGFR2 PM1 Colorectal carcinoma (e.g.,

colorectal adenocarcinoma), large cell lung carcinoma

FGFR2 TACC2 Cancer of unknown primary, gastric cancer, gastoesophageal junction adenocarcinoma

FGFR2 C10orf68 Gastric cancer, gastroesophageal junction adenocarcinoma

FGFR2 NCALD Breast carcinoma

FGFR2 NOL4 Cholangiocarcinoma

FGFR2 PPAPDC1A Prostate carcinoma

FGFR2 ⁵ PARK2 Cholangiocarcinoma

FGFR2 ⁵ ZDHHC6 Cholangiocarcinoma

FGFR2 ⁶ TXLNA Biliary tract cancer

FGFR2 ⁶ KCTD1 Biliary tract cancer

FGFR2 ⁶ BICC1 type 2 Biliary tract cancer

FGFR2 ⁸ CCDC147 Cholangiocarcinoma

FGFR2 ⁸ VCL Cholangiocarcinoma

FGFR2 ⁹ BUB1 Cholangiocarcinoma

FGFR2 ⁹ CDCA8 Cholangiocarcinoma

FGFR2 ⁹ DNAH5 Cholangiocarcinoma

FGFR2 ¹⁰ FGFR2-OGDH Anaplastic thyroid carcinoma

FGFR2 ¹² CCDC3 Breast carcinoma

FGFR2 ¹⁴ KIAA217 Cholangiocarcinoma

FGFR2 ¹⁶ KIAA1598 Intrahepatic cholangiocarcinoma

FGFR3 ELAVL3 Glioblastoma multiforme

FGFR3 TACC3 Bladder cancer, oral cancer, head and neck squamous cell carcinoma, lung squamous cell carcinoma, cervical carcinoma or cancer, cervical adenocarcinoma, gallbladder cancer or carcinoma, lung adenocarcinoma, non-small cell lung cancer, glioma, glioblastoma multiforme, carcinoma of unknown primary,

endometrial adenocarcinoma,

glioma, renal cell carcinoma,

urothelial carcinoma, pancreatic exocrine carcinoma, urothelial carcinoma

FGFR3 BAIAP2L1 Bladder cancer, lung

adenocarcinoma, lung squamous cell carcinoma

FGFR3 IGH Multiple myeloma

FGFR3 MMSET Multiple myeloma

FGFR3 TEL/ETV6 T-cell lymphoma

FGFR3 JAKMIP1 Bladder cancer, bladder urothelial

(transition cell) carcinoma,

urothelial carcinoma

FGFR3 TNIP2 Bladder urothelial (transition cell)

carcinoma, urothelial carcinoma

FGFR3 WHSC1 Breast carcinoma

FGFR3 ADD 1 Urothelial carcinoma

FGFR3 ⁴ RANBP17 Breast carcinoma

^aroy et al., PloS One; l l(9):e0163859. doi: 10.1371/journal.pone.0163859, 2016.

² Ren et al., Int. J. Cancer, 139(4): 836-40, 2016.

³ Marchwicka et al., CellBiosci., 6:7. doi: 10.1186/sl3578-016-0075-9, 2016.

⁴ PCT Patent Application Publication No. WO 2014/071419A2.

⁵ U.S. Patent Application Publication No. 2015/0366866A1.

⁶ PCT Patent Application Publication No. WO 2016/084883 Al .

⁷ PCT Patent Application Publication No. WO 2016/030509A1.

⁸ PCT Patent Application Publication No. WO 2015/150900A2.

⁹ PCT Patent Application Publication No. WO 2015/120094A2.

¹⁰ Kasaian et al., BMC Cancer., 15:984, 2015.

¹¹ Vakil et al., Neuro-Oncology, 18:Supp. Supplement 3, pp. iii93. Abstract Number: LG-64, 17th International Symposium on Pediatric Neuro-Oncology, Liverpool, United Kingdom, 2016.

¹² Astsaturov et al., Journal of Clinical Oncology, 34:Supp. Supplement 15, Abstract Number: 11504, 2016 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

¹³ Heinrich et al., Journal of Clinical Oncology, 34:Supp. Supplement 15, Abstract Number: 11012, 2016 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

¹⁴ Hall et al., Molecular Cancer Therapeutics, Vol. 14, No. 12, Supp.2, Abstract Number: B151, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, 2015.

¹⁵ Reuther et al., Journal of Molecular Diagnostics, Vol. 17, No. 6, pp. 813, Abstract Number: ST02, 2015 Annual Meeting of the Association for Molecular Pathology, Austin, TX.

¹⁶ Moeini et al., Clin. Cancer. Res., 22(2):291-300, 2016. [00287] Autocrine and paracrine signaling

Although many of the mechanisms discussed so far are the result of genetic dysregulation of the FGF/FGFR signaling axis, ligand-dependent signaling is also likely to play a key role in cancer development (e.g., described as "Upregulation of Activity" in Table 2). Autocrine FGF overproduction has been reported in many tumor types (Turner N, Grose R., Nat Rev Cancer 2010; 10: 116-129). In vitro studies have shown that FGF5 overexpression has been associated with a number of tumor cell lines (lung, esophagus, melanoma, colon, and prostate; Hanada K, et al., Cancer Res 2001;61 :5511-5516), and in hepatocellular carcinomas (HCC), the upregulation of FGF2, 8, 17, and 18 initiates autocrine growth stimulation, cell survival, and neoangiogenesis (Uematsu S, et al., J Gastroenterol Hepatol 2005;20:583-588; Hu MC, et al., Mol Cell Biol 1998; 18:6063-6074; Kin M, et al.,. J Hepatol 1997;27:677-687; Gauglhofer C, et al., Hepatology 2011;53 :854-864). Further, HCC has been found to develop in transgenic mice overexpressing the hormonal FGF 19 (Nicholes K, et al., Am J Pathol 2002; 160:2295-2307), and FGF 19 is found on an amplicon on chromosome 1 lq that also invariably contains the adjacent FGF ^' 3, FGF 4, and Cyclin Dl (CCND1) genes. This amplicon is found in various diseases, including head and neck squamous cell carcinoma, breast cancer, and squamous NSCLC. Although there is uncertainty about the key oncogenic gene on this amplicon or a presumption that it is CCND1, genetic knockdown of FGF 19 inhibits the growth of HCC cell lines carrying the amplicon (Sawey ET, et al., Cancer Cell 2011; 19:347-358). Autocrine FGF2-FGFR1 feedback loops have also been reported in NSCLC cell lines and in human melanomas grown as subcutaneous tumors in nude mice (Marek L, et al., Mol Pharmacol 2009; 75: 196-207; Wang Y, Becker D., Nat Med 1997; 3 :887-893).

[00288] Paracrine production of FGFs has also been reported in multiple tumor types. High levels of serum FGF2 have been observed in small cell lung cancer and are associated with a poor prognosis (Ruotsalainen T, et al., Cancer Epidemiol Biomarkers Prev 2002; 11 : 1492-1495), possibly because of an FGF2-mediated cytoprotective effect, whereby the expression of antiapoptotic proteins are upregulated, promoting resistance to current anticancer treatments (Pardo OE, et al., EMBO J 2006;25:3078-3088). Increased paracrine expression of one or more of FGF 1, 2, 4, 5, 8, and 18 has been found to promote tumor neoangiogenesis in preclinical models via the main endothelial FGFRs, FGFR1 and 2 (Presta M, et al., Cytokine Growth Factor Rev 2005; 16: 159-178). Poor prognosis has been associated with neoangiogenesis in ovarian cancer and melanomas (Birrer MJ, et al., J Clin Oncol 2007; 25:2281-2287).

[00289] Altered FGFR mRNA splicing

[00290] In addition to overexpression of FGFs, altered splicing of FGFR mRNAs is another mechanism by which ligand-dependent signaling is upregulated. Altered FGFR mRNA splicing can allow tumor cells to be stimulated by a broader range of FGFs than would be capable under normal physiologic conditions (Zhang X, et al., J Biol Chem 2006; 281 : 15694-15700). Altered splicing of the Iglll domains in FGFRs 1, 2, and 3 can switch receptor binding affinity in cancer cells towards FGFs found in the healthy stroma, creating an aberrant paracrine signaling loop (Wesche J, Haglund K, Haugsten EM. et al., Biochem J 2011; 437: 199-213). In bladder and prostate cancer cell lines, a switch from the FGFR2-IIIb isoform to the IIIc isoform has been associated with tumor progression, epithelial-mesenchymal transition, and increased invasiveness (Wesche J, et al., Biochem J 2011; 437: 199-213).

[00291] Non-limiting examples of FGFR-associated cancers include urothelial carcinoma, breast carcinoma or cancer (e.g., hormone receptor-positive breast cancer, triple-negative breast cancer, neuroendocrine carcinoma of the breast, mammary carcinoma), endometriod endometrial cancer or endometrial cancer (e.g., endometrial adenocarcinoma), ovarian carcinoma or cancer (e.g., ovarian serous cancer), brain cancer (e.g., glioneural tumors, glioma, pilocytic astrocytoma, rosette-forming glioneural tumor), cholangiocarcinoma (e.g., intrahepatic cholangiocarcinoma, metastatic cholangiocarcinoma, medulloblastoma), gastric or stomach cancer (e.g., gastric adenocarcinoma), gastrointestinal stromal tumors, lung cancer (e.g., non-small cell lung carcinoma or lung large cell carcinoma, smoking-associated lung cancer, small cell lung cancer, lung adenocarcinoma, squamous cell lung cancer or carcinoma, lung neuroendocrine carcinoma), pancreatic cancer (e.g., pancreatic exocrine carcinoma, pancreatic ductal adenocarcinoma, pancreatic intraepithelial neoplasia), prostate cancer, colorectal carcinoma or cancer, rectal cancer, renal cell carcinoma, neuroendocrine carcinoma, head and neck (squamous) carcinoma or head and neck adenoid cystic carcinoma, skin cancer (e.g., melanoma), leiomyosarcoma, sarcoma (e.g., osteosarcoma or soft tissue sarcoma), osteosarcoma, bladder cancer, uterine cancer, urinary bladder cancer, rhabdomyosarcoma (e.g., alveolar rhabdomyosarcoma or embryonal rhabdomyosarcoma), esophageal cancer (e.g., esophageal adenocarcinoma), hepatocellular carcinoma or liver cancer, biliary tract cancer, salivary gland tumors (e.g., pleomorphic salivary gland adenocarcinoma), glioblatoma multiforme, myxoid lipocarcinoma, oral cancer (e.g., oral squamous cell carcinoma), thyroid cancer or carcinoma, anaplastic thyroid carcinoma, adenoid cystic carcinoma (e.g., salivary adenoid cystic cancer), glioblastoma multiforme, myeloproliferative disorders/hematological malignancies (e.g., 8pl l myeloproliferative syndrome, lymphoma (e.g., T-lymphoblastic lymphoma, T-cell lymphoma, B-cell lymphoma), leukemia (e.g., acute lymphoblatic leukemia (ALL), chronic myelogenous leukemia (CML), acute myeloid leukemia (AML)), myeloproliferative neoplasm, myeloid and lymphoid neoplasms, stem cell myeloproliferative disorders, myeloproliferative disorder stem cell leukemia/lymphoma syndrome, chronic myeloid disorder, myeloma (e.g., multiple myeloma)), phosphaturic mesenchymal tumor, cervical cancer (e.g., cervical squamous cell carcinoma), gallbladder cancer, spermatocytic seminoma, seborrheic keratosis, testicular cancer, mesothelioma, dysembryoplastic neuroepithelial tumor, and dedifferentiated liposarcoma. Additional examples of FGFR- associated cancers are listed in Tables 1-3.

[00292] Non-limiting examples of additional FGFR-associated diseases that are caused by dysregulation of FGFR are listed in Table D. A subject having any of the additional FGFR- associated diseases described herein or known in the art can be treated by administering to the subject a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein).

Table D. Additional FGFR-associated diseases caused or caused in part by deregulation of a

FGFR FGFR

A167S

V174A

C178S

D224H

Y228D

G237D

G237S

1239T

L245P

R250Q

R250W

R254Q

G270D

V273M

E274G

V273M

E274G

C277Y

P283R

S332C

Y339C

L342S

A343V

S346C

G348R

P366L

R470L

P483T

A520T

I538V

V607M

K618N

H621R

R622G

R622Q

W666R

E670K

A671P

S685F

G687R

E692G

I693F

G703R

G703S

M719R

P722H P745S

D768Y

P772S

V975I

FGFR1 N330I Osteoglyoph

Y374C Dysplasia

C381R

FGFR1 L165S Hartsfield Syndrome

L191 S

G490R

D623Y

R627T

N628K

C725Y

FGFR1 BOOT Trigonocephaly 1

FGFR1 C.730 731insG Craniosynostosis 14

FGFR1 N546K Encephalocraniocutaneous

K656E lipomatosis ³¹

FGFR1 P33Afs* 17 Kallman syndrome 37

Y654*

W4C

S96C

M719V

A353T in alternatively spliced

xon 8A

FGFR1 FNl Tumor-induced

osteomalacia (TIP)

FGFR1 C178S Kallman syndrome 39

FGFR1 R473Q Congenital heart disease associated with

ambiguous genitalia ⁴¹

FGFR2 D321A Pfeiffer Syndrome

T341P

C342R

C342Y

FGFR2 S267P Crouzon Syndrome 10

C278F

Q289P

Y328C

Y340H

C342Y

C342R

C342S

72

FGFR3 R621H CATSHL syndrome Yong-Xing et al., Hum. Mol. Genet. 9(13):2001-2008, 2000.

Eeva-Maria Laitinen et al., PLoS One 7(6):e39450, 2012.

Hart et al., Oncogene 19(29):3309-3320, 2000.

Shiang et al., Cell 76:335-342, 1994.

Rosseau et al., Nature 371 :252-254, 1994.

Tavormina et al., Nature Genet. 9:321-328, 1995.

Bellus et al., Nature Genet. 10:357-359, 1995.

Muenke et al., Nature Genet. 8:269-274, 1994.

Rutland et al., Nature Genet. 9: 173-176, 1995.

Reardon et al., Nature Genet. 8:98-103, 1994.

1 Wilkie et al., Nature Genet. 9: 165-172, 1995.

Jabs et al., Nature Genet. 8:275-279, 1994.

Japanese Patent No. JP05868992B2.

Ye et al., Plast. Reconstr. Surg., 137(3):952-61, 2016.

U.S. Patent No. 9447098B2.

Bellus et al., Am. J. Med. Genet. 85(l):53-65, 1999.

PCT Patent Application Publication No. WO2016139227A1.

Australian Patent Application Publication No. AU2014362227 Al . Chinese Patent No. CN102741256B. ²⁰ Ohishi et al., Am. J. Med. Genet. A., doi: 10.1002/ajmg.a.37992, 2016.

²¹ Nagahara et al., Clin. Pediatr. Endocrinol, 25(3): 103-106, 2016.

²² Hibberd et al., Am. J. Med. Genet. A., doi: 10.1002/ajmg.a.37862, 2016.

²³ Dias et al., Exp. Mol. Pathol, 101(1): 116-23, 2016.

²⁴ Lin et al., Mol. Med. Rep., 14(3): 1941-6, 2016.

²⁵ Barnett et al., Hum. Mutat, 37(9):955-63, 2016.

²⁶ Krstevska-Konstantinova et a\., Med. Arch., 70(2): 148-50, 2016.

²⁷ Kuentz et al., Br. J. Dermatol, doi: 10.1111/bjd.14681, 2016.

²⁸ Ron et al., Am. J. Case Rep., 15; 17:254-8, 2016.

²⁹ Fernandes et al., Am. J. Med. Genet. A., 170(6): 1532-7, 2016.

³⁰ Lindy et al., Am. J. Med. Genet. A., 170(6): 1573-9, 2016.

³¹ Bennett et al., Am. J. Hum. Genet., 98(3):579-87, 2016.

³² Ichiyama et al., J. Eur. Acad. Dermatol. Venereol, 30(3):442-5, 2016.

³³ Zhao et al., Int. J. Clin. Exp. Med, 8(10): 19241-9, 2015.

³⁴ Hasegawa et al., Am. J. Med. Genet. A., 170A(5): 1370-2, 2016.

³⁵ Legeai-Mallet, Endocr. Dev., 30:98-105, 2016.

³⁶ Takagi, Am. J. Med. Genet. A., 167A(11):2851-4, 2015.

³⁷ Goncalves, Fertil. Steril, 104(5): 1261-7.el, 2015.

³⁸ Miller et al., Journal of Clinical Oncology, 34:Supp. Supplement 15, pp. iii93. Abstract Number: e22500, 2016 Annual Meeting of the American Society of Clinical Oncology, Chicago, IL.

³⁹ Sarabipour et al., J. Mol. Biol, 428(20):3903-3910, 2016.

⁴⁰ Escobar et al., Am. J. Med. Genet. A., 170(7): 1908-11, 2016.

⁴¹ Mazen et al., Sex Dev., 10(1): 16-22, 2016.

Additional point mutations in FGFR1, FGFR2, FGFR3, and FGFR4 have been identified to result in resistance of a cancer cell to a FGFR inhibitor. Non-limiting examples of these mutations are depicted in Table E. In some embodiments, a FGFR-associated disorder (e.g., any of the cancers described herein) can have one or more of the point mutations listed in Table D. Also provided herein are methods of treating a subject that include identifying a subject having one or more of the point mutations listed in Table D, and administering to the identified subject a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt of solvate thereof. Also provided are methods of treating a subject that include administering to a subject identified as having one or more of the point mutations listed in Table D a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein).

Table E. Exemplary FGFR Inhibitor Resistance Point Mutations

FGFR Point Mutation Cancer FGFR1 V561M ³ In vitro study

FGFR1 N546K ⁵ In vitro study

V561M ⁵

FGFR1 V561M ⁷ In vitro study

Y563C ⁷

FGFR2 M536I ¹ In vitro study

M538I ¹

I548V ¹

N550H ¹

N550K ¹

N550S ¹

V565I ¹

E566G ¹

L618M ¹

K642N ¹

K660E ¹

E719G ¹

Y770IfsX14 ¹

FGFR2 N550H ² In vitro study

V565I ²

E566G ²

K660M ²

K660N ²

FGFR2 V562L ⁴ In vitro study

V564F ⁴

FGFR3 V555M ⁶ KMS-11 myeloma cell line derivative

FGFR4 G388R ⁸ Breast cancer

[00293] In some embodiments, provided herein is a method for treating a subject diagnosed with a FGFR-associated disorder (e.g., a FGFR-associated cancer), that include administering to the subject a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof. For example, the FGFR-associated cancer can be any of exemplary FGFR-associated cancers described herein.

[00294] In some embodiments, the compounds of the present invention are useful for treating a FGFR-associated disease (e.g., a FGFR-associated cancer) in combination with one or more additional therapeutic agents or therapies that work by the same or a different mechanism of action. [00295] In some embodiments, the additional therapeutic agent(s) is selected from the group of: receptor tyrosine kinase-targeted therapeutic agents, including cabozantinib, crizotinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, pertuzumab, regorafenib, and sunitinib.

[00296] In some embodiments, the additional therapeutic agent(s) is selected from signal transduction pathway inhibitors, including, e.g., Ras-Raf-MEK-ERK pathway inhibitors (e.g., sorafenib, trametinib, or vemurafenib), PI3K-Akt-mTOR-S6K pathway inhibitors (e.g., everolimus, rapamycin, perifosine, or temsirolimus) and modulators of the apoptosis pathway (e.g., obataclax).

[00297] In some embodiments, the additional therapeutic agent(s) is selected from the group of: cytotoxic chemotherapeutics, including, e.g., arsenic trioxide, bleomycin, cabazitaxel, capecitabine, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, etoposide, fluorouracil, gemcitabine, irinotecan, lomustine, methotrexate, mitomycin C, oxaliplatin, paclitaxel, pemetrexed, temozolomide, and vincristine.

[00298] In some embodiments, the additional therapeutic agent(s) is selected from the group of angiogenesis-targeted therapies, including e.g., aflibercept and bevacizumab.

[00299] In some embodiments, the additional therapeutic agent(s) is selected from the group of immune-targeted agents, e.g., including aldesleukin, ipilimumab, lambrolizumab, nivolumab, and sipuleucel-T.

[00300] In some embodiments, the additional therapeutic agent(s) is selected from agents active against the downstream FGFR pathway, including, e.g., Ras, MEK, INK, and p38 kinase inhibitor.

[00301] In some embodiments, the additional therapeutic agent or therapy is radiotherapy, including, e.g., radioiodide therapy, external-beam radiation, and radium 223 therapy. In some embodiments, the additional therapeutic agent(s) includes any one of the above listed therapies or therapeutic agents which are standards of care in cancers wherein the cancer has a dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same.

[00302] Methods of detecting dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, include, e.g., detection of FGFR gene translocations, e.g., using Fluorescent In Situ Hybridization (FISH) (e.g., the commercially available kits from Empire Genomics and Cell Signaling Technology). [00303] In some embodiments, provided herein is a method of treating cancer (e.g., a FGFR- associated cancer) in a patient, comprising administering to said subject a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one additional therapy or therapeutic agent selected from radiotherapy (e.g., radioiodide therapy, external-beam radiation, or radium 223 therapy), cytotoxic chemotherapeutics (e.g., arsenic trioxide, bleomycin, cabazitaxel, capecitabine, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, etoposide, fluorouracil, gemcitabine, irinotecan, lomustine, methotrexate, mitomycin C, oxaliplatin, paclitaxel, pemetrexed, temozolomide, or vincristine); tyrosine kinase targeted-therapeutics (e.g., afatinib, cabozantinib, cetuximab, crizotinib, dabrafenib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, panitumumab, pertuzumab, regorafenib, sunitinib, or trastuzumab); FGFR inhibitors (e.g., ARQ-087, AZD-4547, BGJ398, nintadanib (BfflF 1120), BLU9931, brivanib (BMS-582664), CH5183284, Dovitinib (TKI258, CHIR258), E-3810, EWMD-2076, JNJ-42756493, lenvatinib ((E7080), LY2874455, Orantinib (TSU-68, SU6668), PD089828, PD166866, PD173074, Ponatinib (AP-24534), Semaxanib (SU5416), SSR128129E, SU4984, SU5402, SUN11602), AB1010, BAY 1163877, Debio-1347, FGF401, FIIN-2, HMPL-453, MK-2461, pazopanib (Votrient, GW-786034), PD161570, PD173074, PF- 477736, PHA-739358 (danusertib), PRN1371, regorafenib (Stivarga), SPP86, and Tyrphostin AG 1296 and TAS120; apoptosis modulators and signal transduction inhibitors (e.g. everolimus, perifosine, rapamycin, sorafenib, temsirolimus, trametinib, or vemurafenib); immune-targeted therapies (e.g., aldesleukin, interferon alfa-2b, ipilimumab, lambrolizumab, nivolumab, prednisone, or sipuleucel-T); and angiogenesis-targeted therapies (e.g., aflibercept or bevacizumab), wherein the amount of the compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, in combination with the additional therapy or therapeutic agent, is effective in treating said cancer. These additional therapeutic agents may be administered with one or more doses of the compound of General Formula I, or the pharmaceutically acceptable salt or solvate thereof, as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical practice known to one skilled in the art. In some embodiments, provided herein is a method of treating cancer (e.g., a FGFR-associated cancer) in a patient, comprising administering to said subject a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one additional therapy or therapeutic agent selected from radiotherapy (e.g., radioiodide therapy, external-beam radiation, or radium 223 therapy), cytotoxic chemotherapeutics (e.g., arsenic trioxide, bleomycin, cabazitaxel, capecitabine, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, etoposide, fluorouracil, gemcitabine, irinotecan, lomustine, methotrexate, mitomycin C, oxaliplatin, paclitaxel, pemetrexed, temozolomide, or vincristine), tyrosine kinase targeted-therapeutics (e.g., afatinib, cabozantinib, cetuximab, crizotinib, dabrafenib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, panitumumab, pertuzumab, regorafenib, or sunitinib), apoptosis modulators and signal transduction inhibitors (e.g. everolimus, perifosine, rapamycin, sorafenib, temsirolimus, trametinib, or vemurafenib), immune-targeted therapies (e.g., aldesleukin, interferon alfa-2b, ipilimumab, lambrolizumab, nivolumab, prednisone, or sipuleucel- T) and angiogenesis-targeted therapies (e.g., aflibercept or bevacizumab), wherein the amount of the compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, in combination with the additional therapy or therapeutic agent, is effective in treating said cancer. These additional therapeutic agents may be administered with one or more doses of the compound of General Formula I, or the pharmaceutically acceptable salt or solvate thereof, as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical practice known to one skilled in the art.

[00304] Also provided herein is (i) a pharmaceutical combination for treating cancer (e.g., a FGFR-associated cancer) in a subject in need thereof, which comprises (a) a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, (b) an additional therapeutic agent and (c) optionally at least one pharmaceutically acceptable carrier (e.g., for simultaneous, separate or sequential use for the treatment of a cancer), wherein the amounts of the compound of General Formula I, or the pharmaceutically acceptable salt or solvate thereof and of the additional therapeutic agent are together effective in treating said cancer; (ii) a pharmaceutical composition including such a combination; (iii) the use of such a combination for the preparation of a medicament for the treatment of cancer (e.g., a FGFR-associated cancer); and (iv) a commercial package or product including such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of cancer (e.g., FGFR-associated cancer) in a subject in need thereof.

[00305] Also provided are methods of treating a subject identified or diagnosed as having a FGFR-associated disease (e.g., a FGFR-associated cancer) (e.g., a subject that has been identified or diagnosed as having a FGFR-associated disease (e.g., a FGFR-associated cancer) through the use of a regulatory agency-approved, e.g., FDA-approved, kit for identifying dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, in a subject or a biopsy sample from the subject) (e.g., any of the FGFR-associated cancers described herein or known in the art) that include administering the subject a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof. Also provided is a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, for use in treating a FGFR-associated disease (e.g., a FGFR-associated cancer) in a subject identified or diagnosed as having a FGFR-associated disease (e.g., a FGFR-associated cancer) (e.g., a subject that has been identified or diagnosed as having a FGFR-associated cancer through the use of a regulatory agency-approved, e.g., FDA-approved, kit for identifying dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same,, in a subject or a biopsy sample from the subject) (e.g., any of the FGFR-associated cancers described herein or known in the art). Also provided is the use of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for treating a FGFR-associated disease (e.g., FGFR- associated cancer) in a subject identified or diagnosed as having a FGFR-associated disease (e.g., FGFR-associated cancer) (e.g., a subject that has been identified or diagnosed as having a FGFR- associated cancer through the use of a regulatory agency-approved, e.g., FDA-approved, kit for identifying dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, in a subject or a biopsy sample from the subject) (e.g., any of the FGFR-associated cancers described herein or known in the art).

[00306] Also provided are methods of treating a subject (e.g., a subject suspected of having a FGFR-associated disease (e.g., a FGFR-associated cancer), a subject presenting with one or more symptoms of a FGFR-associated disease (e.g., a FGFR-associated cancer), or a subject having an elevated risk of developing a FGFR-associated disease (e.g., FGFR-associated cancer)) that include performing an assay (e.g., an assay that utilizes next generation sequencing, immunohistochemistry, or break apart FISH analysis) (e.g., using a regulatory agency-approved, e.g., FDA-approved, kit) on a sample obtained from the subject to determine whether the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, and administering (e.g., specifically or selectively administering) a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, to a subject determined to have dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or levels of the same. Additional assays, non-limiting assays that may be used in these methods are described herein. Additional assays are also known in the art. Also provided is use of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, for use in treating a FGFR-associated disease (e.g., FGFR- associated cancer) in a subject identified or diagnosed as having a FGFR-associated disease (e.g., a FGFR-associated cancer) through a step of performing an assay (e.g., an in vitro assay) (e.g., an assay that utilizes next generation sequencing, immunohistochemistry, or break apart FISH analysis) (e.g., using a regulatory agency-approved, e.g., FDA-approved, kit) on a sample obtained from the subject to determine whether the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, where the presence of dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, identifies that the subject has a FGFR-associated disorder (e.g., FGFR-associated cancer). Also provided is the use of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for treating a FGFR-associated disease (e.g., FGFR-associated cancer) in a subject identified or diagnosed as having a FGFR-associated disease (e.g., FGFR-associated cancer) through a step of performing an assay (e.g., an in vitro assay) (e.g., an assay that utilizes next generation sequencing, immunohistochemistry, or break apart FISH analysis) (e.g., using a regulatory agency-approved, e.g., FDA-approved, kit) on a sample obtained from the subject to determine whether the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, where the presence of dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, identifies that the subject has a FGFR-associated disease (e.g., FGFR- associated cancer). Some embodiments of any of the methods or uses described herein further include recording in the subject's clinical record (e.g., a computer readable medium) that the subject determined to have dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, through the performance of the assay, should be administered a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof.

[00307] In some embodiments of any of the methods or uses described herein, the subject has been identified or diagnosed as having a cancer with dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same (e.g., as determined using a regulatory agency-approved, e.g., FDA-approved, assay or kit). In some embodiments of any of the methods or uses described herein, the subject has a tumor that is positive for dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same (e.g., as determined using a regulatory agency-approved assay or kit). In some embodiments of any of the methods or uses described herein, the subject can be a subject with a tumor(s) that is positive for dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same (e.g., identified as positive using a regulatory agency-approved, e.g., FDA-approved, assay or kit). In some embodiments of any of the methods or uses described herein, the subject can be a subject whose tumors have dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or a level of the same (e.g., where the tumor is identified as such using a regulatory agency-approved, e.g., FDA-approved, kit or assay). In some embodiments of any of the methods or uses described herein, the subject is suspected of having a FGFR-associated cancer. In some embodiments of any of the methods or uses described herein, the subject has a clinical record indicating that the subject has a tumor that has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same (and optionally the clinical record indicates that the subject should be treated with any of the compositions provided herein).

[00308] Also provided are methods of treating a subject that include administering a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, to a subject having a clinical record that indicates that the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same. Also provided is the use of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for treating a FGFR- associated disease (e.g., FGFR-associated cancer) in a subject having a clinical record that indicates that the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same. Also provided is the use of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for treating a FGFR-associated disease (e.g., a FGFR-associated cancer) in a subject having a clinical record that indicates that the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same. Some embodiments of these methods and uses can further include: a step of performing an assay (e.g., an in vitro assay) (e.g., an assay that utilizes next generation sequencing, immunohistochemistry, or break apart FISH analysis) (e.g., using a regulatory agency-approved, e.g., FDA-approved, kit) on a sample obtained from the subject to determine whether the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, and recording information in a subject's clinical file (e.g., a computer-readable medium) that the subject has been identified to have dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same.

[00309] Also provided are methods (e.g., in vitro methods) of selecting a treatment for a subject that include selecting a treatment including administration of a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, for a subject identified or diagnosed as having a FGFR-associated disease (e.g., a FGFR-associated cancer) (e.g., a subject that has been identified or diagnosed as having a FGFR-associated cancer through the use of a regulatory agency-approved, e.g., FDA-approved, kit for identifying dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, in a subject or a biopsy sample from the subject) (e.g., any of the FGFR-associated cancers described herein or known in the art). Some embodiments can further include administering the selected treatment to the subject identified or diagnosed as having a FGFR-associated disease (e.g., a FGFR-associated cancer). Some embodiments can further include a step of performing an assay (e.g., an in vitro assay) (e.g., an assay that utilizes next generation sequencing, immunohistochemistry, or break apart FISH analysis) (e.g., using a regulatory agency-approved, e.g., FDA-approved, kit) on a sample obtained from the subject to determine whether the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, and identifying or diagnosing a subject determined to have dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, as having a FGFR-associated disease (e.g., a FGFR-associated cancer).

[00310] Also provided are methods of selecting a treatment for a subject that include administration of a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, wherein the methods include a step of performing an assay (e.g., an in vitro assay) (e.g., an assay that utilizes next generation sequencing, immunohistochemistry, or break apart FISH analysis) (e.g., using a regulatory agency-approved, e.g., FDA-approved, kit) on a sample obtained from the subject to determine whether the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, and identifying or diagnosing a subject determined to have dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, as having a FGFR-associated cancer, and selecting a therapeutic treatment including administration of a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, for the subject identified or diagnosed as having a FGFR- associated disease (e.g., a FGFR-associated cancer). Some embodiments further include administering the selected treatment to the subject identified or diagnosed as having a FGFR- associated disorder (e.g., a FGFR-associated cancer).

[00311] Also provided are methods of selecting a subject for treatment including administration of a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof, that include selecting, identifying, or diagnosing a subject having a FGFR- associated disorder (e.g., a FGFR-associated cancer), and selecting the subject for treatment including administration of a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, identifying or diagnosing a subject as having a FGFR- associated disease (e.g., an FGFR-associated cancer) can include a step of performing an assay (e.g., an in vitro assay) (e.g., an assay that utilizes next generation sequencing, immunohistochemistry, or break apart FISH analysis) (e.g., using a regulatory agency-approved, e.g., FDA-approved, kit) on a sample obtained from the subject to determine whether the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, and identifying or diagnosing a subject determined to have dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, as having a FGFR-associated disorder (e.g., a FGFR-associated cancer). In some embodiments, the selecting a treatment can be used as part of a clinical study that includes administration of various treatments of an FGFR-associated disorder (e.g., a FGFR-associated cancer).

[00312] In some embodiments of any of the methods or uses described herein, an assay used determine whether the subject has dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or level of the same, using a sample (e.g., a biological sample or a biopsy sample (e.g., a paraffin-embedded biopsy sample) from a subject (e.g., a subject suspected of having a FGFR- associated disease (e.g., a FGFR-associated cancer), a subject having one or more symptoms of a FGFR-associated disease (e.g., a FGFR-associated cancer), and/or a subject that has an increased risk of developing a FGFR-associated disease (e.g., a FGFR-associated cancer)) can include, for example, next generation sequencing, immunohistochemistry, fluorescence microscopy, break apart FISH analysis, Southern blotting, Western blotting, FACS analysis, Northern blotting, and PCR-based amplification (e.g., RT-PCR). As is well-known in the art, the assays are typically performed, e.g., with at least one labelled nucleic acid probe or at least one labelled antibody or antigen-binding fragment thereof. Assays can utilize other detection methods known in the art for detecting dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or levels of the same (see, e.g., the references cited herein).

[00313] Exemplary assays for detecting dysregulation of a FGFR gene, a FGFR protein, or expression or activity, or levels of the same are commercially available, e.g., FGFR Pathway Mutation PCR Array (Qiagen), HTG Edge FGFR Expression Assay (HTG Molecular Diagnostics), HTScan® FGF Receptor 1 Kinase Assay Kit (Cell Signaling Technology), Vysis LSI IGH/FGFR3 Dual Color, Dual Fusion Translocation Probe (Abbott Molecular), FGFRl FISH Probe (Empire Genomics), FGFRl FISH (Sonic Genomics), FISH IGH/FGFR3 (Quest Diagnostics), FGFRl (8pl l) [RUO] (Leica Biosystems), FGFRl Break Apart FISH Probe (Empire Genomics), FGFR2/CEN10p FISH Probe (Abnova Corporation), FGFR2 (10q26) [ASR] (Leica Biosystems), Anti-FGFR-4 (IN), Z-FISH (AnaSpec), ZytoLight® SPEC FGFR2 Break Apart Probe (Bio-Optica), FGFR3 (4pl6.3) (Zyto Vision), and ZytoLight® SPEC FGFR3/CEN4 Dual Color Probe (Zyto Vision). Additional assays for detecting dysregulation of a FGFR gene, a FGFR protein, or expression or activity or levels of the same are known in the art. [00314] Also provided are methods of increasing the time of remission of a FGFR- associated cancer in a patient that include (a) selecting, identifying, or diagnosing a patient as having a FGFR-associated cancer (e.g., any of the FGFR-associated cancers described herein), and (b) administering a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof. Also provided are methods of increasing the time of remission of a FGFR- associated cancer in a patient that include administering a therapeutically effective amount of a compound of General Formula I (e.g., any of the exemplary compounds described herein), or a pharmaceutically acceptable salt or solvate thereof to a patient having a FGFR-associated cancer (e.g., any of the exemplary FGFR-associated cancers described herein). In some examples of any of the methods of increasing the time of remission of a FGFR-associated cancer in a patient, the increase in the time of remission is compared to a control patient (e.g., a patient or a population of patients having the same or a similar type of FGFR-associated cancer). In some examples, the patient is not yet in remission. In other examples, the patient is already in remission. In some examples, the increase in remission is a statistically significant increase. In some examples, the increase in the time of remission is about 1 day to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, about 8 months, about 6 months, about 4 months, about 2 months, about 1 month, or about 2 weeks; about 2 weeks to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, about 8 months, about 6 months, about 4 months, about 2 months, or about 1 month; about 1 month to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, about 8 months, about 6 months, about 4 months, or about 2 months; about 2 month to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, about 8 months, about 6 months, or about 4 months; about 4 month to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, about 8 months, or about 6 months; about 6 month to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, or about 8 months; about 8 month to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, or about 10 months; about 10 month to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, or about 1 year; about 1 year to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, or about 1.5 years; about 1.5 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, to about 2 years; about 2 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, or about 2.5 years; about 2.5 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, or about 3 years; about 3 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, or about 3.5 years; about 3.5 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, or about 4 years; about 4 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, or about 4.5 years; about 4.5 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, or about 5 years; about 5 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, or about 5.5 years; about 5.5 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, or about 6 years; about 6 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, or about 6.5 years; about 6.5 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, or about 7 years; about 7 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, or about 7.5 years; about 7.5 years to about 10 years, about 9.5 years, about 9 years, about 8.5 years, or about 8 years; about 8 years to about 10 years, about 9.5 years, about 9 years, or about 8.5 years; about 8.5 years to about 10 years, about 9.5 years, or about 9 years; about 9 years to about 10 years or about 9.5 years; or about 9.5 years to about 10 years (e.g., compared to a control patient, e.g., a patient or a population of patients having the same or a similar type of FGFR-associated cancer).

[00315] Also provided is a compound of General Formula I or pharmaceutically acceptable salt or solvate thereof for use in increasing the time of remission of a FGFR-associated cancer in a patient. Also provided is the use of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for increasing the time of remission of a FGFR-associated cancer in a patient.

[00316] Methods for determining whether or not a patient is in remission are known by those skilled in the art. For example, a PET scan, MRI, CT scan, ultrasound, and X-ray of the patient's body may be obtained, and such data can be used to determine whether or not a patient is in remission. In some examples, diagnostic tests can be performed on samples from a patient (e.g., a blood sample or a biopsy) to determine whether or not the patient is still in remission.

[00317] Also provided are methods of increasing the time of survival of a patient having a FGFR-associated cancer that include: selecting, diagnosing, or identifying a patient as having a FGFR-associated cancer; and administering to a subject selected, diagnosed, or identified as having a FGFR-associated cancer a therapeutically effective amount of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof. Also provided are methods of increasing the time of survival of a patient having a FGFR-associated cancer that include administering to a subject having a FGFR-associated cancer a therapeutically effective amount of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof. In some embodiments of any of the methods of increasing the time of survival of a subject having a FGFR-associated cancer, the increase in the time of survival is compared to a control patient (e.g., a patient or a population of patients having the same or a similar type of FGFR-associated cancer). In some examples, the patient can have an early stage of a FGFR-associated cancer (e.g., Stage 1 or 2). In some embodiments, the patient can have a late stage of a FGFR-associated cancer (e.g., Stage 3 or 4). In some examples, the increase in the time of survival is a statistically significant increase. In some examples, the increase in the time of survival is about 1 day to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, about 8 months, about 6 months, about 4 months, about 2 months, about 1 month, or about 2 weeks; about 2 weeks to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, about 8 months, about 6 months, about 4 months, about 2 months, or about 1 month; about 1 month to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, about 8 months, about 6 months, about 4 months, or about 2 months; about 2 months to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, about 8 months, about 6 months, or about 4 months; about 4 months to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, about 8 months, or about 6 months; about 6 months to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, about 10 months, or about 8 months; about 8 months to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, about 1 year, or about 10 months; about 10 months to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, about 1.5 years, or about 1 year; about 1 year to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, about 2 years, or about 1.5 years; about 1.5 year to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, about 2.5 years, or about 2 years; about 2 year to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, about 3 years, or about 2.5 years; about 2.5 year to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, about 3.5 years, or about 3 years; about 3 year to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, about 4 years, or about 3.5 years; about 3.5 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, about 4.5 years, or about 4 years; about 4 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, about 5 years, or about 4.5 years; about 4.5 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, about 5.5 years, or about 5 years; about 5 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, about 6 years, or about 5.5 years; about 5.5 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, about 6.5 years, or about 6 years; about 6 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, about 7 years, or about 6.5 years; about 6.5 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, about 7.5 years, or about 7 years, about 7 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, about 8 years, or about 7.5 years; about 7.5 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, about 8.5 years, or about 8 years; about 8 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, about 9 years, or about 8.5 years; about 8.5 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, about 9.5 years, or about 9 years; about 9 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, about 10 years, or about 9.5 years; about 9.5 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, about 12 years, or about 10 years; about 10 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, about 14 years, or about 12 years; about 12 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, about 16 years, or about 14 years; about 14 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, about 18 years, or about 16 years; about 16 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, about 20 years, or about 18 years; about 18 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, about 22 years, or about 20 years; about 20 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, about 24 years, or about 22 years; about 22 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, about 26 years, or about 24 years; about 24 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, about 28 years, or about 26 years; about 26 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, about 30 years, or about 28 years; about 28 years to about 40 years, about 38 years, about 36 years, about 34 years, about 32 years, or about 30 years; about 30 years to about 40 years, about 38 years, about 36 years, about 34 years, or about 32 years; about 32 years to about 40 years, about 38 years, about 36 years, or about 34 years; about 34 years to about 40 years, about 38 years, or about 36 years; about 36 years to about 40 years or about 38 years; or about 38 years to about 40 years (e.g., compared to a control patient, e.g., a patient or a population of patients having the same or a similar type of FGFR-associated cancer).

[00318] Also provided is the use of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof for increasing the time of survival of a patient having a FGFR- associated cancer. Also provided is the use of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for increasing the time of survival of a patient having a FGFR-associated cancer.

[00319] Also provided are methods of decreasing the risk of developing a metastasis or an additional metastasis in a patient having a FGFR-associated cancer that include: selecting, identifying, or diagnosing a patient as having a FGFR-associated cancer, and administering a therapeutically effective amount of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof to the patient selected, identified, or diagnosed as having a FGFR- associated cancer. Also provided are methods of decreasing the risk of developing a metastasis or an additional metastasis in a patient having a FGFR-associated cancer that includes administering a therapeutically effective amount of a compound of General Formula I or a pharmaceutically acceptable salt or solvent thereof to a patient having a FGFR-associated cancer. The decrease in the risk of developing a metastasis or an additional metastasis in a patient having a FGFR- associated cancer can be compared to the risk of developing a metastasis or an additional metastasis in the patient prior to treatment, or as compared to a patient or a population of patients having a similar or the same FGFR-associated cancer that has received no treatment or a different treatment. The decrease in the risk of developing a metastasis or an additional metastasis can be about 1% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, or about 5%; about 5% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, or about 10%; about 10% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, or about 15%; about 15% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, or about 20%; about 20% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, or about 25%; about 25% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, or about 30%; about 30% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, or about 35%; about 35% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, or about 40%; about 40% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, or about 45%; about 45% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, or about 50%; about 50% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, or about 55%; about 55% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, or about 60%; about 60% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, or about 65%; about 65% to about 99%, about 95%, about 90%, about 85%, about 80%, about 75%, or about 70%; about 70% to about 99%, about 95%, about 90%, about 85%, about 80%, or about 75%; about 75% to about 99%, about 95%, about 90%, about 85%, or about 80%; about 80% to about 99%, about 95%, about 90%, or about 85%; about 85% to about 99%, about 95%, or about 90%; about 90% to about 99% or about 90%; or about 95% to about 99% as compared to the risk of developing a metastasis or an additional metastasis in the patient prior to treatment, or as compared to a patient or a population of patients having a similar or the same FGFR-associated cancer that has received no treatment or a different treatment.

[00320] In some examples, the risk of developing a metastasis or an additional metastasis is over about 2 weeks, 1 month, 1.5 months, 2 months, 2.5 months, 3 months, 3.5 months, 4 months, 4.5 months, 5 months, 5.5 months, 6 months, 6.5 months, 7 months, 7.5 months, 8 months, 8.5 months, 9 months, 9.5 months, 10 months, 10.5 months, 11 months, 11.5 months, 12 months, 1.5 years, 2 years, 2.5 years, 3 years, 3.5 years, 4 years, 4.5 years, 5 years, 5.5 years, 6 years, 6.5 years, 7 years, 7.5 years, 8 years, 8.5 years, 9 years, 9.5 years, or 10 years.

[00321] Also provided is the use of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof for decreasing the risk of developing a metastasis or an additional metastasis in a patient having a FGFR-associated cancer. Also provided is the use of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for decreasing the risk of developing a metastasis or an additional metastasis in a patient having a FGFR-associated cancer.

[00322] Also provided are methods of increasing sensitivity of a resistant cancer cell to an anti-cancer drug that include: selecting, identifying, or diagnosing a patient as having a resistant cancer cell (e.g., a resistant FGFR-associated cancer cell, e.g., a cancer cell identified as having one or more of the point mutations listed in Table E), and administering to the selected, identified, or diagnosed subject a therapeutically effective amount of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof. Also provided are methods of increasing sensitivity of a resistant cancer cell to an anti -cancer drug that include administering to a patient having a resistant cancer cell to an anti-cancer drug a therapeutically effective amount of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof. Some embodiments of any of these methods further include administering the anti-cancer drug to the patient. In such examples, the anti-cancer drug can be co-administered with the compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof. In some examples, the anti-cancer drug can be administered at substantially the same time as the compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof. In some examples, a first dose of the compound of General Formula I is administered prior to the first dose of the anti-cancer compound. In some examples, a first dose of the anti-cancer compound is administered prior to the first dose of the compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof. In some examples, the increase in the sensitivity of the resistant cancer cell to the anti-cancer drug can result in a decrease in the rate of growth and/or proliferation of the resistant cancer cell when contacted with the anti-cancer drug and at least one of the compounds described herein, of between about 1% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 2% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 3% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 5% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10%; about 5% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 5% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10%; about 10% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 5% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 15%; about 15% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 5% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, or 20%; about 20% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 5% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, or 25%; about 25% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, or 20%; about 20% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 5% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, or 30%; about 30% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, or 35%; about 35% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, or 40%; about 40% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, or 45%; about 45% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, or 50%; about 50% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, or 55%; about 55% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, or 60%; about 60% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, or 65%; about 65% to about 100%, 95%, 90%, 85%, 80%, 75%, or 70%; about 70% to about 100%, 95%, 90%, 85%, 80%, or 75%; about 75% to about 100%, 95%, 90%, 85%, or 80%; about 80% to about 100%, 95%, 90%, or 85%; about 85% to about 100%, 95%, or 90%; about 90% to about 100% or 95%; or about 95% to about 100%), as compared to the rate of growth and/or proliferation of a resistant cancer cell when contacted with the anti-cancer drug alone.

[00323] A method of treating an angiogenesis-related disorder (e.g., any of the angiogenesis-related disorders described herein or known in the art) in a patient that include: identifying, selecting, or diagnosing a angiogenesis-related disorder in a patient, and administering to the identified, selected, or diagnosed patient with a therapeutically effective amount of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof. A method of treating an angiogenesis-related disorder in a patient that includes administering a therapeutically effective amount of a compound of General Formula I or a pharmaceutically acceptable salt or solvent thereof to a patient having an angiogenesis-related disorder. In some examples, the treating can result in a decrease in the diameter of a blood vessel and/or a decrease in the number of blood vessels in a tissue in need of a reduction in the number of blood vessels (e.g., as compared to the diameter of the blood vessel and/or the number of blood vessels in the tissue in the patient prior to treatment). In some examples the methods can result in, e.g., a decrease in the diameter of a blood vessel of about 1% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 2% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 3% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 5% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10%; about 10% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 15%; about 15% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, or 20%; about 20% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, or 25%; about 25% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, or 30%; about 30% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, or 35%; about 35% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, or 40%; about 40% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, or 45%; about 45% to about 80%, 75%, 70%, 65%, 60%, 55%, or 50%; about 50% to about 80%, 75%, 70%, 65%, 60%, or 55%; about 55% to about 80%, 75%, 70%, 65%, or 60%; about 60% to about 80%, 75%, 70%, or 65%; about 65% to about 80%, 75%, or 70%; about 70% to about 80% or 75%,; or about 75% to about 80% (e.g., as compared to the diameter of the blood vessel in the patient prior to treatment). In some examples the methods can result in, e.g., a decrease in the number of blood vessels in a tissue in need of a reduction in the number of blood vessels of about 5% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10%; about 10% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 15%; about 15% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, or 20%; about 20% or about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, or 25%; about 25% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, or 30%; about 30% to about about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, or 35%; about 35% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, or 40%; about 40% to about 80%, 75%, 70%, 65%, 60%, 55%, 50%, or 45%; about 45% to about 80%, 75%, 70%, 65%, 60%, 55%, or 50%; about 50% to about 80%, 75%, 70%, 65%, 60%, or 55%; about 55% to about 80%, 75%, 70%, 65%, or 60%; about 60% to about 80%, 75%, 70%, or 65%; about 65% to about 80%, 75%, or 70%; about 70% to about 80% or 75%; or about 75% to about 80% (e.g., as compared to the diameter of the blood vessel and/or the number of blood vessels in the tissue in the patient prior to treatment). These methods can also result in a decrease in the rate of formation of new blood vessels in a tissue in need thereof in a patient having an angiogenesis- related disorder (e.g., as compared to the rate of formation of new blood vessels in the tissue in the patient prior to treatment, or the rate of formation of new blood vessels in a patient or a population of patients having the same or similar angiogenesis-related disorder). The decrease in the rate of formation of a new blood vessels in a tissue in need thereof in a patient having an angiogenesis- related disorder can be about 1% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, or 5%; about 5% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, or 10%; about 10% to about 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, or 15%; about 15% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, or 20%; about 20% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, or 25%; about 25% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, or 30%; about 30% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, or 35%; about 35% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, or 40%; about 40% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, or 45%; about 45% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, or 50%; about 50% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, or 55%; about 55% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, 65%, or 60%; about 60% to 100%, 95%, 90%, 85%, 80%, 75%, 70%, or 65%; about 65% to 100%, 95%, 90%, 85%, 80%, 75%, or 70%; about 70% to 100%, 95%, 90%, 85%, 80%, or 75%; about 75% to 100%, 95%, 90%, 85%, or 80%; about 80% to 100%, 95%, 90%, or 85%; about 85% to 100%, 95%, or 90%; about 90% to about 100%) or 95%; or about 95% to about 100% (e.g., as compared to the rate of formation of new blood vessels in the tissue in the patient prior to treatment, or the rate of formation of new blood vessels in a patient or a population of patients having the same or similar angiogenesis- related disorder).

[00324] Also provided is the use of a compound of General Formula I or a pharmaceutically acceptable salt or solvent thereof for treating an angiogenesis-related disorder in a patient. Also provided is the use of a compound of General Formula I or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating an angiogenesis-related disorder in a patient.

[00325] Also provided are methods for treating cancer in a patient in need thereof, the method comprising: (a) determining if the cancer in the patient is an FGFR-associated cancer (e.g., using a regulatory-agency approved, e.g., FDA-approved, kit for identifying dysregulation of dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same, in a patient or a biopsy sample from the patient, or by performing any of the non-limiting examples of assays described herein); and (b) if the cancer in the patient is determined to be an FGFR-associated cancer, administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof.

[00326] Also provided is use of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof for use in treating an FGFR-associated cancer (e.g., any of the FGFR- associated cancers described herein) in a patient identified or diagnosed as having an FGFR- associated cancer through a step of performing an assay (e.g., an in vitro assay) (e.g., an assay that utilizes next generation sequencing, immunohistochemistry, or break apart FISH analysis) (e.g., using a regulatory agency-approved, e.g., FDA-approved kit) on a sample obtained from the patient to determine whether the patient has dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same, where the presence of dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same, identifies that the patient has an FGFR-associated cancer. Also provided is the use of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for treating an FGFR-associated cancer in a patient identified or diagnosed as having an FGFR- associated cancer through a step of performing an assay (e.g., an in vitro assay) (e.g., an assay that utilizes next generation sequencing, immunohistochemistry, or break apart FISH analysis) (e.g., using a regulatory agency-approved, e.g., FDA-approved, kit) on a sample obtained from the patient to determine whether the patient has a dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same where the presence of dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same, identifies that the patient has an FGFR-associated cancer. Some embodiments of any of the methods or uses described herein further include recording in the patient's clinical record (e.g., a computer readable medium) that the patient determined to have dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same, through the performance of the assay, should be administered a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof.

[00327] Also provided is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of a cancer (e.g., an FGFR-associated cancer) in a patient in need thereof or a patient identified or diagnosed as having an FGFR-associated cancer (e.g., a patient that has been identified or diagnosed as having an FGFR-associated cancer through the use of a regulatory agency-approved, e.g., FDA-approved, kit for identifying dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same, in a patient or a biopsy sample from the sample) (e.g., any of the FGFR-associated cancers described herein or known in the art). Also provided is the use of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for treating a cancer (e.g., an FGFR- associated cancer) in a patient identified or diagnosed as having an FGFR-associated cancer (e.g., a patient that has been identified or diagnosed as having an FGFR-associated cancer through the use of a regulatory agency-approved, e.g., FDA-approved, kit for identifying dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same, in a patient or a biopsy sample from the patient) (e.g., any of the FGFR-associated cancers described herein or known in the art).

[00328] In some embodiments of any of the methods or uses described herein, the patient has been identified or diagnosed as having a cancer with dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same (e.g., as determined using a regulatory agency-approved, e.g., FDA-approved, assay or kit). In some embodiments of any of the methods or uses described herein, the patient has a tumor that is positive for dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same (e.g., as determined using a regulatory-agency-approved assay or kit). In some embodiments of any of the methods or uses described herein, the patient can be a patient with a tumor(s) that is positive for dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same (e.g., identified as positive using a regulatory agency-approved, e.g., FDA-approved, assay or kit). In some embodiments of any of the methods or uses described herein, the patient can be a patient whose tumors have dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same (e.g., where the tumor is identified as such using a regulatory agency-approved, e.g., FDA-approved, kit or assay). In some embodiments of any of the methods or uses described herein, the patient is suspected of having an FGFR-associated cancer. In some embodiments of any of the methods or uses described herein, the patient has a clinical record indicating that the patient has a tumor that has dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same (and optionally the clinical record indicates that the patient should be treated with any of the compounds of Formula I or a pharmaceutically acceptable salts or solvates thereof or compositions provided herein).

[00329] Also provided herein are methods of selecting a treatment for a patient that include administration of a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof that include a step of performing an assay (e.g., an in vitro assay) (e.g., an assay that utilizes next generation sequencing, immunohistochemistry, or break apart FISH analysis) (e.g., using a regulatory agency-approved, e.g., FDA-approved, kit) on a sample obtained from the patient to determine whether the patient has dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same, identifying or diagnosing a patient determined to have dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same, as having an FGFR-associated cancer, and selecting a therapeutic treatment including administration of a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof to the patient identified or diagnosed as having an FGFR-associated cancer. Some embodiments further include administering the selected treatment to the patient identified or diagnosed as having an FGFR- associated cancer.

[00330] In some embodiments of any of the methods or uses described herein, the cancer

(e.g., FGFR-associated cancer) is a hematological cancer. In some embodiments of any of the methods or uses described herein, the cancer (e.g., an FGFR-associated cancer) is a solid tumor. In some embodiments of any of the methods or uses described herein, the cancer (e.g., FGFR- associated cancer) is any of the exemplary cancers (e.g., any of the exemplary FGFR-associated cancers) described herein.

[00331] Also provided herein is a method of treating a disease or disorder mediated by

FGFR (e.g., dysregulation of a FGFR gene, a FGFR protein, or expression or activity or level of any of the same) in a patient in need of such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition thereof. For example, the FGFR-associated disease can be any of the FGFR-associated cancers described herein or known in the art.

[00332] Although the genetic basis of tumorigenesis may vary between different cancer types, the cellular and molecular mechanisms required for metastasis appear to be similar for all solid tumor types. During a metastatic cascade, the cancer cells lose growth inhibitory response, undergo alterations in adhesiveness and produce enzymes that can degrade extracellular matrix components. This leads to detachment of tumor cells from the original tumor, infiltration into the circulation through newly formed vasculature (e.g., lymph vessels or blood vessels), migration and extravasation of the tumor cells at favorable distant sites, where they may form colonies. A number of genes have been identified as being promoters or suppressors of metastasis. FGFR proteins have been implicated for a role in metastasis (Qian et al., Oncogene 33 :341 1-3421, 2014).

[00333] Accordingly, also provided herein are methods for inhibiting, preventing, aiding in the prevention, or decreasing the symptoms of metastasis of a cancer (e.g., a FGFR-associated cancer) in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof. Such methods can be used in the treatment of one or more of the cancers described herein. In some embodiments, the cancer is an FGFR-associated cancer. In some embodiments, the compound of Formula I or a pharmaceutically acceptable salt or solvate thereof is used in combination with an additional therapy or another therapeutic agent, including a chemotherapeutic agent, such as a kinase inhibitor.

[00334] Also provided is a method for inhibiting activity of FGFR1, FGFR2, FGFR3 and/or

FGFR4 in a mammalian cell, comprising contacting the cell with a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof. In one embodiment, the contacting is performed in vitro. In another embodiment, the contacting is performed in vivo (e.g., in a human). In one embodiment, when the contacting is performed in vivo, the method can include administering an effective amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof to a subject. In some embodiments, the mammalian cell is a mammalian cancer cell. In one embodiment, the mammalian cancer cell is any cancer as described herein. In some embodiments, the mammalian cancer cell is an FGFR-associated cancer cell.

[00335] As used herein, the term "contacting" refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, "contacting" an FGFR with a compound provided herein includes the administration of a compound provided herein to an individual or patient, such as a human, having FGFR1, FGFR2, FGFR3 and/or FGFR4, as well as, for example, introducing a compound provided herein into a sample containing a cellular or purified preparation containing the FGFR1, FGFR2, FGFR3 and/or FGFR4.

[00336] In the field of medical oncology it is normal practice to use a combination of different forms of treatment to treat each patient with cancer. In medical oncology the other component(s) of such conjoint treatment or therapy in addition to compositions provided herein may be, for example, surgery, radiotherapy, and chemotherapeutic agents, such as kinase inhibitors, signal transduction inhibitors and/or monoclonal antibodies. Compounds of Formula I therefore may also be useful as adjuvants to cancer treatment, that is, they can be used in combination with one or more additional therapies or therapeutic agents, for example a chemotherapeutic agent that works by the same or by a different mechanism of action.

[00337] In some embodiments of any the methods described herein, the compound of

Formula I (or a pharmaceutically acceptable salt or solvate thereof) is administered in combination with a therapeutically effective amount of at least one additional therapeutic agent selected from one or more additional therapies or therapeutic (e.g., chemotherapeutic) agents. Non-limiting examples of additional therapeutic agents include: receptor tyrosine kinase-targeted therapeutic agents, such as afatinib, cabozantinib, cetuximab, crizotinib, dabrafenib, erlotinib, gefitinib, imatinib, lapatinib, lestaurtinib, nilotinib, pazopanib, panitumumab, pertuzumab, sunitinib, AG 879, AZ-23, AZ623, Go 6976, GNF-5837, GTx-186, GW 441756, LOXO-101, MGCD516, RPI- 1, RXDX101, and TSR-011; FGFR-targeted therapeutic agents, such as signal transduction pathway inhibitors, such as Ras-Raf-MEK-ERK pathway inhibitors (e.g., binimetinib, selumetinib, encorafinib, sorafenib, trametinib, and vemurafenib), PI3K-Akt-mTOR-S6K pathway inhibitors (e.g. everolimus, rapamycin, perifosine, temsirolimus), other kinase inhibitors, such as baricitinib, brigatinib, capmatinib, danusertib, ibrutinib, milciclib, quercetin, regorafenib, ruxolitinib, semaxanib, AP32788, BLU285, BLU554, INCB39110, INCB40093, INCB50465, INCB52793, INCB54828, MGCD265, MS-088, MS-1286937, PF 477736, PLX3397, PLX7486, PLX8394, PLX9486, PRN1008, PRN1371, RXDX103, RXDX106, RXDX108, and TG101209; FGFR inhibitors (e.g., ARQ-087, AZD-4547, BGJ398, nintadanib (BIBF 1120), BLU9931, brivanib (BMS-582664), CH5183284, Dovitinib (TKI258, CHIR258), E-3810, EWMD-2076, JNJ-42756493, lenvatinib ((E7080), LY2874455, Orantinib (TSU-68, SU6668), PD089828, PD166866, PD173074, Ponatinib (AP-24534), Semaxanib (SU5416), SSR128129E, SU4984, SU5402, SUN11602), AB1010, BAY 1163877, Debio-1347, FGF401, FIIN-2, HMPL- 453, MK-2461, pazopanib (Votrient, GW-786034), PD161570, PD173074, PF-477736, PHA- 739358 (danusertib), PRN1371, regorafenib (Stivarga), SPP86, and Tyrphostin AG 1296, and TAS120; checkpoint inhibitors, such as ipilimumab, tremelimumab, nivolumab, pidilizumab, MPDL3208A, MEDI4736, MSB0010718C, BMS-936559, BMS-956559, BMS-935559 (MDX- 1105), AMP -224, and pembrolizumab; modulators of the apoptosis pathway (e.g. obataclax); cytotoxic chemotherapeutics, such as arsenic trioxide, bleomycin, cabazitaxel, capecitabine, carboplatin, cisplatin, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, docetaxel, doxorubicin, etoposide, fluorouracil, gemcitabine, irinotecan, lomustine, methotrexate, mitomycin C, oxaliplatin, paclitaxel, pemetrexed, temozolomide, and vincristine; angiogenesis-targeted therapies, such as aflibercept and bevacizumab; immune-targeted agents, such as aldesleukin, interferon alfa-2b, ipilimumab, lambrolizumab, nivolumab, prednisone, sipuleucel-T; radiotherapy, such as radioiodide therapy, external -beam radiation, and radium 223 therapy.

[00338] Yet other therapeutic agents that can be administered with a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, include FGFR inhibitors such as those described, for example, LY2874455 (Lilly), dovitinib (TKI258) (Novartis), BGJ398 (Novartis), AZD4547 (AstraZeneca), ponatinib (Ariad), E-3810 (EOS), JNJ-42756493 (Astex/Janssen), and ARQ 087 (ArQule).

[00339] In some embodiments, the amount of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof is, in combination with the at least one additional therapeutic agent, effective in treating the cancer (e.g., an FGFR-associated cancer). The at least one additional therapeutic agent may be administered with a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules according to standard pharmaceutical practice known to one skilled in the art.

[00340] Also provided herein is (i) a pharmaceutical combination for treating cancer in a patient in need thereof, which comprises (a) a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, (b) at least one additional therapeutic agent (e.g., any of the exemplary additional therapeutic agents described herein or known in the art), and (c) optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use for the treatment of cancer, wherein the amounts ofthe compound of Formula I or pharmaceutically acceptable salt or solvate thereof and of the additional therapeutic agent are together effective in treating the cancer; (ii) a pharmaceutical composition comprising such a combination; (iii) the use of such a combination for the preparation of a medicament for the treatment of cancer; and (iv) a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of cancer a patient in need thereof. In one embodiment the patient is a human.

[00341] The term "pharmaceutical combination", as used herein, refers to a pharmaceutical therapy resulting from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients. The term "fixed combination" means that a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof and at least one additional therapeutic agent (e.g., a chemotherapeutic agent), are both administered to a patient simultaneously in the form of a single composition or dosage. The term "non-fixed combination" means that a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof and at least one additional therapeutic agent (e.g., chemotherapeutic agent) are administered to a patient as separate compositions or dosages, either simultaneously, concurrently or sequentially with variable intervening time limits, wherein such administration provides effective levels of the two or more compounds in the body of the patient. These also apply to cocktail therapies, e.g. the administration of three or more active ingredients

[00342] Accordingly, also provided herein is a method of treating cancer, comprising administering to a patient in need thereof a pharmaceutical combination for treating cancer which comprises (a) a compound of Formula I or pharmaceutically acceptable salt or solvate thereof, (b) an additional therapeutic agent, and (c) optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use for the treatment of cancer, wherein the amounts of the compound of Formula I or pharmaceutically acceptable salt or solvate thereof and the additional therapeutic agent are together effective in treating the cancer. In one embodiment, the compound of Formula I or pharmaceutically acceptable salt or solvate thereof, and the additional therapeutic agent are administered simultaneously as separate dosages. In one embodiment, the compound of Formula I or pharmaceutically acceptable salt or solvate thereof, and the additional therapeutic agent are administered as separate dosages sequentially in any order, in jointly therapeutically effective amounts, e.g. in daily or intermittently dosages. In one embodiment, compound of Formula I or pharmaceutically acceptable salt or solvate thereof, and the additional therapeutic agent are administered simultaneously as a combined dosage.

[00343] Also provided herein is a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of an FGFR-associated disease or disorder as defined hereinabove.

[00344] Also provided herein are methods of treating a FGFR-associated disease (e.g., a FGFR-associated cancer, e.g., any of the FGFR-associated cancers described herein or known in the art) in a patient that include: (a) administering to a patient identified or diagnosed as having an FGFR-associated disease (e.g., an FGFR-associated cancer) one or more doses of a first FGFR inhibitor over a treatment period; (b) determining a level of phosphate in a biological sample including blood, serum, or plasma obtained from the patient after the treatment period; (c) selecting a patient having an elevated level of phosphate in the biological sample as compared to a reference level of phosphate; and (d) ceasing administration of the first FGFR inhibitor (or instructing the selected patient to cease administration) and initiating administration of a therapeutically effective amount of a compound of Formula I or pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical agent or composition comprising a compound of Formula I or pharmaceutically acceptable salt or solvate thereof (e.g., any of the pharmaceutical agents or compositions described herein), to the selected patient . Some embodiments of these methods can further include identifying or diagnosing a patient as having a FGFR-associated disease (e.g., a FGFR-associated cancer) using any of the methods described herein.

[00345] In certain embodiments of these methods, the treatment period can be from about 1 day to about 30 days (e.g., from about 1 day to about 15 days; e.g. about 7 days; e.g., from about 16 days to about 30 days, e.g., about 21 days). In other embodiments of these methods, the treatment period can be from 30 days to about 12 months (e.g., from about 30 days to about 9 months, from about 30 days to about 6 months, from about 30 days to about 120 days, from about 30 days to about 90 days, from about 30 days to about 60 days). In still other embodiments, the treatment period is 7 days or more or 21 days or more (e.g., more than 7 days or more than 21 days to about 12 months, more than 7 days or more than 21 days to about 9 months, more than 7 days or more than 21 days to about 6 months, more than 7 days or more than 21 days to about 120 days, more than 7 days or more than 21 days to about 90 days, more than 7 days or more than 21 days to about 60 days, more than 7 days or more than 21 days to about 30 days).

[00346] In some embodiments of these methods, the treatment period is at least or about 1 day, at least or about 2 days, at least or about 3 days, at least or about 4 days, at least or about 5 days, at least or about 6 days, at least or about 7 days, at least or about 8 days, at least or about 9 days, at least or about 10 days, at least or about 11 days, at least or about 12 days, at least or about 13 days, at least or about 14 days, at least or about 15 days, at least or about 16 days, at least or about 17 days, at least or about 18 days, at least or about 19 days, at least or about 20 days, at least or about 21 days, at least or about 22 days, at least or about 23 days, at least or about 24 days, at least or about 25 days, at least or about 26 days, at least or about 27 days, at least or about 28 days, at least or about 29 days, at least or about 30 days, at least or about 31 days, at least or about 45 days, at least or about 60 days, at least or about 90 days, at least or about 120 days, at least or about 6 months, at least or about 9 months, at least or about 12 months.

[00347] As used herein, the term "first FGFR inhibitor" means an FGFR inhibitor that is not a compound of Formula I or a salt or solvate thereof, or a pharmaceutical composition that includes a compound of Formula I or a salt or solvate thereof. Non-limiting examples of first FGFR inhibitor include JNJ-42756493 or BGJ398.

[00348] In some embodiments, the treatment period is at least 7 days (e.g., at least or about 8 days, at least or about 9 days, at least or about 10 days, at least or about 11 days, at least or about 12 days, at least or about 13 days, at least or about 14 days, at least or about 15 days, at least or about 16 days, at least or about 17 days, at least or about 18 days, at least or about 19 days, at least or about 20 days, at least or about 21 days, at least or about 22 days, at least or about 23 days, at least or about 24 days, at least or about 25 days, at least or about 26 days, at least or about 27 days, at least or about 28 days, at least or about 29 days, or at least or about 30 days), the FGFR inhibitor is JNJ-42756493, and a daily dose of about 6 mg to about 12 mg (e.g., about 6 mg to about 11 mg, about 10 mg, about 9 mg, about 8 mg, or about 7 mg; about 7 mg to about 12 mg, about 11 mg, about 10 mg, about 9 mg, or about 8 mg; about 8 mg to about 12 mg, about 11 mg, about 10 mg, or about 9 mg; about 9 mg to about 12 mg, about 1 1 mg, or about 10 mg; about 10 mg to about 12 mg or about 11 mg; or about 11 mg to about 12 mg) of the first FGFR inhibitor is administered to the patient over the treatment period.

[00349] In some embodiments, the treatment period is at least 21 days (e.g., at least or about 22 days, at least or about 23 days, at least or about 24 days, at least or about 25 days, at least or about 26 days, at least or about 27 days, at least or about 28 days, at least or about 29 days, at least or about 30 days, at least or about 31 days, at least or about 32 days, at least or about 33 days, at least or about 34 days, at least or about 35 days, at least or about 36 days, at least or about 37 days, at least or about 38 days, at least or about 39 days, or at least or about 40 days) the first FGFR is BGJ398, and a daily dose of about 50 mg to about 125 mg (e.g., about 50 mg to about 120 mg, about 115 mg, about 110 mg, about 105 mg, about 100 mg, about 95 mg, about 90 mg, about 85 mg, about 80 mg, about 75 mg, about 70 mg, about 65 mg, about 60 mg, or about 55 mg; about 55 mg to about 120 mg, about 115 mg, about 110 mg, about 105 mg, about 100 mg, about 95 mg, about 90 mg, about 85 mg, about 80 mg, about 75 mg, about 70 mg, about 65 mg, or about 60 mg; about 60 mg to about 120 mg, about 115 mg, about 110 mg, about 105 mg, about 100 mg, about 95 mg, about 90 mg, about 85 mg, about 80 mg, about 75 mg, about 70 mg, or about 65 mg; about 65 mg to about 120 mg, about 115 mg, about 110 mg, about 105 mg, about 100 mg, about 95 mg, about 90 mg, about 85 mg, about 80 mg, about 75 mg, or about 70 mg; about 70 mg to about 120 mg, about 115 mg, about 110 mg, about 105 mg, about 100 mg, about 95 mg, about 90 mg, about 85 mg, about 80 mg, or about 75 mg; about 75 mg to about 120 mg, about 115 mg, about 110 mg, about 105 mg, about 100 mg, about 95 mg, about 90 mg, about 85 mg, or about 80 mg; about 80 mg to about 120 mg, about 115 mg, about 110 mg, about 105 mg, about 100 mg, about 95 mg, about 90 mg, or about 85 mg; about 85 mg to about 120 mg, about 115 mg, about 110 mg, about 105 mg, about 100 mg, about 95 mg, or about 90 mg; about 90 mg to about 120 mg, about 115 mg, about 110 mg, about 105 mg, about 100 mg, or about 95 mg; about 95 mg to about 120 mg, about 115 mg, about 110 mg, about 105 mg, or about 100 mg; about 100 mg to about 120 mg, about 115 mg, about 110 mg, or about 105 mg; about 105 mg to about 120 mg, about 115 mg, or about 110 mg; about 110 mg to about 120 mg or about 115 mg; or about 115 mg to about 120 mg) of the first FGFR inhibitor is administered to the patient over the treatment period.

[00350] Hyperphosphatemia refers to an abnormally elevated level of phosphate in the blood. In some embodiments, the presence of hyperphosphatemia in a subject (e.g., a patient) can be determined by measuring a level(s) of phosphate in a biological sample including blood, serum, or plasma (e.g., peripheral blood) obtained from the patient after a particular treatment period (e.g., any of the treatment periods described herein). Determining the phosphate level in peripheral blood can be achieved using conventional methods known in the art (see, e.g., serum phosphate test offered, e.g., by the Mayo Clinic Laboratories, which utilizes the Roche Phosphorus reagent (Roche Diagnostics, Inc.; the test is based on the reaction of phosphate with ammonium molybdate to form ammonium phosphomolybdate (without reduction)).

[00351] In certain embodiments, the serum phosphate level exhibited by a subject (e.g., a subject treated wth a first FGFR inhibitor; e.g., a subject selected in step (c) above) is at least or about 5 mg/dL, at least or about 5.5 mg/dL, at least or about 6.0 mg/dL, at least or about 6.5 mg/dL, at least or about 7.0 mg/dL, at least or about 7.5 mg/dL, at least or about 8.0 mg/dL, at least or about 8.5 mg/dL, at least or about 9.0 mg/dL, at least or about 9.5 mg/dL, at least or about 10 mg/dL, at least or about 10.5 mg/dL, at least or about 11 mg/dL, at least or about 11.5 mg/dL, at least or about 12 mg/dL, at least or about 12.5 mg/dL, at least or about 13 mg/dL, at least or about 13.5 mg/dL, at least or about 14 mg/dL, or at least or about 15 mg/dL. In some embodiments, the reference level of phosphate can be the level in a healthy subject or the average level in a population of healthy subjects (e.g., subjects not having hyperphosphatemia or a subjects not at risk for developing hyperphosphatemia, such as those having a serum phosphate level of from about 2.0 mg/dL to about 5.0 mg/dL; e.g., from about 2.5 mg/dL to about 4.5 mg/dL).

[00352] In some examples, the step (c) further includes selecting a patient having an elevated level of phosphate in the biological sample as compared to a reference level of phosphate (e.g., any of the reference level of phosphate described herein) and one or both of: (i) a calcium- phosphate product (serum calcium in mg/dL x serum phosphate in mg/dL) of at least or about 50 mg ² /dL ² (e.g., at least or about 52 mg ² /dL ² , at least or about 54 mg ² /dL ² , at least or about 56 mg ² /dL ² , at least or about 58 mg ² /dL ² , at least or about 60 mg ² /dL ² , at least or about 62 mg ² /dL ² , at least or about 64 mg ² /dL ² , at least or about 66 mg ² /dL ² , at least or about 68 mg ² /dL ² , at least or about 70 mg ² /dL ² , at least or about 72 mg ² /dL ² , at least or about 74 mg ² /dL ² , at least or about 76 mg ² /dL ² , at least or about 78 mg ² /dL ² , at least or about 80 mg ² /dL ² , at least or about 82 mg ² /dL ² , at least or about 84 mg ² /dL ² , at leats or about 86 mg ² /dL ² , at least or about 88 mg ² /dL ² , at least about 90 mg ² /dL ² , at least or about 92 mg ² /dL ² , at least or about 94 mg ² /dL ² , at least or about 96 mg ² /dL ² , at least about 98 mg ² /dL ² , or at least about 100 mg ² /dL ² ) in the biological sample and (ii) a serum creatinine level of grade 1 or greater (e.g., grade 2, grade 3) in the biological sample. Exemplary assays for determining the calcium level of a biological sample including blood, serum, or plasma are commercially available from BioVision Inc. (Milpitas, CA) and Sigma-Aldrich (St. Louis, MO). Exemplary assays for determining the creatinine level in a biological sample including blood, serum, or plasma are commercially available from BioVision Inc. (Milpitas, CA) and Diazyme (Poway, CA). In other embodiments, the subject exhibits a serum phosphate level of greater than about 7.0 mg/dL (e.g., a serum phosphate level of greater than 7 mg/dL lasting for more than 7 days despite phosphate-lowering therapies). In still other embodiments, the subject exhibits a serum phosphate level of greater than about 9.0 mg/dL (e.g., a serum phosphate level of greater than about 9.0 mg/dL for any duration despite phosphate-lowering therapies). In still other embodiments, the subject exhibits a serum phosphate level of greater than about 10.0 mg/dL (e.g., a serum phosphate level of greater than about 10.0 mg/dL for any duration).

[00353] In some embodiments, the patient is administered a therapeutically effective amount of a phosphate binder over the treatment period. Non-limiting examples of phosphate binders include aluminum salts (e.g., Alucaps and Basaljel), calcium carbonate (e.g., Calcichew and Titralac), calcium acetate (e.g., Lenal Ace and PhosLo), sevelamer hydrochloride (e.g., Renegel or Renvela), and lanthanum carbonate (e.g., Fosrenol). In some embodiments, the patient is administered a therapeutically effective amount of a phosphate binder each day over the treatment period. The phosphate binder can be administered at a total daily dose of about 2.0 g to about 5.0 g (e.g., about 2.0 g to about 4.8 g, about 4.6 g, about 4.4 g, about 4.2 g, about 4.0 g, about 3.8 g, about 3.6 g, about 3.4 g, about 3.2 g, about 3.0 g, about 2.8 g, about 2.6 g, about 2.4 g, or about 2.2 g; about 2.2 g to about 5.0 g, about 4.8 g, about 4.6 g, about 4.4 g, about 4.2 g, about 4.0 g, about 3.8 g, about 3.6 g, about 3.4 g, about 3.2, about 3.0 g, about 2.8 g, about 2.6 g, or about 2.4 g; about 2.4 to about 5.0 g, about 4.8 g, about 4.6 g, about 4.4 g, about 4.2 g, about 4.0 g, about 3.8 g, about 3.6 g, about 3.4 g, about 3.2, about 3.0 g, about 2.8 g, or about 2.6 g; about 2.6 g to about 5.0 g, about 4.8 g, about 4.6 g, about 4.4 g, about 4.2 g, about 4.0 g, about 3.8 g, about 3.6 g, about 3.4 g, about 3.2, about 3.0 g, or about 2.8 g; about 2.8 g to about 5.0 g, about 4.8 g, about 4.6 g, about 4.4 g, about 4.2 g, about 4.0 g, about 3.8 g, about 3.6 g, about 3.4 g, about 3.2, or about 3.0 g; about 3.0 g to about 5.0 g, about 4.8 g, about 4.6 g, about 4.4 g, about 4.2 g, about 4.0 g, about 3.8 g, about 3.6 g, about 3.4 g, or about 3.2 g; about 3.2 g to about 5.0 g, about 4.8 g, about 4.6 g, about 4.4 g, about 4.2 g, about 4.0 g, about 3.8 g, about 3.6 g, or about 3.4 g; about 3.4 g to about 5.0 g, about 4.8 g, about 4.6 g, about 4.4 g, about 4.2 g, about 4.0 g, about 3.8 g, or about 3.6 g; about 3.6 g to about 5.0 g, about 4.8 g, about 4.6 g, about 4.4 g, about 4.2 g, about 4.0 g, or about 3.8 g; about 3.8 g to about 5.0 g, about 4.8 g, about 4.6 g, about 4.4 g, about 4.2 g, or about 4.0 g; about 4.0 g to about 5.0 g, about 4.8 g, about 4.6 g, about 4.4 g, or about 4.2 g; about 4.2 g to about 5.0 g, about 4.8 g, about 4.6 g, or about 4.4 g; about 4.4 g to about 5.0 g, about 4.8 g, or about 4.6 g; about 4.6 g to about 5.0 g or about 4.8 g; or about 4.8 g to about 5.0 g) over the treatment period. In some embodiments of these methods, step (d) further includes ceasing administration of the phosphate binder to the selected patient or instructing the selected patient to cease administration of the phosphate binder. In some embodiments of these methods, step (d) further includes administering a decreased dose of the phosphate binder to the selected patient relative to the dose of the phosphate binder administered to the patient over the treatment period.

[00354] Also provided herein are methods of treating a FGFR-associated cancer (e.g., any of the FGFR-associated cancers described herein or known in the art) in a patient that includes administering a therapeutically effective dose of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, to a patient identified or diagnosed as having an FGFR-associated cancer over a treatment period of at least 8 days, where the patient is determined to have about the same or a decreased level of phosphate in one or more biological sample(s) including blood, serum, or plasma obtained from the patient over the treatment period as compared to a reference level of phosphate (e.g., any of the reference levels of phosphate described herein). In some embodiments of any of these methods, the patient is identified or diagnosed as having a FGFR-associated cancer using any of the methods described herein or known in the art. Some embodiments of any of these methods can further include identifying or diagnosing a subject as having a FGFR-associated cancer using any of the methods described herein or known in the art. In some embodiments, the treatment period of at least 8 days can be any of the exemplary treatment periods (or ranges of treatment periods) described herein. In some embodiments, the patient is administered a daily dose of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof (e.g., any of the pharmaceutical compositions described herein) over the treatment period. [00355] In some embodiments of these methods, the patient is administered a low dose of a phosphate binder (e.g., any of the exemplary phosphate binders described herein or known in the art) over the treatment period. In some embodiments of these methods, the phosphate binder is sevelamer hydrochloride. In some embodiments of these methods, the lose dose of the phosphate binder (e.g., sevelamer hydrochloride) can be a total daily administration of about 0.1 g to about 2.0 g (e.g., about 0.1 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, about 1.2 g, about 1.1 g, about 1.0 g, about 0.9 g, about 0.8 g, about 0.7 g, about 0.6 g, about 0.5 g, about 0.4 g, about 0.3 g, or about 0.2 g; about 0.2 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, about 1.2 g, about 1.1 g, about 1.0 g, about 0.9 g, about 0.8 g, about 0.7 g, about 0.6 g, about 0.5 g, about 0.4 g, or about 0.3 g; about 0.3 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, about 1.2 g, about 1.1 g, about 1.0 g, about 0.9 g, about 0.8 g, about 0.7 g, about 0.6 g, about 0.5 g, or about 0.4 g; about 0.4 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, about 1.2 g, about 1.1 g, about 1.0 g, about 0.9 g, about 0.8 g, about 0.7 g, about 0.6 g, or about 0.5 g; about 0.5 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, about 1.2 g, about 1.1 g, about 1.0 g, about 0.9 g, about 0.8 g, about 0.7 g, or about 0.6 g; about 0.6 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, about 1.2 g, about 1.1 g, about 1.0 g, about 0.9 g, about 0.8 g, or about 0.7 g; about 0.7 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, about 1.2 g, about 1.1 g, about 1.0 g, about 0.9 g, or about 0.8 g; about 0.8 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, about 1.2 g, about 1.1 g, about 1.0 g, or about 0.9 g; about 0.9 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, about 1.2 g, about 1.1 g, or about 1.0 g; about 1.0 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, about 1.2 g, or about 1.1 g; about 1.1 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, about 1.3 g, or about 1.2 g; about 1.2 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, about 1.4 g, or about 1.3 g; about 1.3 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, about 1.5 g, or about 1.4 g; about 1.4 g to about 1.9 g, about 1.8 g., about 1.7 g, about 1.6 g, or about 1.5 g; about 1.5 g to about 1.9 g, about 1.8 g., about 1.7 g, or about 1.6 g; about 1.6 g to about 1.9 g, about 1.8 g., or about 1.7 g; about 1.7 g to about 2.0 g, about 1.9 g, or about 1.8 g; about 1.8 g to about 2.0 g or about 1.9 g; or about 1.9 g to about 2.0 g) of the phosphate binder.

[00356] In some embodiments, the patient is determined to have about the same or a decreased level of phosphate in one or more (e.g., two, three, four, five, or six) biological sample(s) including blood, serum, or plasma obtained from the patient at 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days (1 week), 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days (2 weeks), 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 32 days, 33 days, 34 days, 35 days, 36 days, 37 days, 38 days, 39 days, 40 days, 41 days, 42 days, 43 days, 44 days, 45 days, 46 days, 47 days, 48 days, 49 days, 50 days, 51 days, 52 days, 53 days, 54 days, 55 days, 56 days, 57 days, 58 days, 59 days, 60 days, 61 days, 62 days, 63 days, 64 days, 65 days, 66 days, 67 days, 68 days, 69 days, 70 days, 71 days, 72 days, 73 days, 74 days, 75 days, 76 days, 77 days, 78 days, 79 days, 80 days, 81 days, 82 days, 83 days, 84 days, 85 days, 86 days, 87 days, 88 days, 89 days, 90 days, 91 days, 92 days, 93 days, 94 days, 95 days, 96 days, 97 days, 98 days, 99 days, or 100 days following the start of the treatment period as compared to a reference level of phosphate (e.g., any of the reference levels of phosphate described herein).

[00357] Also provided are methods of treating a FGFR-associated cancer (e.g., any of the FGFR-associated cancers described herein or known in the art) that include administering a therapeutically effective dose of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof (e.g., any of the pharmaceutical compositions described herein) to a patient identified or diagnosed as having an FGFR-associated cancer over a treatment period (e.g., any of the treatment periods described herein), wherein the patient is not administered a phosphate binder (e.g., any of the phosphate binders described herein or known in the art) over or during the treatment period. In some embodiments of any of these methods, the patient is identified or diagnosed as having a FGFR-associated cancer using any of the methods described herein or known in the art. Some embodiments of any of these methods can further include identifying or diagnosing a subject as having a FGFR-associated cancer using any of the methods described herein or known in the art. In some embodiments, the treatment period can be any of the exemplary treatment periods described herein or any of the exemplary ranges of treatment periods described herein. In some embodiments, the patient is administered a daily dose of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof (e.g., any of the pharmaceutical compositions described herein) over the treatment period.

[00358] Also provided herein are methods of treating a FGFR-associated cancer (e.g., any FGFR-associated cancer described herein or known in the art) in a patient that include administering a therapeutically effective dose of a compound of Formula I or pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof (e.g., any of the pharmaceutical compositions described herein) to a patient identified or diagnosed as having an FGFR-associated cancer over a treatment period (e.g., any of the treatment periods described herein), wherein the patient is further administered a low dose of a phosphate binder (e.g., any of the phosphate binders described herein, e.g., sevelamer hydrochloride) (e.g., any of the low doses of a phosphate binder described herein) over or over at least a part of the treatment period. Some embodiments of any of these methods can further include identifying or diagnosing a subject as having a FGFR- associated cancer using any of the methods described herein or known in the art. In some embodiments, the treatment period can be any of the exemplary treatment periods described herein or any of the exemplary ranges of treatment periods described herein. In some embodiments, the patient is administered a daily dose of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof (e.g., any of the pharmaceutical compositions described herein) over the treatment period.

[00359] Also provided are methods of treating a patient having a FGFR-associated cancer (e.g., any of the FGFR-associated cancers described herein or known in the art) that include administering a therapeutically effective dose of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I of a pharmaceutically acceptable salt or solvate thereof (e.g., any of the pharmaceutical compositions described herein) to a patient identified or diagnosed as having an FGFR-associated cancer over a treatment period (e.g., any of the treatment periods described herein), where the patient does not experience or is less likely to experience one or more (e.g., two, three, four, five, six, seven, eight, or nine) of soft tissue calcification, stomatitis, dry mouth, nail changes, fatigue, asthenia, anorexia, malaise, and muscle aches over the treatment period or after the treatment period (e.g., as compared to a patient or a population of patients having the same FGFR-associated cancer and administered a therapeutically effective dose of a FGFR inhibitor that is not a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, over the same treatment period). Some embodiments of any of these methods can further include identifying or diagnosing a subject as having a FGFR-associated cancer using any of the methods described herein or known in the art. In some embodiments, the treatment period can be any of the exemplary treatment periods described herein or any of the exemplary ranges of treatment periods described herein. In some embodiments, the patient is administered a daily dose of a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof (e.g., any of the pharmaceutical compositions described herein) over the treatment period.

[00360] In some embodiments of these methods, the patient is not administered a phosphate binder (e.g., any of the phosphate binders described herein or known in the art) during the treatment period. In such methods, the patient can be, e.g., less likely to experience one or more (e.g., two, three, four, five, six, seven, eight, or nine) of soft tissue calcification, stomatitis, dry mouth, nail changes, fatigue, asthenia, anorexia, malaise, and muscle aches over the treatment period or after the treatment period (e.g., as compared to a patient or a population of patients having the same FGFR-associated cancer and administered a therapeutically effective dose of a FGFR inhibitor that is not a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, and is not administered a phosphate binder, over the same treatment period).

[00361] In some embodiments of these methods, the patient is administered a low dose of a phosphate binder (e.g., any of the phosphate binders described herein, e.g., sevelamer hydrochloride) (e.g., any of the exemplary low doses of a phosphate binder described herein). In such methods, the patient can be, e.g., less likely to experience one or more (e.g., two, three, four, five, six, seven, eight, or nine) of soft tissue calcification, stomatitis, dry mouth, nail changes, fatigue, asthenia, anorexia, malaise, and muscle aches over the treatment period or after the treatment period (e.g., as compared to a patient or a population of patients having the same FGFR- associated cancer and administered a therapeutically effective dose of a FGFR inhibitor that is not a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, and is administered the same low dose of phosphate binder, over the same treatment period).

[00362] The level of soft tissue calcification can be detected/determined in a patient by a medical professional using, e.g., ultrasound, radiography, computed tomography, and magnetic resonance imaging. The level of stomatitis, dry mouth, nail changes, fatigue, asthenia, anorexia, malaise, and muscle aches in a patient can be determined by a medical professional through the physical examination of the patient and/or interviewing the patient (e.g., using a survey).

[00363] In some embodiments, the patient is less likely to experience one or more (e.g., two, three, four, five, six, seven, eight, or nine) of soft tissue calcification, stomatitis, dry mouth, nail changes, fatigue, asthenia, anorexia, malaise, and muscle aches over the treatment period or after the treatment period (e.g., as compared to a patient or a population of patients having the same FGFR-associated cancer and administered a therapeutically effective dose of a FGFR inhibitor that is not a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition including a compound of Formula I or a pharmaceutically acceptable salt or solvate thereof, and is administered the same low dose of phosphate binder, over the same treatment period).

[00364] The phrase "effective amount" means an amount of compound that, when administered to a patient in need of such treatment, is sufficient to (i) treat a particular disease, condition, or disorder mediated by FGFR1, FGFR2 FGFR3 and/or FGFR4, (ii) attenuate, ameliorate, or eliminate one or more symptoms of the particular disease, condition, or disorder, or (iii) delay the onset of one or more symptoms of the particular disease, condition, or disorder described herein. The amount of a compound of Formula I that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight) of the patient in need of treatment, but can nevertheless be routinely determined by one skilled in the art.

[00365] When employed as pharmaceuticals, the compounds provided herein can be administered in the form of pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable

[00366] Also provided herein pharmaceutical compositions which contain, as the active ingredient, a compound as provided herein or a pharmaceutically acceptable salt or solvate thereof, in combination with one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical administration. In making the compositions provided herein, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. In one embodiment, the composition is formulated for oral administration. In one embodiment, the composition is formulated as a tablet or capsule.

[00367] The compositions comprising a compound provided herein or a pharmaceutically acceptable salt or solvate thereof can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other patients, each unit containing a predetermined quantity of active material (i.e., a compound for Formula I as provided herein) calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

[00368] In some embodiments, the compositions provided herein contain from about 5 mg to about 50 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compounds or compositions containing about 5 mg to about 10 mg, about 10 mg to about 15 mg, about 15 mg to about 20 mg, about 20 mg to about 25 mg, about 25 mg to about 30 mg, about 30 mg to about 35 mg, about 35 mg to about 40 mg, about 40 mg to about 45 mg, or about 45 mg to about 50 mg of the active ingredient.

[00369] In some embodiments, the compositions provided herein contain from about 50 mg to about 500 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compounds or compositions containing about 50 mg to about 100 mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 200 mg to about 250 mg, about 250 mg to about 300 mg, about 350 mg to about 400 mg, or about 450 mg to about 500 mg of the active ingredient.

[00370] In some embodiments, the compositions provided herein contain from about 500 mg to about 1,000 mg of the active ingredient. One having ordinary skill in the art will appreciate that this embodies compounds or compositions containing about 500 mg to about 550 mg, about 550 mg to about 600 mg, about 600 mg to about 650 mg, about 650 mg to about 700 mg, about 700 mg to about 750 mg, about 750 mg to about 800 mg, about 800 mg to about 850 mg, about 850 mg to about 900 mg, about 900 mg to about 950 mg, or about 950 mg to about 1,000 mg of the active ingredient.

[00371] The active compound may be effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like. In some embodiments, the active compound is administered at a dosage of from about 0.001 mg/Kg to about 500 mg/Kg (e.g., from about 0.001 mg/Kg to about 200 mg/Kg; from about 0.01 mg/Kg to about 200 mg/Kg; from about 0.01 mg/Kg to about 150 mg/Kg; from about 0.01 mg/Kg to about 100 mg/Kg; from about 0.01 mg/Kg to about 50 mg/Kg; from about 0.01 mg/Kg to about 10 mg/Kg; from about 0.01 mg/Kg to about 5 mg/Kg; from about 0.01 mg/Kg to about 1 mg/Kg; from about 0.01 mg/Kg to about 0.5 mg/Kg; from about 0.01 mg/Kg to about 0.1 mg/Kg; from about 0. 1 mg/Kg to about 200 mg/Kg; from about 0. 1 mg/Kg to about 150 mg/Kg; from about 0. 1 mg/Kg to about 100 mg/Kg; from about 0.1 mg/Kg to about 50 mg/Kg; from about 0. 1 mg/Kg to about 10 mg/Kg; from about 0. 1 mg/Kg to about 5 mg/Kg; from about 0. 1 mg/Kg to about 1 mg/Kg; from about 0. 1 mg/Kg to about 0.5 mg/Kg).

[00372] Provided herein are pharmaceutical kits useful, for example, in the treatment of FGFR-associated diseases or disorders, such as cancer, which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound provided herein. Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, etc., as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.

[00373] One skilled in the art will recognize that, both in vivo and in vitro trials using suitable, known and generally accepted cell and/or animal models are predictive of the ability of a test compound to treat or prevent a given disorder.

[00374] One skilled in the art will further recognize that human clinical trials including first- in-human, dose ranging and efficacy trials, in healthy patients and/or those suffering from a given disorder, may be completed according to methods well known in the clinical and medical arts.

EXAMPLES

[00375] The following examples illustrate the invention.

[00376] Synthetic Examples

[00377] Synthesis of Synthetic Intermediates

[00378] Abbreviations

DMF N,N-Dimethylformamide

dppf 1,1'- bis(diphenylphosphanyl) ferrocene

eq equivalent/equivalents

Et ₂ 0 Diethyl ether

EtOAc Ethyl Acetate

EtOH Ethanol

GFF paper or GF/F paper Whatman glass microfiber filter paper

h hour/hours

HATU 2-(7-Aza- IH-benzotriazole- 1 -yl)- 1,1,3,3 -tetram ethyl uronium hexafluorophosphate

iPrOH Isopropanol

KOAc Potassium Acetate

MeOH Methanol

min minute/minutes

MsCl methansulfonyl chloride

BS N-Bromosuccinimide

Pd(OAc) ₂ Palladium (II) Acetate

Pd(PPh ₃ ) ₄ Tetrakis(triphenylphosphine)palladium (0)

PdCl ₂ fdppf CH ₂ Cl ₂ l,l'-Bis(diphenylphosphino)ferrocene-palladium(II)di chloride dichloromethane complex

TEA Triethylamine

TFA Trifluoroacetic acid

THF tetrahydrofuran

TLC thin layer chromatography

X-Phos dicyclohexyl(2',4',6'-triisopropyl-[l, -biphenyl]-2-yl)phosphine

[00379] Synthesis of Synthetic Intermediates

[00380] Intermediate SI

[00381] [00382] (2R.5R)-tert-butyl 5-ηΐ6ΐ1ιν1-2-(((ηΐ6ΐ1ΐνΐ5^ΓοηνΠοχν)ηΐ6� �1ΐνΠηΐθφ1ΐο1ίη6-4- carboxylate

[00383] A cold (0 °C) solution of (2R,5R)-tert-butyl 2-(hydroxymethyl)-5- methylmorpholine-4-carboxylate (275 mg, 1.19 mmol) and DIPEA (312 μΐ,, 1.78 mmol) in DCM (6 mL) was treated with MsCl (1 10 μΐ., 1.43 mmol). The resulting mixture was stirred overnight at ambient temperature. The mixture was partitioned between saturated NaHC0 ₃ ( _aq ) (30 mL) and DCM (20 mL), and the aqueous extracts were washed with additional DCM (2 x 10 mL). The combined organic extracts were washed with brine (10 mL), dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum affording the title compound (367 mg, 99% yield). This material was of sufficient purity to be used directly without further purification.

[00384] The following intermediates shown in Table SI were prepared according the method used for the synthesis of Intermediate S I using the appropriate chiral hydroxym ethyl - (morpholine)carboxylate starting materials. The reaction progression in each was followed by TLC (50%) Hexanes/ EtOAc, KMn0 ₄ stain) and reaction times were adjusted as necessary.

Table SI

00385] Intermediate S6

[00387] (l-cyanocyclopropyl)m ethyl methanesulfonate

[00388] A solution of l-(hydroxymethyl)cyclopropanecarbonitrile (1.14 g, 11.7 mmol) in

DCM (24 mL) was treated with TEA (3.50 mL, 25.8 mmol). The resulting reaction mixture was cooled to 0 °C, treated dropwise with MsCl (1.37 mL, 17.6 mmol) and stirred for 1 h at 0 °C. The reaction mixture was stirred at ambient temperature for an additional 2 h before being diluted with additional DCM (100 mL) and washed with brine (25 mL). The organic extracts were dried over anhydrous Na ₂ S04(s), filtered and concentrated under vacuum to afford the title compound (2.057 g, 100% yield). This material was of sufficient purity to be used directly without further purification. 1H MR (400 MHz, DMSO-d6) δ 4.27 (s, 2H), 3.23 (s, 3H), 1.42-1.38 (m, 2H), 1.21-1.18 (m, 2H).

[00389] Intermediate PI

[00390]

[00391] tert-butyl (2R.5R)-5-methyl-2-((4-(4.4.5.5-tetramethyl-1.3.2-dioxaborol an-2-vn- lH-pyrazol-l-yl)methyl)morpholine-4-carboxylate

[00392] A mixture of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (276 mg, 1.42 mmol), (2R,5R)-tert-butyl 5-methyl-2-(((methylsulfonyl)oxy)methyl)morpholine-4- carboxylate (Intermediate SI; 367 mg, 1.19 mmol), and Cs ₂ C03( _S ) (966 mg, 2.97 mmol) was suspended in DMF (5.93 mL) and stirred for 1 day at ambient temperature. The mixture was partitioned between EtOAc (100 mL) and H ₂ 0 (50 mL). The organic extracts were separated and then dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (0-100% EtOAc /Hexanes) to afford the title compound (483 mg, 100% yield). MS (apci) m/z = 408.2 (M+H).

[00393] The following intermediates shown in Table PI were prepared according the method used for the synthesis of Intermediate PI, tert-butyl (2R,5R)-5-methyl-2-((4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l-yl)methyl) morpholine-4-carboxylate, using the appropriate chiral methanesulfonoxy-methyl-mo holine-4-carboxylate starting materials (Intermediates S2-S5 from Table SI). All compounds were purified using a method similar to that used for purifying Intermediate PI utilizing the appropriate gradient for the silica chromatography.

Table PI

e-4-carboxylate [00394] Intermediate P6

[00396] l-((4-(4.4.5.5-tetramethyl-1.3.2-dioxaborolan-2-vn-lH-pyrazo l-l- yl)methyl)cyclopropane- 1 -carbonitrile

[00397] A solution of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (1.52 g,

7.83 mmol) in DMA (31 mL) was treated with l-cyanocyclopropyl)methyl methanesulfonate (Intermediate S6; 1.99 g, 11.4 mmol), Cs ₂ C0 ₃ ( _S ) (3.83 g, 11.8 mmol) and 4A molecular sieves (250 mg). The resulting suspension was stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was filtered, and the solids collected were rinsed with EtOAc (50 mL). The filtrate was diluted with toluene (150 mL) and concentrated under vacuum. The resulting crude residue was azeotroped with toluene (150 mL) several times to remove most of the DMA and subsequently purified by silica chromatography (5- 75% Hexanes/EtOAc as the gradient eluent) to afford the title compound (1.38 g, 65% yield). ¾ MR (400 MHz, DMSO-d ₆ ) δ 8.03 (s, 1H), 7.65 (s, 1H), 4.28 (s, 2H), 1.33-1.23 (m, 16H).

[00398] Intermediate P7

[00399]

[00400] 4 A4-trifluoro- 1 -(4-(4 A 5.5-tetramethyl- 1.3.2-dioxaborolan-2-yiy lH-pyrazol- 1 - yl)butan-2-ol

[00401] A mixture of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (500 mg, 2.58 mmol), 2-(2,2,2-trifluoroethyl)oxirane (390 mg, 3.09 mmol), and Cs ₂ C0 _3(s) (1.68 g, 5.15 mmol) was suspended in DMF (2.58 mL) and stirred overnight at 80 °C. The mixture was partitioned between EtOAc (50 mL) and H ₂ 0 (25 mL). The organic extracts were separated then dried over anhydrous Na ₂ S04( _S ) filtered and concentrated under vacuum to afford the title compound (825 mg, 100% yield). MS (apci) m/z = 321.1 (M+H). This material was of sufficient purity to be used directly without further purification.

[00402] Intermediate P8

[00403] [00404] 2-methyl-2-(4-(4.4.5.5-tetrametfayl-l .2-dioxaborolan-2-yl)-lH-pyrazol-l- yPpropanenitrile

[00405] Step 1 : Preparation of 2-(4-(4.4.5.5-tetramethyl-1.3.2-dioxaborolan-2-vn-lH- pyrazol- 1 -vDacetonitrile. A solution of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazole (5.11 g, 26.3 mmol) in DMF (50 mL) was treated with bromoacetonitrile (2.20 mL, 31.6 mmol) and K2C0 ₃ ( _S ) (5.46 g, 39.5 mmol). The resulting suspension was stirred for 24 h at 100 °C. The reaction mixture was cooled to ambient temperature, diluted with water (100 mL) then extracted with EtOAc (3 x 250 mL). The combined organic extracts were washed with water (3 x 50 mL) and brine (50 mL) then dried over anhydrous Na2S04( _S ). Following filtration, the organic extracts were concentrated under vacuum then purified by silica chromatography (10-60% Hexanes/EtOAc as the gradient eluent) to afford the title compound (2.42 g, 39% yield). ¾ NMR (400 MHz, DMSO-de) δ 8.04 (s, 1H), 7.71 (s, 1H), 5.49 (s, 2H), 1.25 (s, 12H).

[00406] Step 2: Preparation of 2-methyl-2-(4-(4.4.5.5-tetramethyl-1.3.2-dioxaborolan-2- vP- lH-pyrazol- 1 -vOpropanenitrile. A cold (0 °C) solution of 2-(4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazol-l-yl)acetonitrile (2.42 g, 10.4 mmol) in THF (26 mL) was treated with iodomethane (1.94 mL, 31.1 mmol) then drop-wise with sodium bis(trimethylsilyl)amide (22.8 mL, 22.8 mmol). The resulting mixture was stirred 1 h at 0 °C before quenching with the addition of saturated FLCltaq) (25 mL). At ambient temperature the reaction mixture was then partitioned between EtOAc (250 mL) and water (100 mL). The organic extracts were washed again with water (50 mL) and brine (50 mL), then dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (5-50%, Hexanes/EtOAc as the gradient eluent) to afford the title compound (1.35 g, 50% yield). ¾ NMR (400 MHz, DMSO-de) δ 8.20 (s, 1H), 7.75 (s, 1H), 1.97 (s, 6H), 1.26 (s, 12H).

[00407] Intermediate P9

[00408]

[00409] 2-methyl-l-(4-(4.4.5.5-tetramethyl-1.3.2-dioxaborolan-2-ylVl H-pyrazol-l- yl)propan-2-ol

[00410] A mixture of 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (2.16 g,

11.1 mmol) and Cs2C0 ₃ ( _S ) (3.81 g, 11.7 mmol) in 2,2-dimethyloxirane (3 mL, 33.6 mmol) was stirred overnight at 100 °C. The reaction mixture was filtered through GFF paper and the filtrate was concentrated under vacuum to afford the title compound (2.48 g, 84 % yield). This material was of sufficient purity to be used directly without further purification. ¾ MR (CDC13) δ 7.81 (s, 1H), 7.69 (s, 1H

00411] Intermediate Yl

[00413] tert-butyl 4-(5-aminopyrazin-2-yl)-lH-pyrazole-l-carboxylate

[00414] A mixture of 2-amino-5-bromopyrazine (100 mg, 0.575 mmol), tert-butyl 4-

(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole -l-carboxylate (338 mg, 1.15 mmol), PdCl ₂ dppf CH ₂ Cl ₂ (47.3 mg, 0.0575 mmol), K ₂ C0 _3(S ) (238 mg, 1.72 mmol) was suspended in a mixture of dioxane (5.75 mL) and water (1.15 mL). The mixture was sparged with A%), then sealed and stirred for 4 h at 90 °C. After cooling to ambient temperature, the reaction mixture was diluted with EtOAc, filtered then concentrated under vacuum. The crude residue was purified by silica chromatography (70-100% EtOAc in Hexanes as the eluent) to afford the title compound (84 mg, 56% yield). MS (apci) m/z = 162.1 (desBoc M+H).

[00415] The following 4-(5-aminopyrazin-2-yl)-lH-pyrazole intermediates, shown in Table

Yl, were prepared in a manner similar to the method used for the synthesis of Intermediate Yl, using the appropriate arylboronate starting materials (commercially available or synthesized according to Examples provided herein), excess K ₂ C0 ₃ ( _S > (0.1-0.2 equivalents), 0.1-0.2 M in 5: 1 dioxane:water and temperatures between 85 - 90 °C. Reaction progression in each was followed by LCMS and reactions times were adjusted as necessary. All compounds were purified by silica chromatography as in Intermediate Yl utilizing the appropriate eluent.

Table Yl

carboxylate

[00416] Intermediate Y2

[00418] 5 -( 1 -methyl- 1 H-pyrazol-4-yl)pyrazin-2-amine

[00419] A solution of 2-amino-5-bromopyrazine (5.7 g, 33 mmol) in 4: 1 dioxane:water (300 mL) was treated with l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazole (7.2 g, 34 mmol), PdCl ₂ dppf CH ₂ Cl ₂ (1.3 g, 1.6 mmol), K ₂ C0 _3(S ) (14 g, 98 mmol). The mixture was sparged with A¾), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM/iPrOH (500 mL), and the resulting solution was extracted with water (2 x 100 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (1-30% DCM/MeOH as the gradient eluent) to afford the title compound (63.4 mg, 63% yield). MS (apci) m/z = 176.1 (M+H).

[00420] Intermediate Y3

[00422] 5-(l-isopropyl-lH-pyrazol-4-yl)pyrazin-2-amine

[00423] A mixture of 2-amino-5-bromopyrazine (0.505 g, 2.90 mmol), l-isopropyl-4-

(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (0.822 g, 3.48 mmol), Pd(PPh ₃ ) ₄ (0.168 g, 0.145 mmol), 2M Na ₂ C0 ₃ ( _aq ) (3.05 mL, 6.09 mmol) in dioxane (9 mL) was stirred overnight at 90 °C. After cooling to ambient temperature, the reaction mixture was diluted with DCM then extracted with water and brine. The organic extracts were dried over anhydrous Na2S04( _S ), filtered then concentrated under vacuum. The resulting crude residue was purified by silica chromatography to afford the title compound (0.415 g, 70% yield). MS (apci) m/z = 204.1 (M+H).

[00424] The following 4-(5-aminopyrazin-2-yl)-lH-pyrazole intermediates, shown in Table

Y3, were prepared according the method used for the synthesis of Intermediate Y3 using the appropriate arylboronate starting materials (commercially available or prepared as described herein). Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified by silica chromatography according to the method for the isolation of Intermediate Y3 utilizing the appropriate eluent.

Table Y3

methylpropan-2-ol 00425] Intermediate Y5

[00427] 5-(l-(pentan-3-yl)-lH-pyrazol-4-yl)pyrazin-2-amine

[00428] A mixture of 2-amino-5-bromopyrazine (90.6 mg, 0.521 mmol), l-(pentan-3-yl)-4-

(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (194 mg, 0.573 mmol), PdCl ₂ dppf CH ₂ Cl ₂ (42.84 mg, 0.0521 mmol), K ₂ C0 _3(S ) (216 mg, 1.56 mmol ) was suspended in a mixture of dioxane (5.21 mL), and water (1.04 mL). The mixture was sparged with A%), then sealed and stirred overnight at 90 °C. After cooling to ambient temperature, the reaction mixture was diluted with DCM and water. The organic extracts were washed with water and brine then dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (70-100% EtOAc in Hexanes as the eluent) to afford the title compound (40 mg, 33% yield). MS (apci) m/z = 232.1 (M+H).

00429] Intermediate Y14

[00431] 1 -((4-(5-aminopyrazin-2-yl)- IH-pyrazol- 1 -vDmethyDcyclopropane- 1 -carbonitrile

[00432] A solution of l-((4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyraz ol-l- yl)methyl)cyclopropanecarbonitrile (Intermediate P6; 560.0 mg, 2.050 mmol) in 4: 1 dioxane:water (10 mL) was treated with 2-amino-5-bromopyrazine (356.7 mg, 2.050 mmol), Pd(PPh ₃ ) ₄ (236.9 mg, 0.2050 mmol), K ₂ C0 _3(S ) (850.1 mg, 6.151 mmol). The mixture was sparged with Ar(g), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (200 mL) and the resulting solution was extracted with water (2 x 50 mL). The organic extracts were dried over anhydrous Na ₂ S0 ₄ ( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (1-30% DCM/MeOH as the gradient eluent) to afford the title compound (246.6 mg, 51% yield). MS (apci) m/z = 241.1 (M+H).

00433] Intermediate Y15

[00435] l-(4-(5-aminopyrazin-2-yl)-lH-pyrazol-l-yl)-4,4,4-trifluorob utan-2-ol

[00436] The title compound was prepared (83.2 mg, 23% yield) according to the method described for Intermediate Y14, using 4,4,4-trifluoro-l-(4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazol-l-yl)butan-2-ol (Intermediate P7) in place of l-((4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l-yl)methyl) cyclopropanecarbonitrile

(Intermediate P6). MS (apci) m/z = 288.0 (M+H).

00437] Intermediate Y16

[00439] 2-(4-(5-aminopyrazin-2-yl)-lH-pyrazol-l-yl)-2-methylpropanen itrile

[00440] A solution of 2-amino-5-bromopyrazine (258.9 mg, 1.488 mmol) in 4: 1 dioxane:water (10 mL) was treated with l-((4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazol-l-yl)methyl)cyclopropanecarbonitrile (Intermediate P8; 560.0 mg, 2.050 mmol), PdCl ₂ fdppf CH ₂ Cl ₂ (122.4 mg, 0.1488 mmol), K ₂ C0 _3(S) (616.9 mg, 4.464 mmol). The mixture was sparged with A%), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (250 mL) and the resulting solution was extracted with water (2 x 50 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by C18 reverse phase chromatography (5-95% water/ ACN with 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (100 mL) and extracted with saturated NaHC0 ₃ (aq) (1 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to cleanly afford the title compound (77 mg, 23% yield). MS (apci) m/z = 229.1 (M+H).

00441] Intermediate Y18

[00443] 2-(4-(5-aminopyrazin-2-yl)-lH-pyrazol-l-yl)-2-methylpropan-l -ol

[00444] The title compound was prepared (97.2 mg, 23% yield) according to the method described for Intermediate Y16, using 2-methyl-2-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-lH-pyrazol-l-yl)propan-l-ol in place of l-((4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- lH-pyrazol-l-yl)methyl)cyclopropanecarbonitrile (Intermediate P9). MS (apci) m/z = 234.1 (M+H).

[00445] Intermediate Y19

[00447] tert-butyl 4-(4-(5-aminopyrazin-2-yl)-lH-pyrazol-l-yl)piperidine-l-carb oxylate

[00448] A mixture of 2-amino-5-bromopyrazine (5.0 g, 28.7 mmol), tert-butyl 4-(4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l-y l)piperidine-l-carboxylate (11.9 g, 31.6 mmol), Pd(PPh ₃ ) ₄ (3.32 g, 2.87 mmol), 2M Na ₂ C0 ₃ ( _a q) (35.9 mL, 71.8 mmol) in dioxane (57.5 mL) was purged with N ₂ ( _g > for 6 min then sealed and stirred for 16 h at 90 °C. After cooling to ambient temperature, the reaction mixture was diluted with EtOAc (300 mL) and washed with water (2 x 80 mL). The combined organic extracts were dried over anhydrous MgS04( _S ), filtered and concentrated under vacuum. The resulting crude residue was precipitated from hot ACN (X mL) to provide pure title compound (6.35 g). Mother liquor was concentrated under vacuum and the residue obtained was purified by flash chromatography on silica gel (Redi Sep 220 g) eluting with 5-60% acetone/DCM (15CV) to provide additional title compound (3.17 g; 96% total yield). MS (apci) m/z = 245.1 [(M-Boc)+H]. MS data are for the purified forms of batch land batch 2.

[00449] Intermediate Y20

[00451] 5 -( 1 -methyl- 1 H-pyrazol-4-yl)pyri din-2-amine

[00452] A solution of 2-amino-5-bromopyrazine 1.03 g, 5.95 mmol) in 4: 1 dioxane:water

(20 mL) was treated with l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH- pyrazole (1.30 g, 6.25 mmol), PdCl ₂ fdppf CH ₂ Cl ₂ (0.490 g, 0.595 mmol), K ₂ C0 ₃ ( _S ) (2.47 g, 17.9 mmol). The mixture was sparged with A%), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (250 mL) and the resulting solution was extracted with water (2 x 50 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (1-30% DCM/MeOH as the gradient eluent) to afford the title compound (845.5 mg, 82% yield). MS (apci) m/z = 175.1 (M+H).

00453] Intermediate Y21

[00455] tert-butyl 4-(4-(6-aminopyridin-3 -yl)- lH-pyrazol- 1 -vDpiperidine- 1 -carboxylate

[00456] The title compound was prepared (1.12 g, 85% yield) according to the method described for Intermediate Y21, using tert-butyl 4-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-lH-pyrazol-l-yl)piperidine-l-carboxylate in place of l-methyl-4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazole and a step wise gradient eluent system of 5-60% DCM/EtOAc then 1-25% DCM/MeOH in the silica chromatography. MS (apci) m/z = 344.1 (M+H).

00457] Intermediate LI

[00459] tert-butyl 4-(5-amino-6-bromopyrazin-2-yl)- lH-pyrazole- 1 -carboxylate [00460] A solution of tert-butyl 4-(5-aminopyrazin-2-yl)-lH-pyrazole-l-carboxylate

(Intermediate Yl ; 84 mg, 0.32 mmol) in CHCh (3.2 mL) was treated with pyridine (29 μΐ _^ , 0.35 mmol) and the resulting solution was cooled to 0 °C. Br ₂ (17 μΐ _^ , 0.34 mmol) was added dropwise to the solution and the resulting reaction mixture was stirred at 0 °C for 30 min. The reaction mixture was then stirred at ambient temperature for 2 h prior to quenching with 10% Na ₂ S ₂ 0 ₃ ( _aq ). The resulting biphasic mixture was extracted with DCM. The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (30-100%) EtOAc in Hexanes as the gradient eluent) to afford the title compound (69 mg, 63% yield). MS (apci) m/z = 242.0 [(M-Boc)+H+2], 240 [(M- Boc)+H], with Br pattern.

[00461] The following intermediates shown in Table LI were prepared according the method used for the synthesis of Intermediate LI . Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified by silica chromatography according the method used for purifying Intermediate LI using the appropriate gradient eluent.

Table LI

[00462] Intermediate L2

[00464] 3 -bromo-5 -( 1 -methyl - 1 H-pyrazol-4-yl)pyrazin-2-amine

[00465] A cold (0 °C) solution of 5-(l-methyl-lH-pyrazol-4-yl)pyrazin-2-amine

(Intermediate Y2; 0.210 g, 1.20 mmol) and pyridine (0.107 mL, 1.32 mmol) in CHCh (10 mL) was treated a solution of Br ₂ (0.422 g, 2.64 mmol) in CHC1 ₃ (4 mL). The resulting reaction mixture was maintained at 0 °C for 5 min and then allowed to stir at ambient temperature for 2 h. The reaction mixture was then diluted with DCM (50 mL) prior to quenching with saturated Na ₂ S ₂ 03(aq) (20 mL). The resulting biphasic mixture was separated, the organic extracts were reserved and the aqueous extracts were washed with DCM (50 mL). The combined organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (1 : 1 EtOAc/ Hexanes as the eluent) to afford the title compound (0.266 g, 87% yield). MS (apci) m/z = 256.0 [(M+H)+2], 254.0 (M+H), with Br pattern.

00466] Intermediate L3

[00468] 3 -bromo-5 -( 1 -i sopropyl - 1 H-pyrazol-4-yl)pyrazin-2-amine

[00469] A cold (0 °C) solution of 5-(l-isopropyl-lH-pyrazol-4-yl)pyrazin-2-amine

(Intermediate Y3; 0.365 g, 1.80 mmol) and pyridine (0.160 mL, 1.98 mmol) in CHCh (12 mL) was treated with Br ₂ (0.0971 mL, 1.89 mmol). The reaction mixture was stirred overnight at ambient temperature then diluted with DCM and extracted with saturated Na ₂ S ₂ 03(aq). The organic extracts were washed with brine, then dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography to afford the title compound (0.247 g, 49% yield). MS (apci) m/z = 282.0 (M+H), 284.0 [[(M+H)+2]] (bromine pattern). [00470] The following intermediates shown in Table L3 were prepared according the method used for the synthesis of Intermediate L3 in CHCb (0.1 - 0.15 M). Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified by silica chromatography according the method used for isolating Intermediate L3 using the appropriate gradient eluent.

Table L3

pattern) 00471] Intermediate L10

[00473] tert-butyl (2S.5R)-2-((4-(5-amino-6-bromopyrazin-2-vn-lH-pyrazol-l- yl)methyl)-5-methylmorpholine-4-carboxylate

[00474] A solution of (2S,5R)-tert-butyl 2-((4-(5-aminopyrazin-2-yl)-lH-pyrazol-l- yl)methyl)-5-methylmorpholine-4-carboxylate (Intermediate Y10; 150 mg, 0.401 mmol) and pyridine (35.61 μΐ _^ , 0.441 mmol) in CHCb (4.01 mL) was cooled to 0 °C, stirred for 30 min, then treated dropwise with Br ₂ (21.552 μΐ _^ , 0.421 mmol). The reaction mixture, then was stirred overnight at ambient temperature prior to quenching with 10% Na ₂ S ₂ 0 ₃ ( _aq ). The resulting biphasic mixture was extracted with DCM (3x). The organic extracts were washed with water (2x) and brine then dried over anhydrous MgS04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (60-100%) EtOAc/ Hexanes as the gradient eluent) to afford the title compound (50 mg, 28% yield). MS (apci) m/z = 455.0 [(M+H)+2], 453 (M+H), with Br pattern.

[00475] The following intermediates shown in Table L10 were prepared according the method used for the synthesis of Intermediate L10 in CHCh (0.1 - 0.2 M), from the appropriate starting materials prepared as described herein. Reaction progression was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified by silica chromatography as in Intermediate L10 using the appropriate gradient eluent.

Table L10

Intermediate

Structure Name MS (apci) m/z

#

4-carboxylate

tert-butyl (R)-6-((4-

N NH ₂ (5-amino-6- bromopyrazin-2-yl)- 465.1

L13 lH-pyrazol-1- (M+),

Boc-N o yl)methyl)-7-oxa-4- 467.1 (M+2) azaspiro[2.5 ] octane-

4-carboxylate

Additional Br ₂ (0.5 equivalents) was necessary 00476] Intermediate L16

[00478] 2-(4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l-yl)-2-methyl propanenitrile

[00479] A solution of 2-(4-(5-aminopyrazin-2-yl)-lH-pyrazol-l-yl)-2-methylpropanen itrile

(Intermediate Y16; 77.0 mg, 0.337 mmol) in CHCb (3.4 mL) was treated with pyridine (30.1 0.371 mmol). The resulting solution was cooled to 0 °C and then treated with Br ₂ (18.2 μΐ., 0.354 mmol). The reaction mixture was stirred 16 h at ambient temperature prior to quenching with 10% Na ₂ S ₂ 0 ₃ (aq) (10 mL). The resulting biphasic mixture was diluted with 4: 1 DCM:iPrOH (50 mL) and washed with water (2 x 25 mL). The combined organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (1-25% DCM/MeOH as the gradient eluent) to afford the title compound (79.3 mg, 77% yield). MS (apci) m/z = 307.0 [(M+H)+2], 308.9 (M+H), with Br pattern.

[00480] The following intermediates shown in Table LI 6 were prepared according the method used for the synthesis of Intermediate L16 from the appropriate starting materials prepared as described herein. Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified by silica chromatography according to the method for isolating Intermediate L16 using the appropriate gradient eluent.

Table L16

[00481] Intermediate L20

[00482] [00483] 3-bromo-5-(l-methyl-lH-pyrazol-4-yl)pyridin-2-amine

[00484] A solution of 5-(l-methyl-lH-pyrazol-4-yl)pyridin-2-amine (Intermediate Y20;

845.5 mg, 4.854 mmol) in CHCb (25 mL) was treated with pyridine (431.8 μί, 5.339 mmol). The resulting solution was cooled to 0 °C then treated with Br ₂ (261.1 5.096 mmol). The reaction mixture was stirred 16 h at ambient temperature prior to quenching with 10% Na ₂ S ₂ 0 ₃ ( _aq ) (10 mL). The resulting biphasic mixture was extracted with CHCb (2 x 100 mL). The combined organic extracts washed with 10% Na ₂ S ₂ 0 ₃ ( _aq ) (25 mL), then dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (1-25% DCM/MeOH as the gradient eluent) to afford the title compound (500.5 mg, 41% yield). MS (apci) m/z = 254.9 [(M+H)+2], 252.9 (M+H), with Br pattern.

[00485] Intermediate L21

[00487] tert-butyl 4-(4-(6-amino-5-bromopyridin-3-yl)-lH-pyrazol-l-yl)piperidin e-l- carboxylate

[00488] The title compound was prepared (622.4 mg, 45% yield) according to the method described for Intermediate L20, using tert-butyl 4-(4-(6-aminopyridin-3-yl)-lH-pyrazol-l- yl)piperidine-l -carboxylate (Intermediate Y21) in place of 5-(l-methyl-lH-pyrazol-4-yl)pyridin- 2-amine with excess bromine/ pyridine (1.6 eq each) and a gradient eluent system of 10-90%) DCM/EtOAc in the silica chromatography. MS (apci) m/z = 424 [(M+H)+2], 422.0 (M+H) with Br pattern.

[00489] Intermediate L22

[00491] 3-bromo-5-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazol-4 -yl)pyrazin-2- amine

[00492] Step 1 : Tert-butyl 4-(4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l- yl)piperidine-l -carboxylate (Intermediate L19; 2.0 g, 4.7 mmol) was treated with TFA (5 mL) and stirred at ambient temperature. After 30 minutes, the TFA was removed in vacuo and the residue was treated with 4N HC1 in dioxane (50 mL) to form the HC1 salt. The resulting mixture was concentrated in vacuo and the residue was dried under high vacuum to a constant weight to provide 3-bromo-5-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-amin e dihydrochloride (2.1 g, 5.3 mmol, 112 % yield) as a white solid. MS (apci) m/z = 325 [(M+H)+2], 323.0 (M+H) with Br pattern.

[00493] Step 2: 3-Bromo-5-(l-(piperidin-4-yl)-lH-pyrazol-4-yl) pyrazin-2-amine dihydrochloride (1.9 g, 4.797 mmol) was dissolved in DMF (100 mL) and treated with K2CO3 (2.652 g, 19.19 mmol). The mixture was cooled to 0°C and treated dropwise with l-bromo-2- methoxyethane (0.4508 ml, 4.797 mmol) while maintaining the internal temperature at 0 °C, and then allowed to warm to ambient temperature while stirring for 72 hours. The reaction mixture was poured into ice water (1.0 L) and extracted with 5% IP A in DCM. The organics were washed with brine, then, dried over MgS0 ₄ , filtered and concentrated in vacuo. The crude product was purified by flash chromatography (2-15% MeOH in DCM with 2% H ₄ OH) to provide the title compound (1.2 g, 3.147 mmol, 65.62 % yield) as an off white solid. MS (apci) m/z = 383.1 [(M+H)+2], 381 (M+H) with Br pattern.

00494] Intermediate X2

[00496] 6-chloro-2-(3 -methoxy-5 -(trifluoromethoxy)phenyl)pyridazin-3 (2H)-one

[00497] A mixture of 6-chloropyridazin-3(2H)-one (0.125 g, 0.958 mmol), (3-methoxy-5-

(trifluoromethoxy)phenyl)boronic acid (0.339 g, 1.44 mmol), Cu(OAc) ₂ (0.0348 g, 0.192 mmol) and pyridine (0.155 mL, 1.92 mmol) in DCM (9.58 mL) was stirred overnight at ambient temperature. The mixture was diluted with DCM and washed with water and brine then dried over anhydrous Na ₂ S0 ₄ (s), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography to afford the title compound (307 mg, 82% yield). MS (apci) m/z = 323.0 [(M+H)+2], 321.0 (M+H) with CI pattern.

[00498] The following intermediates, shown in Table X2 were prepared according the method used for the synthesis of Intermediate X2 using the appropriate arylboronic acid starting materials. Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified by silica chromatography according to the method used to isolate Intermediate X2.

Table X2

procedure was as described for Intermediate X2 00499] Intermediate X3

[00501] 6-chloro-2-(3-ethoxy-5-(trifluoromethoxy)phenyl)pyridazin-3( 2H)-one

[00502] 6-chloro-2-(3-ethoxy-5-(trifluoromethoxy)phenyl)pyridazin-3( 2H)-one was made according to the procedure of Intermediate X2 substituting (3-methoxy-5- (trifluoromethoxy)phenyl)boronic acid for (3-ethoxy-5-(trifluoromethoxy)phenyl)boronic acid.

[00503] Intermediate X4

[00505] 6-chloro-2-(3 -methoxy-5 -(trifluoromethyl)phenv0pyridazin-3 (2H)- one

[00506] 6-chloro-2-(3 -methoxy-5 -(trifluoromethyl)phenyl)pyridazin-3(2H)-one was made according to the procedure for Intermediate X2, substituting (3-methoxy-5- (trifluoromethoxy)phenyl)boronic acid for (3 -methoxy-5 -(trifluoromethyl)phenyl)boronic acid.

[00507] Intermediate X6

[00508]

[00509] 6-chloro-2-(2-chloro-3-methoxyphenyl)pyridazin-3(2H)-one

[00510] 6-chloro-2-(2-chloro-3-methoxyphenyl)pyridazin-3(2H)-one was made according to the procedure for Intermediate X2, substituting (3-methoxy-5- (trifluoromethoxy)phenyl)boronic acid for (2-chloro-3-methoxyphenyl)boronic acid.

[00511] Intermediate X8

[00513] 6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(^H)-one

[00514] A solution of 6-chloropyridazin-3(2H)-one (506.5 mg, 3.880 mmol) in DCM (38 mL) was treated with 3,5-dimethoxyphenylboronic acid (776.8 mg, 4.268 mmol), Cu(OAc) ₂ (1410 mg, 7.760 mmol), and pyridine (627.7 μΐ., 7 ^' .760 mmol). The resulting mixture was stirred open to the atmosphere for 60 h at ambient temperature. The reaction mixture was filtered, and the filtrate was concentrated under vacuum. The resulting crude residue was purified by silica chromatography (5-60% DCM/ EtOAc as the gradient eluent) to afford the title compound (560 mg, 54% yield). MS (apci) m/z = 269.0 [(M+H)+2], 267.0 (M+H), with CI pattern.

[00515] The following intermediates shown in Table X8 were prepared according the method used for the synthesis of Intermediate X8 using the appropriate arylboronic acid starting materials. Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified by silica chromatography according to the method used to isolate Intermediate X8.

Table X8

[00516] Intermediate X10

[00517]

[00518] 6-chloro-2-(5-methoxy-2-methylphenyl)pyridazin-3(2H)-one

[00519] A solution of 6-chloropyridazin-3(2H)-one (811.1 mg, 6.214 mmol) in DCM (31 mL) was treated with (5-methoxy-2-methylphenyl)boronic acid (1031 mg, 6.214 mmol), Cu(OAc) ₂ (2257 mg, 12.43 mmol), and pyridine (1005 μΐ., 12.43 mmol). The resulting mixture was stirred open to the atmosphere for 16 h at ambient temperature. The reaction mixture was filtered, and the filtrate was concentrated under vacuum. The resulting crude residue was purified by C18 reverse phase chromatography (5-95% water/ ACN with 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (100 mL) and extracted with saturated NaHC0 ₃ (aq) (1 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum cleanly affording the title compound (251 mg, 16% yield). MS (apci) m/z = 253.0 [(M+H)+2], 251.0 (M+H) with CI pattern.

[00520] Intermediate XI 1

[00521]

[00522] 6-chloro-2-( 1.5 -dimethyl - 1 H-indazol-4-yl)p yridazin-3 (2H)-one

[00523] The title compound was prepared (52 mg, 12% yield) according to the method described for Intermediate X10, using l,5-dimethyl-lH-indazole-4-boronic acid in place of (5- methoxy-2-methylphenyl)boronic acid. MS (apci) m/z = 277.0 [(M+H)+2], 275.0 (M+H) with CI pattern.

[00524] Intermediate X12

[00526] 3-(3-chloro-6-oxopyridazin-l(6H)-yl)-5-methoxybenzonitrile

[00527] Step 1 : Preparation of (3-cyano-5-methoxyphenyl)boronic acid. A mixture of 3- methoxy-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzo nitrile (0.450 g, 1.74 mmol), sodium periodate (1.11 g, 5.21 mmol) and 1 M CH ₃ COO H4(aq) (3.47 mL, 3.47 mmol) in acetone (7 mL) was stirred 3 h at ambient temperature. The reaction was quenched with 4 M HCl(aq) (1 mL) then stirred for 20 min. The mixture was then diluted with EtOAc and extracted with water and brine, then dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to afford the title compound (0.300 g, 98% yield).

[00528] Step 2: Preparation of 3 -(3 -chloro-6-oxopyridazin- 1 (6H)-yl)-5 - methoxyb enzonitril e . A mixture of 6-chloropyridazin-3(2H)-one (0.200 g, 1.53 mmol), (3-cyano- 5-methoxyphenyl)boronic acid (0.298 g, 1.69 mmol), Cu(OAc) ₂ (0.0557 g, 0.306 mmol) and pyridine (0.273 mL, 3.37 mmol) in DCM (9.58 mL) was stirred overnight at ambient temperature. The mixture was then diluted with DCM and extracted with water and brine, then dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography to afford the title compound (197 mg, 49% yield). ¾ MR (CDCb) δ 7.60 (t, 1H), 7.49 (t, 1H), 7.28 (d, 1H), 7.18 (m, 1H), 7.40(d, 1H), 3.88 (s, 3H).

[00529] Intermediate X13

[00530]

[00531] 6-chloro-2-(2-fluoro-3 , 5 -dimethoxyphenyl)pyridazin-3 (2H)-one

[00532] Step 1 : Preparation of (2-fluoro-3,5-dimethoxyphenyl)hydrazine. A cold (0 °C) solution of 2-fluoro-3,5-dimethoxyaniline (1.00 g, 5.84 mmol) in 12.5 M HCl _(aq ) (7.01 mL, 87.6 mmol) was slowly treated with NaN0 ₂ (s) (0.605 g, 8.76 mmol) then stirred for 1 h at ambient temperature. The resulting reaction mixture then was treated with SnCl ₂ ^» H ₂ 0 (2.64 g, 11.7 mmol), and stirred overnight at ambient temperature. The reaction mixture then was filtered, washing the solids with water. The filtrate was cooled to 0°C and slowly basified with the addition of NaOH pellets. The resulting mixture was extracted with ethyl acetate (5 x 250 mL), and the combined organic extracts were washed with brine, then dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound (724 mg, 67% yield). MS (apci) m/z = 187.1 (M+H). This material was used without purification in the subsequent step.

[00533] Step 2: Preparation of l-(2-fluoro-3,5-dimethoxyphenyl)-L2-dihydropyridazine-

3,6-dione. A solution of furan-2,5-dione (0.381 g, 3.89 mmol) and (2-fluoro-3,5- dimethoxyphenyl)hydrazine (from step 1; 0.724 g, 3.89 mmol) in EtOH (absolute; 19.4 mL) was heated for 1 day at 95 °C then treated with 6 N HC1 in iPrOH (2.5 mL). After 3 h the reaction mixture was concentrated under vacuum. The resulting residue was suspended in DCM and the insoluble material was removed by filtration. The filtrate then was concentrated under vacuum, and the residue was purified by silica chromatography (0-100%> EtOAc / hexanes as the gradient eluent) to cleanly afford the title compound (140.5 mg, 14% yield). MS (apci) m/z = 267.0 (M+H).

[00534] Step 3 : Preparation of 6-chloro-2-(2-fluoro-3,5-dimethoxyphenyl)pyridazin-

3(2H)-one. A solution of l-(2-fluoro-3,5-dimethoxyphenyl)-l,2-dihydropyridazine-3,6-d ione (140 mg, 0.526 mmol) in POCh (490 μί, 5.26 mmol) was heated at 85°C for 1 h. The reaction mixture was then concentrated under vacuum, and the resulting residue was partitioned between EtOAc and saturated NaHC0 ₃ ( _aq ). The phases were separated and treated independently. The aqueous extracts were washed with EtOAc (2x) and the organic extracts from the wash were combined with the original organic extract. The combined organic extracts were washed with brine then dried over anhydrous Na2S04( _S ), filtered and the concentrated under vacuum. The resulting residue was purified by silica chromatography (0-100% EtOAc/hexanes as the gradient eluent) to afford the title compound (94 mg, 63% yield). MS (apci) m/z = 285.0 (M+H).

00535] Intermediate X14

[00537] 6-chloro-2-(2-fluoro-5-methoxyphenyl)pyridazin-3(2H)-one

[00538] Step 1 : Preparation of l-(2-fluoro-5-methoxyphenyl)-L2-dihydropyridazine-3,6- dione. A solution of furan-2,5-dione (255 mg, 2.60 mmol) and (2-fluoro-3,5- dimethoxyphenyl)hydrazine hydrochloride (500 mg, 2.60 mmol) in EtOH (absolute; 152 mL, 2.60 mmol) was heated for 1 day at 95 °C. The reaction mixture was concentrated under vacuum, and the resulting residue was purified by silica chromatography (0-100%> EtOAc / hexanes as the gradient eluent) to cleanly afford the title compound (300 mg, 49%> yield). MS (apci) m/z = 237.0 (M+H).

[00539] Step 2: Preparation of 6-chloro-2-(2-fluoro-5-methoxyphenyl)pyridazin-3(2H)- one. A solution of l-(2-fluoro-5-methoxyphenyl)-l,2-dihydropyridazine-3,6-dione (90 mg, 0.38 mmol) in POCh (355 μΐ _^ , 3.8 mmol) was heated at 85°C for 1 h. The reaction mixture was then concentrated under vacuum, and the resulting residue was partitioned between EtOAc and saturated NaHC0 ₃ ( _aq ). The phases were separated and treated independently. The aqueous extracts were washed with EtOAc (2x), and the organic extracts from the wash were combined with the original organic extract. The combined organic extracts were washed with brine then dried over anhydrous Na2S04( _S ), filtered and the concentrated under vacuum. The resulting residue was purified by silica chromatography (0-100%) EtOAc/hexanes as the gradient eluent) to afford the title compound (38 mg, 39% yield). MS (apci) m/z = 255.0 (M+H). [00540] Intermediate X15

[00542] 6-chloro-2-(2-chloro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00543] A cold (0 °C) solution of 6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

(Intermediate X8; 0.357 g, 1.34 mmol) in ACN (13.4 mL) was treated with SO2CI2 (0.109 mL, 1.34 mmol) and stirred for 20 min. The resulting mixture was quenched with the addition of saturated NaHC0 ₃ (aq). The resulting biphasic mixture was extracted with EtOAc. The organic extracts were washed successively with water and brine then dried over anhydrous Na2S04( _S ), filtered and the concentrated under vacuum. The resulting crude residue was purified by silica chromatography to afford the title compound (310 mg, 77% yield). ¾ NMR (CDC1 ₃ ) δ 7.29 (d, 1H), 7.04 (d, 1H), 6.58 (m, 2H), 3.90 (s, 3H), 3.81 (s, 3H).

[00544] Intermediate 02

[00546] 6-chloro-2-(2-chloro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00547] A cold (0 °C) solution of 6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

(2.496 g, 9.360 mmol) in ACN (93.60 mL, 9.360 mmol) was treated with sulfuryl dichloride (1.484 mL, 18.25 mmol) and stirred for 1 hr. The resulting mixture was quenched with the addition of saturated NaHC0 ₃ ( _aq ). The resulting biphasic mixture was extracted with DCM. The organic extracts were washed successively with water and brine then dried over anhydrous Na2S04( _S ), filtered and then concentrated in vacuo to afford the title compound (3.1 g, 99% yield). This material was of sufficient purity to be used directly without further purification. ¾ NMR (CDC1 ₃ ) δ 7.29 (d, 1H), 7.04 (d, 1H), 6.65 (s, 1H), 3.94 (s, 6H). 00548] Intermediate X17

[00550] 6-chloro-4-methylpyridazin-3(2H)-one

[00551] Step 1 : Preparation of 6-chloro-3-methoxy-4-methylpyridazine. A solution of

2,2,6,6-tetramethylpiperidine (12.9 ml, 76.1 mmol) in THF (100 mL) was sparged with N ₂ (g) then cooled to -78 °C. The -78 °C solution was treated slowly with 2.5 M n-butyllithium in hexane (30.4 mL, 76.1 mmol) then warmed to 0 °C and stirred for 1 h. The resulting reaction mixture was cooled to -78 °C then treated with a 0.46 M solution of 3-Chloro-6-methoxypyridazine in THF (75 mL, 34.6 mmol). After stirring at -78 °C for 1 h, the reaction mixture was treated with iodomethane (4.74 mL, 76.1 mmol), and stirred for an additional 30 min at -78 °C. The reaction mixture was quenched with saturated H ₄ Cl( _a q) (50 mL), warmed to ambient temperature, diluted with water (50 mL) and extracted with EtOAc (2 x 250 mL). The combined organic extracts were washed with brine (1 x 50 mL), dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound (3.31 g, 60% yield). MS (apci) m/z = 159.0 (M+H).

[00552] Step 2: Preparation of 6-chloro-4-methylpyridazin-3(2H)-one. A solution of 6- chloro-3-methoxy-4-methylpyridazine (3.31 g, 20.9 mmol) in 4: 1 dioxane: water (100 mL) was treated with 12.0 M HCl _(aq ) (1.91 mL, 23.0 mmol) and stirred for 60 h at 60 °C. The reaction mixture was concentrated under vacuum, and the resulting crude residue was purified by silica chromatography (1-30% DCM/MeOH with 2% NH ₄ OH as the gradient eluent) to afford the title compound (2.99 g, 99% yield). ¹ H MR (400 MHz, DMSO-d ₆ ) δ 13.03 (s, 1H), 7.44 (s, 1H), 2.05 (s, 3H).

[00553] Intermediate X18

[00554]

[00555] 6-chloro-2-(3 , 5 -dimethoxyphenyl)-4-methylpyridazin-3 (2H)- one

[00556] A solution of 6-chloro-4-methylpyridazin-3-ol (Intermediate X17; 500 mg, 3.46 mmol) in DCM (20.3 mL) and pyridine (1 mL, 3.46 mmol) was treated with (3,5- dimethoxyphenyl)boronic acid (1.26 g, 6.92 mmol), Cu(OAc) ₂ (1.26 g, 6.92 mmol), and pyridine 1-oxide (1.32 g, 13.8 mmol). The resulting mixture was stirred open to the atmosphere overnight at ambient temperature. The reaction mixture was diluted with DCM (100 mL) and filtered. The filtrate was washed with water (2 x 30 mL), and the organics were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The crude residue was precipitated from MeOH to cleanly afford the title compound (780 mg, 80%). MS (apci) m/z = 281.1 (M+H), 283.0 [(M+H)+2] (with CI pattern).

[00557] Intermediate X19

[00558]

[00559] methyl 3-(3-chloro-5-methyl-6-oxopyridazin-l(6H)-yl)-4-methylbenzoa te

[00560] A solution of 6-chloro-4-methylpyridazin-3-ol (Intermediate X17; 0.50 g, 3.4 mmol) in DCM (20 mL) was treated with (5-(methoxycarbonyl)-2-methylphenyl)boronic acid (1.0 g, 5.2 mmol), Cu(OAc) ₂ (1.2 g, 6.9 mmol), pyridine 1-oxide ( 327 mg, 3.44 mmol) and pyridine (1.1 g, 14 mmol). The resulting mixture was stirred at ambient temperature open to the atmosphere for one overnight. The reaction mixture was diluted with DCM (100 mL) and washed with water (2 x 30 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica gel flash chromatography (2-55% EtOAc/hexane as the gradient eluent) to afford the title compound (2.99 g, 99% yield). MS (apci) m/z = 293.0 (M+H), 295.0 [(M+H)+2] (with CI pattern).

00561] Intermediate X20

[00563] 4-bromo-6-chloropyridazin-3(2H)-one

[00564] A solution of 6-chloropyridazin-3-ol (5.01 g, 38.38 mmol), KBr (13.70 g, 115.1 mmol), and KOAc (5.650 g, 57.57 mmol) in water (80 mL) was stirred for 15 min then treated with Br ₂ (5.90 mL, 115 mmol). The resulting mixture was stirred under an atmosphere of N ₂ ( _g ) for 2 h at 90 °C. After cooling to ambient temperature the reaction mixture was quenched with 10% Na2S2C"3(aq) (100 iTiL). The resulting biphasic suspension was filtered, and the filter cake was successively rinsed with water (100 mL) then 10% Na2S20 ₃ ( _aq ) (100 mL). The solid filter cake was dried under high vacuum for 16 h to cleanly afford the title compound (6.14 g, 76% yield). ¾ MR (400 MHz, DMSO-d ₆ ) δ 13.52 (s, 1H), 8.20 (s, 1H).

[00565] Intermediate X21

[00566]

[00567] 4-bromo-6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00568] A mixture of 4-bromo-6-chloropyridazin-3(2H)-one (Intermediate X20; 0.504 g,

2.41 mmol), (3,5-dimethoxyphenyl)boronic acid (0.482 g, 2.65 mmol), Cu(OAc) ₂ (0.0874 g, 0.481 mmol) and pyridine (0.389 mL, 4.81 mmol) in DCM (24.1 mL) was stirred overnight at ambient temperature The mixture was then diluted with DCM and extracted with water. The organic extracts were washed with brine, then dried aver anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography to afford the title compound (0.574 g, 69% yield). ¾ NMR (CDC1 ₃ ) δ 7.69 (s, 1H), 6.73 (d, 2H), 6.51 (t, 1H), 3.81 (s, 6H).

[00569] Intermediate X22

[00570]

[00571] 6-chloro-4-cyclobutyl-2-(3,5-dimethoxyphenyl)pyridazin-3(2H) -one

[00572] A cold (0 °C) solution of 4-bromo-6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-

3(2H)-one (Intermediate X21; 413.7 mg, 1.197 mmol) in THF (12 mL) was treated with 0.5 M cyclobutylmagnesium chloride hexane (3591 μL, 1.796 mmol) and stirred for 1 h at 0 °C. The reaction was quenched with the addition of water (25 mL) and the volatiles were removed under vacuum. The remaining aqueous mixture was diluted with EtOAc (100 mL) and washed successively with water (2 x 25 mL) and brine (25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting residue was purified by silica chromatography (5-60% Hexanes/EtOAc as the gradient eluent) to afford the title compound (283 mg, 72% yield). MS (apci) m/z = 311.0 [(M+H)+2], 309.0 (M+H) with CI pattern.

[00573] The following intermediates shown in Table X22 were prepared according to the method used for the synthesis of Intermediate X22 using the appropriate alkylmagnesium halide starting materials and 4-bromo-6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one. Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified using a method similar to that used to isolate Intermediate X22 utilizing the appropriate gradient eluent.

Table X22

[00574] Intermediate X25

[00575]

[00576] 6-chloro-2-(3,5-dimethoxyphenyl)-4-isobutylpyridazin-3(2H)-o ne

[00577] A cold (0 °C) solution of 4-bromo-6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-

3(2H)-one (Intermediate X21 ; 0.150 g, 0.434 mmol) in THF (2.89 mL) was treated with 2 M isobutylmagnesium bromide in Et ₂ 0 (0.434 mL, 0.868 mmol). The reaction was stirred overnight at ambient temperature and then worked up with EtOAc and water. The organics were washed with brine, then dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting residue was purified by silica chromatography to afford the title compound (0.035 g, 25% yield).

[00578] The following intermediates, shown in Table X25 were prepared according the method used for the synthesis of Intermediate X25 using the appropriate alkylmagnesium halide starting materials and 4-bromo-6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one. All compounds were purified by silica chromatography utilizing the appropriate gradient.

Table X25

Intermediate Structure Name

6-chloro-2-(3 , 5 -dimethoxyphenyl)-4-

X27

propylpyridazin-3(2H)-one

[00579] Intermediate X28

[00580]

[00581] 6-chloro-2-(2,6-dichloro-3,5-dimethoxyphenyl)-4-methylpyrida zin-3(2H)-one

[00582] Sulfuryl chloride (0.152 mL, 1.88 mmol) was added to 6-chloro-2-(3,5- dimethoxyphenyl)-4-methylpyridazin-3(2H)-one (Intermediate XI 8; 0.264 g, 0.940 mmol) in ACN (6.27 mL) at 0 °C. This was then stirred at room temp for 20 min. The mixture was then quenched with saturated aqueous Na ₂ C03. The mixture was partitioned between EtOAc and water. The combined organic layers were washed with water and brine, dried over Na ₂ S0 ₄ , and concentrated. The residue was purified on a silica column using Hexanes:EtOAc (10-90%) to give 6-chloro-2-(2,6-dichloro-3,5-dimethoxyphenyl)-4-methylpyrida zin-3(2H)-one (0.198 g, 0.566 mmol, 60.2 % yield) MS (apci) m/z = 349.0 (M + H).

[00583] Intermediate X29

[00584]

[00585] 6-chloro-2-(3-methylquinolin-7-yl)pyridazin-3(2H)-one

[00586] Step 1 : Preparation of (3 -methyl quinolin-7-yl)boronic acid: A solution of 7-bromo-

3 -methyl quinoline (258 mg, 1.16 mmol), 5,5,5',5'-tetramethyl-2,2'-bi(l,3,2-dioxaborinane) (656 mg, 2.90 mmol), PdC12(dppf)*dcm (47.4 mg, 0.0581 mmol), and KOAc (342 mg, 3.49 mmol) in dioxane (5809 μΐ., 1.16 mmol) was sparged with N ₂ ( _g > for 5 min at ambient temperature and then heated at 90 °C overnight. After cooling to ambient temperature, the reaction mixture was partitioned between EtOAc and water. The combined organic extracts were washed with brine, dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to afford the title compound with higher than expected mass, but assumed with quantitative yield (217 mg, 100% yield). MS (apci) m/z = 188.1 (M+H).

[00587] Step 2: Preparation of: 6-chloro-2-(3-methylquinolin-7-yl)pyridazin-3(2H)-one: A mixture of 6-chloropyridazin-3(2H)-one (0.140 g, 1.07 mmol),(3-methylquinolin-7-yl)boronic acid, (0.221 g, 1.18 mmol), Cu(OAc)2 (0.0390 g, 0.215 mmol) and pyridine(0.191 ml, 2.36 mmol) in DCM (10.7 mL, 1.07 mmol) was stirred at room temperature overnight. The reaction mixture was partitioned between EtOAc and water. The organic extracts were washed with brine, then dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting residue was purified by silica chromatography to afford the title compound (25 mg, 8.6% yield). MS (apci) m/z = 274.0 [(M+H)+2], 272.0 (M+H) with CI pattern.

[00588] Intermediate X30

[00589]

[00590] Methyl 3 -(3 -chloro-5-methyl-6-oxopyridazin- 1 (6H)-yl)-4-methylbenzoate

[00591] A solution of 6-chloro-4-methylpyridazin-3-ol (0.5 g, 3.5 mmol) in dichloromethane (20 mL, 3.4 mmol) was treated with (5-(methoxycarbonyl)-2- methylphenyl)boronic acid (1 g, 5.15 mmol), copper(II) acetate (1.25 g, 6.87 mmol), pyridine 1- oxide (33 mg, 3.44 mmol), and pyridine (1.1 g, 13.75 mmol). The resulting mixture was stirred overnight at RT. The mixture was diluted with DCM (100 mL) and washed with water (2 x 30 mL). The organic layer was separated, dried (Na ₂ S04), filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (Redi Sep 80 g) eluting with 2-55% EtOAc/hexane to provide methyl 3-(3-chloro-5-methyl-6-oxopyridazin-l(6H)-yl)-4- methylbenzoate (430 mg, 43 % yield) as a solid. LCMS (APCI+) m/z 293.0 (M+l); retention time = 4.086 min. [00592] Intermediate Rl

[00593]

[00594] 2-(3-methoxyphenyl)-6-(4^,5,5-tetramethyl-L3,2-dioxaborolan- 2-yl)pyridazin-

3(2H)-one

[00595] A solution of 6-chloro-2-(3-methoxyphenyl)pyridazin-3(2H)-one (Intermediate XI; 104 mg, 0.439 mmol) in dioxane (6 mL) was treated with bis(pinacolato)diboron (123 mg, 0.483 mmol), Pd(OAc) ₂ (10.8 mg, 0.0483 mmol), X-Phos (34.6 mg, 0.0725 mmol), and KOAc (129 mg, 1.32 mmol). The mixture was sparged with A%), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was filtered, and the filter cake was washed with EtOAc (50 mL). The filtrate was concentrated under vacuum to afford the title compound (157 mg, 109% crude yield). This material was used directly without further purification.

00596] Intermediate R2

[00598] 2-(3 -methoxy-5 -( trifluoromethoxy)phenv0-6-( 4.4.5.5 -tetramethyl - 1.3.2- dioxaborolan-2-yl)pyridazin-3(2H)-one

[00599] A mixture of 6-chloro-2-(3-methoxy-5-(trifluoromethoxy)phenyl)pyridazin-3 (2H)- one (Intermediate X2; 0.253 g, 0.789 mmol), bis(pinacolato)diboron (0.220 g, 0.868 mmol), Pd(OAc) ₂ (0.0177 g, 0.0789 mmol), X-Phos (0.0564 g, 0.118 mmol), and KOAc (0.232 g, 2.37 mmol) in dioxane (2.63 mL) was sparged with A%) for 5 min at ambient temperature then stirred for 1 h at 100 °C. After cooling to ambient temperature, the reaction mixture was partitioned between EtOAc and water. The organic extracts were washed with brine, then dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound (320 mg, 98% yield). MS (apci) m/z = 287.0 (M-B(OR) ₂ +H). This material was of sufficient purity to be used directly without further purification. [00600] The following intermediates shown in Table R2 were prepared according the method used for the synthesis of Intermediate R2 using the appropriate 6-chloro-2- (Aryl)pyridazin-3(2H)-one starting materials (Intermediates X3- X7, XI 1-X12, X15). Reaction progression for each was followed by LCMS and reaction time was adjusted as necessary.

Table R2

[00601] Intermediate R7

[00602]

[00603] 6-(4.4.5.5-tetramethyl-1.3.2-dioxaborolan-2-ylV2-(o-tolvnpyr idazin-3(2H -one [00604] 6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2-(o-tolyl)p yridazin-3(2H)-one was made according the procedure of Intermediate R2, substituting Intermediate X2 with Intermediate X7.

[00605] Intermediate R8

[00606]

[00607] 2-(3.5-dimethoxyphenvn-6-(4.4.5.5-tetramethyl-1.3.2-dioxabor olan-2- yl)pyridazin-3(2H)-one

[00608] A solution of 6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Intermediate

X8; 47.9 mg, 0.180 mmol) in dioxane (1.8 mL) was treated with bis(pinacolato)diboron (50.2 mg, 0.198 mmol), Pd(OAc) ₂ (4.03 mg, 0.0180 mmol), X-Phos (12.8 mg, 0.0269 mmol), and KOAc (52.9 mg, 0.539 mmol). The mixture was sparged with A%), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (25 mL) then extracted with water (2 x 10 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound (64 mg, 99% yield). MS (apci) m/z = 233.1 (desB(OR) ₂ M+H). This material was of sufficient purity to be used directly without further purification.

[00609] The following intermediates shown in Table R8, were prepared according the method used for the synthesis of Intermediate R8 using the appropriate 6-chloro-2- (Aryl)pyridazin-3(2H)-one starting materials (Intermediates X9, X10). Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary.

Table R8

yl)pyridazin-3(2H)-one

[00610] Intermediate R13

[00611]

[00612] 2-(2-fluoro-3.5-dimethoxyphenvn-6-(4.4.5.5-tetramethyl-1.3.2 -dioxaborolan-2- yl)pyridazin-3(2H)-one

[00613] A solution of 6-chloro-2-(2-fluoro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one

(Intermediate X13; 94 mg, 0.33 mmol) in dioxane (1.2 mL) was treated with bis(pinacolato)diboron (0.17 g, 0.66 mmol), Pd(OAc) ₂ (7.4 mg, 0.033 mmol), X-Phos (23.6 mg, 0.050 mmol), and KOAc (97 mg, 0.99 mmol). The mixture was sparged with A¾), then sealed and stirred for 3 h at 90 °C. After cooling to ambient temperature, the reaction mixture was partitioned between EtOAc and water. The organic extracts were reserved and the aqueous extracts were independently washed with EtOAc (3x). The combined organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound (124.2 mg, 75% yield). MS (apci) m/z = 251.1 (desB(OR) ₂ M+H). This material was of sufficient purity to be used directly without further purification.

[00614] Intermediate R14

[00615] [00616] 2-(2-fluoro-5-methoxyphenvn-6-(4.4.5.5-tetramethyl-1.3.2-dio xaborolan-2- yl)pyridazin-3(2H)-one

[00617] The title compound was prepared (116.9 mg, 50% yield) according to the method described for Intermediate R14, using 6-chloro-2-(2-fluoro-5-methoxyphenyl)pyridazin-3(2H)- one (Intermediate X14) in place of 6-chloro-2-(2-fluoro-3,5-dimethoxyphenyl)pyridazin-3(2H)- one (Intermediate XI 3). MS (apci) m/z = 221.1 (desB(OR) ₂ M+H). This material was of sufficient purity to be used directly without further purification.

[00618] Intermediate R18

[00619]

[00620] 2-( ^" 3.5-dimethoxyphenvn-4-methyl-6-( ^" 4.4.5.5-tetramethyl-1.3.2-dioxaborolan-2- yl)pyridazin-3(2H)-one

[00621] A solution of 6-chloro-2-(3,5-dimethoxyphenyl)-4-methylpyridazin-3(2H)-one

(Intermediate X18; 199.4 mg, 0.7103 mmol) in dioxane (7.1 mL) was treated with bis(pinacolato)diboron (198.4 mg, 0.7814 mmol), Pd(OAc) ₂ (15.95 mg, 0.07103 mmol), X-Phos (50.80 mg, 0.1066 mmol), and KOAc (209.1 mg, 2.131 mmol). The mixture was sparged with Ar(g), then sealed and stirred for 1 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (50 mL) then extracted with water (2 x 25 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound (264 mg, 100% yield). MS (apci) m/z = 291.1 (B(OH) ₂ M+H), 247.1 (desB(OR) ₂ M+H). This material was of sufficient purity to be used directly without further purification.

[00622] Intermediate R19

[00623] [00624] methyl 4-methyl-3-(5-methyl-6-oxo-3-(4.4.5.5-tetramethyl-1.3.2-diox aborolan-2- yl)pyridazin-l(6H)-yl)benzoate

[00625] A mixture of methyl 3-(3-chloro-5-methyl-6-oxopyridazin-l(6H)-yl)-4- methylbenzoate (Intermediate XI 9; 425 mg, 1.45 mmol), bis(pinacolato)diboron (553 mg, 2.18 mmol), Pd(OAc) ₂ (32.6 mg, 0.145 mmol), X-Phos (104 mg, 0.218 mmol), and KOAc (427 mg, 4.36 mmol) in dioxane (14.5 mL) was sparged with N ₂ ( _g >, then sealed and stirred for 6 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (100 mL) then extracted with water (2 x 30 mL). The organic extracts were dried over anhydrous MgS04( _S ), filtered and concentrated under vacuum to afford the crude title compound. MS (apci) m/z = 384.1 (M+), 259.0 [(M-B(OR) ₂ )+H]. This material was of sufficient purity to be used directly without further purification.

[00626] Intermediate R22

[00627]

[00628] 4-cyclobutyl-2-(3,5-dimethoxyphenyl)-6-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan- 2-yl)pyridazin-3(2H)-one

[00629] A solution of 6-chloro-4-cyclobutyl-2-(3,5-dimethoxyphenyl)pyridazin-3(2H) -one

(Intermediate X22; 149.6 mg, 0.4664 mmol) in dioxane (5.0 mL) was treated with bis(pinacolato)diboron (130.3 mg, 0.5130 mmol), Pd(OAc) ₂ (10.47 mg, 0.04664 mmol), X-Phos (33.35 mg, 0.06996 mmol), and KOAc (137.3 mg, 1.399 mmol). The mixture was sparged with Ar(g), then sealed and stirred for 1 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (50 mL) and then extracted with water (2 x 25 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound (192.2 mg, 100% yield). MS (apci) m/z = 261.0 (B(OH) ₂ M+H), 217.1 (M-B(OR) ₂ +H). This material was of sufficient purity to be used directly without further purification. [00630] The following intermediates shown in Table R22 were prepared according the method used for the synthesis of Intermediate R22 using the appropriate starting materials (Intermediates X23-X27). Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary.

Table R22

[00631] Intermediate R28

[00633] 2-(2-chloro-6-fluoro-3-methoxyphenyl)-6-(4,4,5,5-tetramethyl - 1,3,2- dioxaborolan-2-yl)pyridazin-3(2H)-one

[00634] A solution of 6-chloro-2-(2-chloro-6-fluoro-3-methoxyphenyl)pyridazin-3(2H )- one (ArkPharm, 180 mg, 0.622 mmol), bis(pinacolato)diboron (316 mg, 1.24 mmol), palladium(II) acetate (14.0 mg, 0.062 mmol), X-PHOS (45 mg, 0.093 mmol), and potassium acetate (183 mg, 1.87 mmol). was degassed with nitrogen, sealed, and heated to 100°C overnight (16 hrs). The mixture was cooled to ambient temperature then diluted with 4: 1 DCM:IPA and washed with water. The organic layer was dried over Na ₂ S04 and concentrated. The residue was carried forward to next step without further purification. LCMS (APCI+) m/z= 255.0; retention time 1.60 min.

[00635] Intermediate R29

[00637] 2-(2.6-difluoro-3.5-dimethoxyphenvn-6-(4.4.5.5-tetramethyl-1 .3.2-dioxaborolan- 2-yl)pyridazin-3(2H)-one

[00638] A solution of 6-chloro-2-(2,6-difluoro-3,5-dimethoxyphenyl)pyridazin-3(2H) -one

(ArkPharm 163 mg, 0.539 mmol), bis(pinacolato)diboron (274 mg, 1.08 mmol), palladium(II) acetate (12.1 mg, 0.0539 mmol), X-PHOS (38.5 mg, 0.081 mmol), and potassium acetate (159 mg, 1.62 mmol) was sparged with nitrogen, sealed, and heated to 100°C for 16 h. The reaction mixture was cooled to ambient temperature, then diluted with 4: 1 DCM:IPA, washed with water, dried over Na ₂ S04, filtered through fluted filter paper and concentrated. The residue was used without further purification in excess in a subsequent reaction. LCMS (APCI+) m/z 269.1 (fragment: M- pinacolboronate); Retention time = 1.70 min.

[00639] Intermediate R30

[00641] 2-(3-methylquinolin-7-ylV6-(4.4.5.5-tetramethyl-1.3.2-dioxab orolan-2- yl)pyridazin-3(2H)-one

[00642] A mixture of 6-chloro-2-(3 -methyl quinolin-7-yl)pyridazin-3(2H)-one

(Intermediate X29; 25 mg, 0.09 mmol), Bis(Pinacolato)diboron (70.1 mg, 0.28 mmol), Pd(OAc) ₂ (2.1 mg, 0.01 mmol), and XPHOS (6.6 mg, 0.01 mmol) in dioxane (0.6 mL) was sparged with Ar(g) for 5 min at ambient temperature, then stirred for 3 h at 90 °C. After cooling to ambient temperature, the reaction mixture was partitioned between EtOAc and water. The organic extracts were washed with brine, then dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound (21.8 mg, 99% yield). MS (apci) m/z = 238.1 (M- B(OR) ₂ +H). This material was of sufficient purity to be used directly without further purification.

[00643] Intermediate R31

[00644]

[00645] Methyl 4-methyl-3-( ^" 5-methyl-6-oxo-3-( ^" 4.4.5.5-tetramethyl-1.3.2-dioxaborolan-2- yl)pyridazin-l(6H)-vDbenzoate

[00646] A glass pressure tube was charged with Intermediate X30 [methyl 3-(3-chloro-5- methyl-6-oxopyridazin-l(6H)-yl)-4-methylbenzoate] (425 mg, 1.45 mmol), bis(pinacolato)diboron (553 mg, 2.2 mmol), palladium (II) acetate (33 mg, 0.145 mmol), XPHOS (104 mg, 0.22 mmol), potassium acetate (427.5 mg, 4.4 mmol) and 1,4-dioxane (14519 μΐ,, 1.45 mmol). The mixture was sparged with N ₂ . The tube was sealed with a Teflon screw cap and heated at 100 °C with stirring for 6 hrs. The mixture was then cooled to 0°C, diluted with 4: 1 DCM:IPA (100 mL) and washed with water. The organic layer was separated, dried over MgS0 ₄ and concentrated under reduced pressure. The crude product was used immediately in a subsequent reaction.

00647] Intermediate Ml

[00649] 3-(3-(2-amino-5-bromopyridin-3-yl)-6-oxopyridazin-l(6H)-yl)- N- methylbenzamide

[00650] Step 1 : Preparation of methyl 3-(3-(2-aminopyridin-3-yl)-6-oxopyridazin-l(6H)- yPbenzoate. A solution of methyl 3-(3-chloro-6-oxopyridazin-l(6H)-yl)benzoate (Intermediate X16; 531.9 mg, 2.010 mmol) in 4: 1 dioxane:water (15 mL) was treated with t-butyl 3-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-ylcarbamate (643.5 mg, 2.010 mmol), Pd(PPh ₃ ) ₄ (232.2 mg, 0.2010 mmol), K2C0 ₃ ( _S > (833.3 mg, 6.029 mmol). The mixture was sparged with A%), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with EtOAc (200 mL), and the resulting solution was extracted with water (2 x 50 mL) then brine (25 mL). The organic extracts were dried over anhydrous Na2S0 ₄ ( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by C18 reverse phase chromatography (2-75% water/ ACN with 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (50 mL) and extracted with saturated NaHC0 ₃ (aq) (1 x 25 mL). The organic extracts were dried over anhydrous Na2S0 ₄ ( _S >, filtered and concentrated under vacuum cleanly affording the title compound (160.5 mg, 25% yield). MS (apci) m/z = 323.1 (M+H).

[00651] Step 2: Preparation of methyl 3-(3-(2-amino-5-bromopyridin-3-yl)-6- oxopyridazin- 1 (6H)-yl)benzoate. A solution of methyl 3-(3-(2-aminopyridin-3-yl)-6- oxopyridazin-l(6H)-yl)benzoate (from step 1; 160.5 mg, 0.4980 mmol) in ACN (5.0 mL) was treated with NBS (97.49 mg, 0.5478 mmol) then stirred for 16 h at ambient temperature then concentrated under vacuum. The resulting residue was triturated with EtOAc (10 mL) filtered to afford the title compound (169.0 mg, 85% yield). MS (apci) m/z = 403.0 [(M+H)+2], 401.0 (M+H), with Br pattern. [00652] Step 3 : Preparation of 3-(3-(2-amino-5-bromopyridin-3-yl)-6-oxopyridazin- l(6H)-yl)benzoic acid. A solution of methyl 3-(3-(2-amino-5-bromopyridin-3-yl)-6- oxopyridazin-l(6H)-yl)benzoate (from step 2; 142.8 mg, 0.3559 mmol) in 1 : 1 THF:MeOH (3.6 mL) was treated with 2 M KOH _(aq ) (889.8 μί, 1.780 mmol) then stirred for 1 h at 70 °C. After cooling to ambient temperature, the reaction mixture was diluted with water (10 mL). The resulting suspension was filtered, and the filter cake was washed with water (2 x 10 mL). The solids were dried under high vacuum for 16 h at 55 °C to afford the title compound (93.8 mg, 68% yield). MS (apci) m/z = 389.0 [(M+H)+2], 387.0 (M+H), with Br pattern.

[00653] Step 4: Preparation of 3-(3-(2-amino-5-bromopyridin-3-yl)-6-oxopyridazin-

1 (6H)-yl)-N-methylbenzamide. A solution of methyl 3-(3-(2-amino-5-bromopyridin-3-yl)-6- oxopyridazin-l(6H)-yl)benzoic acid (from step 3; 93.8 mg, 0.242 mmol) in DMF (2.5 mL) was treated with methylamine hydrochloride (49.1 mg, 0.727 mmol), HATU (110 mg, 0.291 mmol), and DIPEA (211 μΕ, 1.21 mmol). The resulting mixture was stirred for 2 h at ambient temperature before directly chromatographing the reaction mixture using C18 reverse phase chromatography (5-95%) water/ ACN w/ 0.1%> TFA as the gradient eluent) to afford the title compound as the TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (25 mL) and extracted with saturated NaHC0 ₃ (aq) (1 x 10 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum cleanly affording the title compound (47.6 mg, 49%> yield). MS (apci) m/z = 402.0 [(M+H)+2], 400.0 (M+H), with Br pattern.

[00654] Intermediate M2

[00655]

[00656] 6-(2-amino-5-bromopyridin-3-yl)-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyridazin-3(2H)-one

[00657] Step 1 : Preparation of 6-(2-aminopyridin-3-yl)-2-(3.5- dimethoxyphenyl)pyridazin-3(2H)-one. A solution of t-Butyl 3-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)pyridin-2-ylcarbamate (923.4 mg, 2.884 mmol) in 4: 1 dioxane:water (15 mL) was treated with 6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Intermediate X8; 807.5 mg, 3.028 mmol), Pd(PPh ₃ ) ₄ (333.2 mg, 0.2884 mmol), K ₂ C0 _3(S) (1195 mg, 8.652 mmol ). The mixture was sparged with Α%), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (100 mL), and the resulting solution was extracted with water (2 x 50 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (1-25% DCM/MeOH as the gradient eluent) to afford the title compound (505.5 mg, 54% yield). MS (apci) m/z = 325.1 (M+H).

[00658] Step 2: Preparation of 6-(2-aminopyridin-3-vO-2-(2.6-dichloro-3.5- dimethoxyphenyl)pyridazin-3(2H)-one. A cold (0 °C) solution of 6-(2-aminopyridin-3-yl)-2-(3,5- dimethoxyphenyl)pyridazin-3(2H)-one (from step 1; 12.7 mg, 0.0392 mmol) in ACN (0.8 mL) was treated with SO2CI2 (6.33 μL, 0.0783 mmol) then stirred for 30 min at ambient temperature. The resulting mixture was quenched with the addition of saturated NaHC0 ₃ ( _aq ) (10 mL). The resulting biphasic mixture was extracted with 4: 1 DCM: iPrOH (2 x 25 mL). The combined organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to afford the title compound (13.1 mg, 85% yield). MS (apci) m/z = 396.9 [(M+H)+4], 394.9 [(M+H)+2], 392.9 (M+H), with di CI pattern.

[00659] Step 3 : Preparation of 6-(2-amino-5-bromopyridin-3-yl)-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyridazin-3(2H)-one. A solution of 6-(2-aminopyridin-3-yl)-2-(2,6-dichloro- 3,5-dimethoxyphenyl)pyridazin-3(2H)-one (from step 2; 12.0 mg, 0.0305 mmol) in ACN (0.6 mL) was treated with NBS (5.97 mg, 0.0336 mmol) then stirred for 16 h at ambient temperature. The resulting mixture was diluted with 4: 1 DCM: iPrOH (25 mL) and extracted with water (2 x 10 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to afford the title compound (14.4 mg, 100% yield). MS (apci) m/z = 474.9 [(M+H)+4], 472.9 [(M+H)+2], 470.9 (M+H) with di CI pattern.

[00660] Intermediate M3

[00662] 6-(3-amino-6-bromopyrazin-2-yl)-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyridazin-3(2H)-one

[00663] 3,5-Dibromopyrazin-2-amine (0.417 g, 1.65 mmol) and sodium carbonate (2.62 ml, 5.24 mmol) were added to a solution of 2-(2,6-dichloro-3,5-dimethoxyphenyl)-6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)pyridazin-3(2H)-one (Intermediate R17; 0.640 g, 1.50 mmol) in 1,4-dioxane (15.0 ml, 1.50 mmol). The reaction mixture was stirred at 55°C for 20 hrs. The reaction was quenched with water (50 mL) and extracted with DCM. The combined organic extracts were washed with water and brine, dried over Na ₂ S04 and concentrated in vacuo. The residue was triturated with DCM (50 mL) and filtered to obtain title compound (0.207 g, 0.438 mmol, 29.2 % yield). MS (apci) m/z = 477.9 [(M+H)+4], 475.9 [(M+H)+2], 473.9 (M+H), 471.9 (M-H) with di CI + Br pattern.

[00664] Intermediate M4

[00665]

[00666] 6-(3-amino-6-bromopyrazin-2-yl)-2-(2,6-dichloro-3,5-dimethox yphenyl)-4- methylpyridazin-3(2H)-one

[00667] A mixture of 3,5-dibromopyrazin-2-amine (0.585 g, 2.31 mmol), 2-(2,6-dichloro-

3,5-dimethoxyphenyl)-4-methyl-6-(4,4,5,5-tetramethyl-l,3, 2-dioxaborolan-2-yl)pyridazin- 3(2H)-one (Intermediate Rl 6; 0.927 g, 2.10 mmol), Pd(PPh ₃ ) ₄ (0.182 g, 0.158 mmol) and Na ₂ C0 ₃ (2.21 mL, 4.41 mmol) in dioxane (10.5 ml, 2.10 mmol) was stirred at 55 °C for 8 hours. The reaction was quenched with water and extracted with DCM. The combined organic extracts were washed with water and brine, dried over Na ₂ S0 ₄ and concentrated in vacuo. The crude residue was purified by flash chromatography (1-9% MeOH in DCM) to give the title compound (0.187 g, 0.384 mmol, 18.3 % yield). MS (apci) m/z = 491.9 [(M+H)+4], 489.9 [(M+H)+2], 487.9 (M+H), 485.9 (M-H) with di CI + Br pattern

[00668] Preparation of Synthetic Examples

[00669] Example 1

[00670] [00671] 6-(3-amino-6-(l-methyl-lH-pyrazol-4-vnpyrazin-2-vn-2-(3.5- dimethoxyphenyl)pyridazin-3(2H)-one

[00672] A solution of 2-(3,5-dimethoxyphenyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxabo rolan-

2-yl)pyridazin-3(2H)-one (Intermediate R8; 275.0 mg, 0.7677 mmol) in 4: 1 dioxane:water (7.7 mL) was treated with 3-bromo-5-(l-methyl-lH-pyrazol-4-yl)pyrazin-2-amine (Intermediate L2; 204.8 mg, 0.8061 mmol), PdCl ₂ fdppf CH ₂ Cl ₂ (63.16 mg, 0.07677 mmol), K ₂ C0 ₃ ( _S ) (318.3 mg, 2.303 mmol). The resulting mixture was sparged with A¾), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (150 mL), and extracted with water (2 x 50 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (5-80% DCM/ Acetone as the gradient eluent) to afford the title compound (189.6 mg, 61% yield). MS (apci) m/z = 406.1 (M+H). ¾ MR (400 MHz, DMSO-d ₆ ) δ 8.67- 8.65 (d, 1H), 8.48 (s, 1H), 8.30 (s, 1H), 8.02 (s, 1H), 7.31 (s, 2H), 7.22-7.20 (d, 1H), 6.86-6.85 (d, 2H), 6.63-6.62 (m, 1H), 3.89 (s, 3H), 3.79 (s, 6H).

[00673] The following compounds shown in Table 1 were prepared according the method used in Example 1 using the appropriate 3-bromo-5-(pyrazoyl)pyrazin-2-amines (Intermediates L2, L14, L15, L16, L19) and 2-(Aryl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyri dazin- 3(2H)-one (Intermediate Rl, R8, R9; 1.00-1.2 equivalents). Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified using a method similar to that followed in Example 1 utilizing the appropriate gradient eluent.

Table 1

pyrazol-l-yl)-2-

EtOAc was used as the work up solvent in place of 4: 1 DCM iPrOH

[00674] Example 8

[00676] 6-(3-amino-6-(l -methyl- lH-pyrazol -4-yl)pyrazin-2 -yl)-2-(3-methoxy-5-

(trifluoromethoxy)phenyl)pyridazin-3(2H)-one 2,2,2-trifluoroacetate salt

[00677] A suspension of 3-bromo-5-(l-methyl-lH-pyrazol-4-yl)pyrazin-2-amine

(Intermediate L2; 0.100 g, 0.394 mmol), 2-(3-methoxy-5-(trifluoromethoxy)phenyl)-6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)pyridazin-3(2H)-one (Intermediate R2; 0.243 g, 0.590 mmol), Pd(PPh ₃ ) ₄ (0.0341 g, 0.0295 mmol) and 2M Na ₂ C0 ₃ (aq) (0.413 mL, 0.826 mmol) in dioxane (1.0 mL) was sparged with Α%), then sealed and stirred for 8 h at 90 °C. After cooling to ambient temperature, the reaction mixture was filtered to remove solids. The filtrate was concentrated under vacuum, and the resulting crude residue was purified by C 18 reverse phase chromatography (5-95% ACN:water with 0.1% TFA) to afford the title compound (0.1014 g, 46% yield). MS (apci) m/z = 460.1 (M+H).

[00678] The following compounds shown in Table 2, were prepared according the method used in Example 8 using the appropriate 3-bromo-5-(pyrazoyl)pyrazin-2-amines (Intermediates L2, L3, L5, L17) and 2-(Aryl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyri dazin-3(2H)- one (Intermediate R3, R4, R6, R7, R8, R12). Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified using a method similar to that used in Example 8 utilizing the appropriate gradient eluent and in each case the mono-TFA salt was isolated.

Table 2

trifluoroacetate salt

[00679] Example 19

[00680] [00681] 6-(3 -amino-6-( 1 -(2-ι ^η οφΗο1ϊ ^η ο6&ν1)- lH-pyrazol-4-yl)pyrazin-2-yl)-2-(3.5- dimethoxyphenyl)pyridazin-3(2H)-one

[00682] A suspension of 3-bromo-5-(l-(2-mo holinoethyl)-lH-pyrazol-4-yl)pyrazin-2- amine (Intermediate L8; 0.044 g, 0.125 mmol), 2-(3,5-dimethoxyphenyl)-6-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)pyridazin-3(2H)-one (Intermediate R8; 0.0892 g, 0.249 mmol), Pd(PPh ₃ ) ₄ (0.0108 g, 0.00934 mmol) and 2M Na ₂ C0 ₃ ( _a q) (0.131 mL, 0.262 mmol) in dioxane (1 mL) was sparged with A%), then sealed and stirred for 8 h at 90 °C. After cooling to ambient temperature, the reaction mixture was filtered to remove solids. The filtrate was concentrated under vacuum, and the resulting crude residue was purified by silica chromatography (5 -95 % DCM:(DCM:MeOH: HOH ₄ (90: 10: 1)) to afford the title compound (0.0538 g, 86% yield). MS (apci) m/z = 505.2 (M+H).

[00683] The following compounds shown in Table 3 were prepared according the method used in Example 19 using the appropriate 3-bromo-5-(pyrazoyl)pyrazin-2-amines (Intermediates L2, L4, L7) and 2-(Aryl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyri dazin-3(2H)-one (Intermediate R5, R8). Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified using a method similar to that followed in Example 19 utilizing the appropriate gradient eluent.

Table 3

dazin-3(2H)-one

[00684] Example 23

[00686] 6-(3-amino-6-(l-methyl-lH-pyrazol-4-vnpyrazin-2-vn-2-(2.6-di chloro-3.5- dimethoxyphenyl)pyridazin-3(2H)-one

[00687] A cold (0 °C) solution of 6-(3-amino-6-(l-methyl-lH-pyrazol-4-yl)pyrazin-2-yl)-

2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 1 ; 13.6 mg, 0.0335 mmol) in ACN (0.7 mL) was treated with SO2CI2 (5.42 μΐ _^ , 0.0671 mmol) then stirred for 30 min at ambient temperature. The resulting mixture was quenched with the addition of saturated NaHC0 ₃ (aq) (10 mL). The resulting biphasic mixture was extracted with 4: 1 DCM: iPrOH (2 x 25 mL). The combined organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (5-50% DCM/Acetone as the gradient eluent) to afford the title compound (189.6 mg, 61% yield). MS (apci) m/z = 476.0 [(M+H)+2], 474.1 (M+H), with di CI pattern. ¾ NMR (400 MHz, DMSO-d ₆ ) δ 8.73-8.70 (d, 1H), 8.47 (s, 1H), 8.27 (s, 1H), 8.00 (s, 1H), 7.30-7.27 (d, 1H), 7.09 (s, 1H), 7.03 (s, 2H), 3.94 (s, 6H), 3.85 (s, 3H).

00688] Ex mple 24

[00690] 6-(3-amino-6-(l -methyl- lH-pyrazol-4-yl)pyrazin-2-yl)-2-(2-bromo-3, 5- dimethoxyphenyl)pyridazin-3(2H)-one 2,2,2-trifluoroacetate salt

[00691] A cold (0 °C) solution of 6-(3-amino-6-(l-methyl-lH-pyrazol-4-yl)pyrazin-2-yl)-

2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 1; 100 mg, 0.247 mmol) in DCM (1.23 mL) was treated with NBS (43.9 mg, 0.247 mmol) then stirred for 3 h at ambient temperature. The resulting mixture was diluted with Ethyl Acetate, washed with Brine (2x), then dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica gel chromatography (30-100% EtOAc/Hexanes as the gradient eluent) to afford the title compound in about 75% purity (17.4 mg, 15% yield). Additional purification by C18 reverse phase chromatography (5-95% Acetonitrile in Water with 0.1% TFA as gradient eluent) provided clean title compound. MS (apci) m/z = 484.0 (M+H), with di Br pattern. ¾ NMR (400 MHz, CDCb) δ 8.67-8.64 (d, 1H), 8.26 (s, 1H), 7.92 (s, 1H), 7.83 (s, 1H), 7.20-7.17 (d, 1H), 6.65- 6.60 (m, 2H), 6.27 (broad s, 2H), 3.96 (s, 3H), 3.92 (s, 3H), 3.82 (s, 3H).

[00692] Example 25

[00694] 6-(3-amino-6-(l -methyl- lH-pyrazol-4-yl)pyrazin-2-yl)-2-(2,6-dibromo-3, 5- dimethoxyphenyl)pyridazin-3(2H)-one 2,2,2-trifluoroacetate salt

[00695] A cold (0 °C) solution of 6-(3-amino-6-(l-methyl-lH-pyrazol-4-yl)pyrazin-2-yl)-

2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 1; 20 mg, 0.0493 mmol) in DCM (0.247 mL mL) was treated with NBS (15 mg, 0.0843 mmol) then stirred overnight at ambient temperature. The resulting mixture was diluted with Ethyl Acetate, washed with Brine (2x), then dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by C18 reverse phase chromatography (5-95% Acetonitrile in Water with 0.1% TFA as the gradient) to afford the title compound (7 mg, 25% yield). MS (apci) m/z = 564.0 (M+H), with di Br pattern. ¾ MR (400 MHz, CDCb) δ 8.84-8.81(d, 1H), 8.36 (s, 1H), 8.16 (s, 1H), 8.03 (s, 1H), 7.27-7.24 (d, 1H), 6.95 (s, 1H), 4.00 (s, 6H), 3.94 (s, 3H).

[00696] Example 26

[00697]

[00698] (R)-6-(3 -amino-6-( 1 -((5.5 -dimethylmorpholin-2-vnmethyiy 1 H-pyrazol-4- yl)pyrazin-2-yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00699] Step 1 : Preparation of tert-butyl (R)-2-((4-(5-amino-6-(l-(3.5-dimethoxyphenvn-

6-oxo- 1 ,6-dihydropyridazin-3 -yl)pyrazin-2-yl)- 1 H-pyrazol- 1 -yl)methyl)-5, 5- dimethylmorpholine-4-carboxylate. A suspension of tert-butyl (R)-2-((4-(5-amino-6- bromopyrazin-2-yl)-lH-pyrazol-l-yl)methyl)-5,5-dimethylmo holine-4-carboxylate

(Intermediate L12; 100 mg, 0.214 mmol), 2-(3,5-dimethoxyphenyl)-6-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)pyridazin-3(2H)-one (Intermediate R8; 192 mg, 0.535 mmol), Pd(PPh ₃ ) ₄ (24.7 mg, 0.0214 mmol), and 2M Na2C0 ₃ ( _aq ) (321 μΐ,, 0.642 mmol) in dioxane (2.14 mL) was sparged with Ar(g), then sealed and stirred 2 h at 90 °C. After cooling to ambient temperature, the reaction mixture was diluted with EtOAc and filtered to remove solids. The filtrate was concentrated under vacuum, and the resulting crude residue was purified by silica chromatography (60-100%) EtOAc in Hexanes) to afford the title compound (35 mg, 26% yield). MS (apci) m/z = 619.2 (M+H).

[00700] Step 2: Preparation of (R)-6-(3-amino-6-(l-((5.5-dimethylmoφholin-2- yl)methyl)-lH-pyrazol-4-yl)pyrazin-2-yl)-2-(3,5-dimethoxyphe nyl)pyridazin-3(2H)-one. The tert-butyl (R)-2-((4-(5 -amino-6-( 1 -(3 , 5 -dimethoxyphenyl)-6-oxo- 1 , 6-dihydropyridazin-3 - yl)pyrazin-2-yl)-lH-pyrazol-l-yl)methyl)-5,5-dimethylmorphol ine-4-carboxylate (35 mg, 0.057 mmol) was dissolved in 1 : 1 TFA:DCM (8.0 mL) then stirred 1 h at ambient temperature. The reaction mixture was concentrated under vacuum then purified by CI 8 reverse phase chromatography (5-95% ACN in H ₂ 0 with 0.1% TFA as the gradient as the gradient eluent). The chromatographic fractions containing the title compound were combined then neutralized with saturated NaHC0 ₃ ( _aq ) and extracted with DCM. The organic extracts were then dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound (24.5 mg, 84% yield). MS (apci) m/z = 519.2 (M+H).

[00701] Example 27

[00702]

[00703] (S>6-(3 - amino-6-( 1 -((5.5 - dimethylmorpholin-2- νΠ ^η ΐ6&νΠ - 1 H-pyrazol-4- yl)pyrazin-2-yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00704] Step 1 : Preparation of tert-butyl (S)-2-((4-(5-amino-6-(l-(3.5-dimethoxyphenyl)- 6-oxo- 1 ,6-dihydropyridazin-3 -vDpyrazin-2-yl)- 1 H-pyrazol- 1 -yl)methyl)-5, 5- dimethylmorpholine-4-carboxylate. The title compound was prepared and isolated according to the method described in step 1 of Example 26, using tert-butyl (S)-2-((4-(5-amino-6- bromopyrazin-2-yl)-lH-pyrazol-l-yl)methyl)-5,5-dimethylmo holine-4-carboxylate

(Intermediate LI 1) in place of tert-butyl (R)-2-((4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l- yl)methyl)-5,5-dimethylmorpholine-4-carboxylate (Intermediate L12). The title compound was carried on to step 2, without silica chromatography. MS (apci) m/z = 446.2 (M+H).

[00705] Step 2: Preparation of (S)-6-(3-amino-6-(l-((5.5-dimethylmoφholin-2- yl)methyl)-lH-pyrazol-4-yl)pyrazin-2-yl)-2-(3,5-dimethoxyphe nyl)pyridazin-3(2H)-one. The title compound was prepared and isolated according to the method described in step 2 of Example 26, using the crude residue from step 1 and neutralizing with 1 M NaOH( _aq ) instead of NaHC0 ₃ ( _aq ) resulting in a 46% yield (39 mg,). MS (apci) m/z = 519.2 (M+H). [00706] Example 28

[00707]

[00708] 6-(3-amino-6-(l-(((2S.5RV5-methylmorpholin-2-vnmethvn-lH-pyr azol-4- yl)pyrazin-2-yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00709] Step 1 : Preparation of tert-butyl (2S.5R)-2-((4-(5-amino-6-(l-(3.5- dimethoxyphenyl)-6-oxo-L6-dihydropyridazin-3-yl)pyrazin-2-yl )-lH-pyrazol-l-yl)m

methylmorpholine-4-carboxylate. The title compound was prepared and isolated according to the method described in step 1 of Example 26, with the exception that the reaction required overnight stirring at 90 °C and utilized tert-butyl (2S,5R)-2-((4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol- l-yl)methyl)-5-methylmorpholine-4-carboxylate (Intermediate L10) in place of tert-butyl (R)-2- ((4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l-yl)methyl)-5, 5-dimethylmo holine-4- carboxylate (Intermediate LI 2). The title compound was carried on to step 2, without silica chromatography (23 mg, 34% yield). MS (apci) m/z = 605.2 (M+H).

[00710] Step 2: Preparation of 6-(3-amino-6-(l-(((2S.5R)-5-methylmorpholin-2- yl)methyl)-lH-pyrazol-4-yl)pyrazin-2-yl)-2-(3,5-dimethoxyphe nyl)pyridazin-3(2H)-one. Using the crude residue from step 1, the title compound was prepared, isolated, purified and neutralized according to the method described in step 2 of Example 26, with the exception that the reaction was allowed to stir 2 d at ambient temperature prior to isolation/ purification (7.0 mg, 84% yield). MS (apci) m/z = 505.2 (M+H).

[00711] Example 29

[00712]

[00713] (R)-6-(6-(l-((7-oxa-4-azaspiror2.51octan-6-yl)methyl)-lH-pyr azol-4-yl)-3- aminopyrazin-2-yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-on e

[00714] Step 1 : Preparation of tert-butyl (R)-6-((4-(5-amino-6-(l-(3.5-dimethoxyphenvn-

6-oxo- 1 ,6-dihydropyridazin-3 -yl)pyrazin-2-yl)- 1 H-pyrazol- 1 -yl)methyl)-7-oxa-4- azaspiro \2.51 octane-4-carb oxyl ate . The title compound was prepared and isolated according to the method described in step 1 of Example 26, using of tert-butyl (R)-6-((4-(5-amino-6- bromopyrazin-2-yl)-lH-pyrazol-l-yl)methyl)-7-oxa-4-azaspiro[ 2.5]octane-4-carboxylate (Intermediate L13) in place of tert-butyl (R)-2-((4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l- yl)methyl)-5,5-dimethylmorpholine-4-carboxylate (Intermediate L12). The title compound was purified by silica chromatography (30-75% EtOAc in Hexanes) which provide the title compound in 38% yield (15 mg). MS (apci) m/z = 617.2 (M+H).

[00715] Step 2: Preparation of (R)-6-(6-(l-((7-oxa-4-azaspiror2.51octan-6-vnmethvn-lH- pyrazol-4-yl)-3-aminopyrazin-2-yl)-2-(3,5-dimethoxyphenyl)py ridazin-3(2H)-one. Using the purified material from step 1, the title compound was prepared, isolated, purified and neutralized according to the method described in step 2 of Example 27 (12.1 mg, 96% yield). MS (apci) m/z = 517.2 (M+H).

[00716] Example 30

[00717]

[00718] 6-(3-amino-6-(l-(((2R.5R)-5-methylmorpholin-2-vnmethvn-lH-py razol-4- yl)pyrazin-2-yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00719] Step 1 : Preparation of tert-butyl (2R.5R)-2-((4-(5-amino-6-(l-(3.5- dimethoxyphenyl)-6-oxo-L6-dihvdropyridazin-3-yl)pyrazin-2-yl )-lH-pyrazol-l-yl)methyl)-5- methylmorpholine-4-carboxylate. The title compound was prepared and isolated according to the method described in step 1 of Example 26, using of tert-butyl (2R,5R)-2-((4-(5-amino-6- bromopyrazin-2-yl)- lH-pyrazol- 1 -yl)methyl)-5-methylmorpholine-4-carboxylate (Intermediate L9) in place of tert-butyl (R)-2-((4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l-yl)meth yl)-5,5- dimethylmorpholine-4-carboxylate (Intermediate LI 2). The title compound was purified by silica chromatography (30-75%) EtOAc in Hexanes) which provided the title compound in 31%> yield (23 mg). MS (apci) m/z = 605.2 (M+H).

[00720] Step 2: Preparation of 6-(3-amino-6-(l-(((2R.5R)-5-methylmorpholin-2- yl)methyl)-lH-pyrazol-4-yl)pyrazin-2-yl)-2-(3,5-dimethoxyphe nyl)pyridazin-3(2H)-one. Using the purified material from step 1, the title compound was prepared, isolated, purified according to the method described in step 2 of Example 26 which provided the title compound in 91% yield (17.4 mg). MS (apci) m/z = 505.2 (M+H).

[00721] Example 31

[00723] 6-(3 - amino-6-( 1 -( piperidin-4-ylV 1 H-p yrazol-4-vQp yrazin-2-v0-2-( 3.5- dimethoxyphenyl)pyridazin-3(2H)-one

[00724] Step 1 : Preparation of tert-butyl 4-(4-(5-amino-6-(l-(3,5-dimethoxyphenyl)-6- oxo- L6-dihydropyridazin-3 -vDpyrazin-2-vD- lH-pyrazol- 1 -vQpiperidine- 1 -carboxylate. A suspension of tert-butyl 4-(4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l-yl)piperidin e-l- carboxylate (Intermediate L19; 398.9 mg, 0.9423 mmol), 2-(3,5-dimethoxyphenyl)-6-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)pyridazin-3(2H)-one (Intermediate R8; 371.3 mg, 1.037 mmol), PdCl ₂ fdppf CH ₂ Cl ₂ (77.52 mg, 0.09423 mmol) and K ₂ C0 _3(S) (390.7 mg, 2.827 mmol) in 4: 1 dioxane:water (10 mL) was sparged with A¾), then sealed and stirred 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM:iPrOH (200 mL) and washed with water (2 x 50 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (5-95%) DCM- Acetone as the gradient eluent) to afford the title compound which was immediately carried on to step 2. MS (apci) m/z = 575.3 (M+H).

[00725] Step 2: Preparation of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-

2-yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one. The tert-butyl 4-(4-(5-amino-6-(l-(3,5- dimethoxyphenyl)-6-oxo-l,6-dihydropyridazin-3-yl)pyrazin-2-y l)-lH-pyrazol-l-yl)piperidine-l- carboxylate was dissolved in 1 : 1 TFA:DCM (5.0 mL) then stirred 30 min at ambient temperature. The reaction mixture was concentrated under vacuum then purified by CI 8 reverse phase chromatography (5-95% ACN in H ₂ 0 with 0.1%> TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (50 mL) and extracted with saturated NaHC0 ₃ ( _aq ) (1 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to cleanly afford the title compound (213.2 mg, 48% yield). MS (apci) m/z = 475.2 (M+H).

[00726] Example 32

[00727]

[00728] 6-(3-amino-6-(l-(l-methylpiperidin-4-vn-lH-pyrazol-4-vnpyraz in-2-vn-2-(3.5- dimethoxyphenyl)pyridazin-3(2H)-one

[00729] A solution of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-y l)-2-

(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 31; 187.2 mg, 0.3945 mmol) in 1 : 1 DCM:MeOH (4 mL) was treated with formaldehyde (592.9 μΐ,, 7.890 mmol) and stirred 15 min at ambient temperature. The resulting reaction mixture was treated with sodium triacetoxyborohydride (334.4 mg, 1.578 mmol) and stirred 16 h at ambient temperature. The reaction mixture was concentrated under vacuum then purified by CI 8 reverse phase chromatography (5-95% water- ACN w/ 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (50 mL) and extracted with saturated NaHC0 ₃ ( _aq ) (1 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to afford the title compound along with imine contaminants. The residue then was dissolved in 1 : 1 : 1 TFA: ACN: water (6 mL) and stirred for 15 min at ambient temperature then concentrated under vacuum. The resultant residue was dissolved in 4: 1 DGVLiPrOH (50 mL) and extracted with saturated NaHC0 ₃ ( _aq ) (1 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The residue was purified further by silica chromatography (1-30% DCM-MeOH w/ 2% NH4OH as the gradient eluent) to cleanly afford the title compound (28.5 mg, 15% yield). MS (apci) m/z = 489.1 (M+H). ¾ NMR (400 MHz, DMSO-d ₆ ) δ 8.71-8.69 (d, 1H), 8.49 (s, 1H), 8.42 (s, 1H), 8.04 (s, 1H), 7.31 (s, 2H), 7.21-7.19 (d, 1H), 6.86-6.85 (d, 2H), 6.63-6.62 (t, 1H), 4.19-4.13 (m, 1H), 3.79 (s, 6H), 2.93-2.88 (m, 2H), 2.25 (s, 3H), 2.15-1.97 (m, 6H). [00730] Example 33

[00731]

[00732] 6-(3-amino-6-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazo l-4-yl)pyrazin-2- yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00733] A solution of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-y l)-2-

(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 31 ; 10.6 mg, 0.0223 mmol) in DMF (0.5 mL) was treated with 1 -bromo-2-methoxy ethane (2.5 μΐ _^ , 0.027 mmol) and K2C0 ₃ ( _S ) (6.1 mg, 0.0447 mmol). The resulting mixture was stirred 16 h at ambient temperature, then additional 1- bromo-2-methoxyethane (2.5 μΐ _^ , 0.027 mmol) and K2C0 ₃ ( _S > (6.1 mg, 0.0447 mmol) were added. The reaction was stirred for an additional period of 24 h at ambient temperature and subsequently diluted with EtOAc (25 mL). The EtOAc solution was washed with water (2 x 10 mL) and brine (1 x 10 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (1 -30% DCM-MeOH w/ 2% H4OH as the gradient eluent) to afford the title compound (6.1 mg, 51% yield). MS (apci) m/z = 533.2 (M+H). ¾ MR (400 MHz, DMSO-d ₆ ) δ 8.72-8.70 (d, 1H), 8.49 (s, 1H), 8.43 (s, 1H), 8.04 (s, 1H), 7.31 (s, 2H), 7.21 -7.18 (d, 1H), 6.86-6.85 (d, 2H), 6.63-6.62 (t, 1H), 4.19-4.12 (m, 1H), 3.79 (s, 6H), 3.47-3.44 (t, 2H), 3.25 (s, 3H), 3.01-2.97 (m, 2H), 2.54-2.51 (m, 2H), 2.19- 2.13 (m, 2H), 2.06-1.94 (m, 4H).

[00734] Example 34

[00736] 6-(3-amino-6-(l-(l-(2-(trifluoromethoxy)ethyl)piperidin-4-yl )-lH-pyrazol-4- yl)pyrazin-2-yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one 2,2,2-trifluoroacetate salt

[00737] A solution of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-y l)-2-

(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 31 ; 100 mg, 0.21 1 mmol) in DMSO (843 μΕ) was treated with l -bromo-2-(trifluoromethoxy)ethane (36.4 μΕ, 0.316 mmol) and Cs2C0 ₃ ( _S > (172 mg, 0.527 mmol). The resulting mixture was stirred overnight at ambient temperature then diluted with EtOAc and washed with water (2x) and brine. The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (50-100% EtOAc in Hexanes as the gradient eluent). The material was further purified by C18 reverse phase chromatography (5-95% Acetonitrile in Water with 0.1% TFA as the gradient eluent) to afford the title compound (15 mg, 12% yield). MS (apci) m/z = 587.2 (M+H).

[00738] Example 35

[00739]

[00740] 6-(3-amino-6-(l-(l-(2,2-difluoroethyl)piperidin-4-yl)-lH-pyr azol-4-yl)pyrazin-2- yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one 2,2,2-trifluoroacetate salt

[00741] A solution of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-y l)-2-

(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 31; 100 mg, 0.211 mmol) in DMF (1.05 mL) was treated with DIPEA (110 μί, 0.632 mmol) and 2,2-difluoroethyl trifluoromethanesulfonate (67.7 mg, 0.316 mmol). The resulting mixture was stirred 4 h at ambient temperature then diluted with EtOAc and washed with water and brine. The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (stepwise gradient eluent of 70-100%) EtOAc in Hexanes then 0-5% MeOH in EtOAc). The material was further purified by CI 8 reverse phase chromatography (5-95% Acetonitrile in Water with 0.1% TFA as the gradient eluent) to afford the title compound (11 mg, 10% yield). MS (apci) m/z = 539.2 (M+H).

[00742] Example 36

[00743]

[00744] 6-(3-amino-6-(l-(l-(2,2,2-trifluoroethyl)piperidin-4-yl)-lH- pyrazol-4-yl)pyrazin- 2-yl)-2-(3 , 5 -dimethoxyphenyl)pyridazin-3 (2H)-one [00745] A solution of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-y l)-2-

(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 31; 100 mg, 0.211 mmol) in DMF (1.05 mL) was treated with DIPEA (110 μί, 0.632 mmol) and 2,2,2-trifluoroethyl trifluoromethanesulfonate (73.4 mg, 0.316 mmol). The resulting mixture was stirred over the weekend at ambient temperature then diluted with a mixture of EtO Ac/water/brine. The organic extracts were washed with water and brine then dried over anhydrous MgS04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (50-80% EtOAc in Hexanes as the gradient eluent) to afford the title compound (30.2 mg, 26% yield). MS (apci) m/z = 557.2 (M+H).

00746] Exam le 37

[00748] 6-(3 -amino-6-( 1 -(piperidin-4-yl)- lH-pyrazol-4-yl)pyrazin-2-yl)-2-(5 -methoxy-2- methylphenyl)pyridazin-3(2H)-one

[00749] Step 1 : Preparation of tert-butyl 4-(4-(5-amino-6-(l-(5-methoxy-2-methylphenyl)-

6-oxo-L6-dihydropyridazin-3-yl)pyrazin-2-yl)-lH-pyrazol-l -yl)piperidine-l-carboxylate. A suspension of tert-butyl 4-(4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l-yl)piperidin e-l- carboxylate (Intermediate L19; 198.5 mg, 0.4689 mmol), 2-(5-methoxy-2-methylphenyl)-6- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridazin-3(2H) -one (Intermediate R10; 320.9 mg, 0.9379 mmol), PdCl ₂ fdppf CH ₂ Cl ₂ (38.58 mg, 0.04689 mmol) and K ₂ C0 ₃ ( _S ) (194.4 mg, 1.407 mmol) in 4: 1 dioxane:water (5.0 mL) was sparged with A%), then sealed and stirred 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM:iPrOH (50 mL) and washed with water (2 x 25 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (5-60% DCM-Acetone as the gradient eluent) to afford the title compound which was immediately carried on to step 2. MS (apci) m/z = 575.3 (M+H).

[00750] Step 2: Preparation of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-

2-yl)-2-(5-methoxy-2-methylphenyl)pyridazin-3(2H)-one. The tert-butyl 4-(4-(5-amino-6-(l-(5- methoxy-2-methylphenyl)-6-oxo-l,6-dihydropyridazin-3-yl)pyra zin-2-yl)-lH-pyrazol-l- yl)piperidine-l-carboxylate was dissolved in 1 : 1 TFA:DCM (5.0 mL) then stirred 1 h at ambient temperature. The reaction mixture was concentrated under vacuum then purified by C 18 reverse phase chromatography (5-95% ACN in H ₂ 0 with 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (50 mL) and extracted with saturated NaHC0 ₃ (aq) (1 x 25 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to cleanly afford the title compound (102.0 mg, 47% yield). MS (apci) m/z = 459.1 (M+H).

00751] Exam le 38

[00753] 6-( 3 -amino-6-( 1 -( 1 -methylpiperidin-4-νΠ- lH-pyrazol-4-v0pyrazin-2-v0-2-(5- methoxy-2-methylphenyl)pyridazin-3(2H)-one

[00754] A solution of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-y l)-2-

(5-methoxy-2-methylphenyl)pyridazin-3(2H)-one (Example 37; 187.2 mg, 0.3945 mmol) in 1 : 1 DCM:MeOH (1.5 mL) was treated with formaldehyde (227 μΕ, 3.02 mmol) and sodium triacetoxyborohydride (128 mg, 0.604 mmol) and stirred 16 h at ambient temperature. The reaction mixture was concentrated under vacuum then purified by CI 8 reverse phase chromatography (5-95% water- ACN w/ 0.1% TFA as the gradient eluent). The chromatographic fractions containing the title compound were dissolved in 1 : 1 : 1 TFA:ACN:water (6 mL) and stirred for 1 h at ambient temperature then concentrated under vacuum. The residue was diluted with 4: 1 DGVLiPrOH (50 mL) and washed with saturated NaHC0 ₃ ( _aq ) (1 x 25 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to cleanly afford the title compound (55.0 mg, 77% yield). MS (apci) m/z = 473.1 (M+H).

00755] Example 39

(5-methoxy-2-methylphenyl)pyridazin-3(2H)-one (Example 37; 22.46 mg, 0.04898 mmol) in DMSO (0.1959 mL) was treated with l-bromo-2-methoxyethane (10.21 mg, 0.07348 mmol) and K2C0 ₃ (s) (27.08 mg, 0.19598 mmol). The resulting mixture was stirred overnight at 50 °C, then cooled to ambient temperature. The reaction was diluted with water and extracted with EtOAc. The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by C18 reverse phase chromatography (5-95% Acetonitrile in Water with 0.1% TFA as the gradient eluent) to afford the title compound (6.5 mg, 26% yield). MS (apci) m/z = 517.3 (M+H).

[00759] Exam le 40

[00761] 6-(3-amino-6-(l-(piperidin-4-vn-lH-pyrazol-4-vnpyrazin-2-vn- 2-(2-fluoro-5- methoxyphenyl)pyridazin-3(2H)-one

[00762] Step 1 : Preparation of tert-butyl 4-(4-(5-amino-6-(l-(2-fluoro-5-methoxyphenyl)-

6-oxo-L6-dihvdropyridazin-3-yl)pyrazin-2-yl)-lH-pyrazol-l -yl)piperidine-l-carboxylate. A suspension of tert-butyl 4-(4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l-yl)piperidin e-l- carboxylate (Intermediate L19; 48.06 mg, 0.1135 mmol), 2-(2-fluoro-5-methoxyphenyl)-6- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridazin-3(2H) -one (Intermediate R14; 117.9 mg, 0.1703 mmol), Pd(PPh ₃ ) ₄ (13.12 mg, 0.01135 mmol), and 2M Na2C0 _3(a q) (170.3 μί, 0.3406 mmol) in dioxane (1135 μΕ) was sparged with A¾), then sealed and stirred overnight at 90 °C. After cooling to ambient temperature, the reaction mixture was partitioned between EtOAc and water then the aqueous extracts were washed with EtOAc . The combined organic extracts were dried over anhydrous Na2S0 ₄ ( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (0-15%MeOH in EtOAc as the gradient eluent) to afford the title compound (15 mg, 23% yield). MS (apci) m/z = 563.3 (M+H).

[00763] Step 2: Preparation of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-

2-yl)-2-(2-fluoro-5-methoxyphenyl)pyridazin-3(2H)-one. The tert-butyl 4-(4-(5-amino-6-(l-(2- fluoro-5-methoxyphenyl)-6-oxo- 1 ,6-dihydropyridazin-3 -yl)pyrazin-2-yl)- 1 H-pyrazol- 1 - yl)piperidine-l-carboxylate (15 mg, 0.027 mmol) was dissolved in 1 : 1 TFA:DCM (2.0 mL) then stirred overnight at ambient temperature. The reaction mixture was concentrated under vacuum then purified by C18 reverse phase chromatography (5-95% ACN in FhO with 0.1% TFA as the gradient eluent). The chromatographic fractions containing the title compound were combined then neutralized with saturated NaHC0 ₃ ( _aq ) and extracted with DCM (3x). The organic extracts were then dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to afford the title compound (6.2 mg, 50% yield). MS (apci) m/z = 463.2 (M+H).

[00764] Example 41

[00765]

[00766] 6-(3 -amino-6-( 1 -(piped din-4-ylV lH-pyrazol-4-yl)pyrazin-2-yl)-2-(2-fluoro-3.5- dimethoxyphenyl)pyridazin-3(2H)-one

[00767] Step 1 : Preparation of tert-butyl 4-(4-(5-amino-6-(l-(2-fluoro-3.5- dimethoxyphenyl)-6-oxo-L6-dihydropyridazin-3-yl)py

carboxylate. A suspension of tert-butyl 4-(4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l- yl)piperidine-l-carboxylate (Intermediate L19; 69.88 mg, 0.1651 mmol), 2-(2-fluoro-3,5- dimethoxyphenyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2 -yl)pyridazin-3(2H)-one

(Intermediate R13; 124.2 mg, 0.2476 mmol), Pd(PPh ₃ ) ₄ (19.08 mg, 0.01651 mmol), and 2M Na2C0 ₃ (aq) (247.6 μΐ., 0.4952 mmol) in dioxane (1651 μΐ.) was sparged with A%), then sealed and stirred overnight at 90 °C. After cooling to ambient temperature, the reaction mixture was partitioned between EtOAc and water then the aqueous extracts were washed with EtOAc . The combined organic extracts were dried over anhydrous Na2S0 ₄ ( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (0-15%MeOH in EtOAc as the gradient eluent) to afford the title compound (50 mg, 51% yield). MS (apci) m/z = 593.3 (M+H).

[00768] Step 2: Preparation of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-

2-yl)-2-(2-fluoro-3 , 5-dimethoxyphenyl)pyridazin-3 (2H)- one. The tert-butyl 4-(4-(5-amino-6-(l- (2-fluoro-3,5-dimethoxyphenyl)-6-oxo-l,6-dihydropyridazin-3- yl)pyrazin-2-yl)-lH-pyrazol-l- yl)piperidine-l -carboxylate (50 mg, 0.084 mmol) was dissolved in 1 : 1 TFA:DCM (2.0 mL) then stirred overnight at ambient temperature. The reaction mixture was concentrated under vacuum then purified by C18 reverse phase chromatography (5-95% ACN in H2O as the gradient eluent). The chromatographic fractions containing the title compound were combined then neutralized with saturated NaHC0 ₃ (aq) and extracted with DCM (3x). The organic extracts were then dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to afford the title compound (37.0 mg, 89% yield). MS (apci) m/z = 493.2 (M+H).

[00769] Example 42

[00770]

[00771] 6-(3-amino-6-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazo l-4-yl)pyrazin-2- yl)-2-(2-fluoro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one 2,2,2-trifluoroacetate salt

[00772] A solution of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-y l)-2-

(2-fluoro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 41; 10 mg, 0.020 mmol) in DMSO (81 μ ) was treated with l-bromo-2-methoxy ethane (6.91 μΐ _^ , 0.0734762 mmol) and K2C0 ₃ ( _S > (11 mg, 0.081 mmol). The resulting mixture was stirred 3 h at ambient temperature. The reaction was diluted with water and extracted with DCM. The organic extracts were washed with brine and were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by C18 reverse phase chromatography (25-75%) ACN in water with 0.1%> TFA as the gradient eluent) to afford the title compound (4 mg, 36%> yield). MS (apci) m/z = 551.2 (M+H).

[00773] Example 43

[00774]

[00775] 6-(3-amino-6-(l -methyl- lH-pyrazol-4-yl)pyrazin-2-yl)-2-(3,5-dimethoxyphenyl)-

4-methylpyridazin-3(2H)-one

[00776] A solution of 3-bromo-5-(l-methyl-lH-pyrazol-4-yl)pyrazin-2-amine

(Intermediate L2; 101.7 mg, 0.4003 mmol) in 4: 1 dioxane:water (4.0 mL) was treated with 2-(3,5- dimethoxyphenyl)-4-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxa borolan-2-yl)pyridazin-3(2H)-one (Intermediate R18; 260.724 mg, 0.7004 mmol), PdChfdppf^CHzCh (32.93 mg, 0.04003 mmol), K ₂ C0 ₃ ( _S ) (166.0 mg, 1.201 mmol). The resulting mixture was sparged with A%), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (50 mL), and extracted with water (2 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (5-75% DCM/ Acetone as the gradient eluent). The chromatographic fractions containing the title compound were combined, concentrated under vacuum then triturated with DCM (20 mL). The resulting suspension was filtered and the solids collected were dried under vacuum to cleanly afford the title compound (90.8 mg, 54% yield). MS (apci) m/z = 420.1 (M+H). ¾NMR (400 MHz, DMSO-d ₆ ) δ 8.55-8.54 (d, 1H), 8.46 (s, 1H), 8.32 (s, 1H), 8.07 (s, 1H), 7.30 (s, 2H), 6.84-6.83 (d, 2H), 6.62-6.61 (t, 1H), 3.90 (s, 3H), 3.79 (s, 6H), 2.29 (s, 3H).

[00777] Example 44

[00779] 6-(3-amino-6-(l -methyl- lH-pyrazol-4-yl)pyrazin-2-yl)-2-(3,5-dimethoxyphenyl)-

4-ethylpyridazin-3(2H)-one 2,2,2-trifluoroacetate salt

[00780] A suspension of 3-bromo-5-(l-methyl-lH-pyrazol-4-yl)pyrazin-2-amine

(Intermediate L2; 0.025 g, 0.098 mmol), 2-(3,5-dimethoxyphenyl)-4-ethyl-6-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)pyridazin-3(2H)-one (Intermediate R26; 0.042 g, 0.11 mmol), Pd(PPh ₃ ) ₄ (0.0085 g, 0.0074 mmol) and 2M Na ₂ C0 ₃ ( _a q) (0.10 mL, 0.21 mmol) in dioxane (1.0 mL) was sparged with A%), then sealed and stirred for 8 h at 90 °C. After cooling to ambient temperature, the reaction mixture was filtered to remove solids. The filtrate was concentrated under vacuum, and the resulting crude residue was purified by CI 8 reverse phase chromatography (5-95 % ACN:water with 0.1% TFA) to afford the title compound as the TFA salt (0.0056 g, 11% yield). MS (apci) m/z = 434.1 (M+H).

[00781] The following compounds shown in Table 4 were prepared according the method used for the synthesis of Example 44 using 3-bromo-5-(l-methyl-lH-pyrazol-4-yl)pyrazin-2- amine (Intermediate L2) and 2-(3,5-dimethoxyphenyl)-4-alkyl-6-(4,4,5,5-tetramethyl-l,3,2 - dioxaborolan-2-yl)pyridazin-3(2H)-one (Intermediates R25, R27). Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified using a method similar to that used in Example 44 utilizing the appropriate gradient eluent.

Table 4

tri fluoroacetate salt

[00782] Example 47

[00783]

[00784] 6-(3-amino-6-(l -methyl- lH-pyrazol-4-yl)pyrazin-2-yl)-2-(3,5-dimethoxyphenyl)- 4-isopropylpyridazin-3(2H)-one

[00785] A solution of 3-bromo-5-(l-methyl-lH-pyrazol-4-yl)pyrazin-2-amine

(Intermediate L2; 100.0 mg, 0.3936 mmol) in 4: 1 dioxane: water (4.0 mL) was treated with 2-(3,5- dimethoxyphenyl)-4-isopropyl-6-(4,4,5,5-tetramethyl-l,3,2-di oxaborolan-2-yl)pyridazin-3(2H)- one (Intermediate R23; 173.3 mg, 0.4329 mmol), PdChfdppfj'CHiCh (32.93 mg, 0.04003 mmol), K2C0 ₃ (s) (163.2 mg, 1.181 mmol). The resulting mixture was sparged with A%), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (50 mL), and extracted with water (2 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (5-60% DCM/ Acetone as the gradient eluent) to cleanly afford the title compound (27.1 mg, 15% yield). MS (apci) m/z = 448.1 (M+H). ¾ NMR (400 MHz, DMSO-de) δ 8.47 (s, 1H), 8.40 (s, 1H), 8.26 (s, 1H), 8.01 (s, 1H), 7.30 (s, 2H), 6.85- 6.84 (d, 2H), 6.62-6.61 (t, 1H), 3.91 (s, 3H), 3.79 (s, 6H), 3.24-3.17 (m, 1H), 1.30-1.29 (d, 6H).

[00786] The following compounds shown in Table 5 were prepared according the method used for the synthesis of Example 47 using 3-bromo-5-(l-methyl-lH-pyrazol-4-yl)pyrazin-2- amine (Intermediate L2) and 2-(3,5-dimethoxyphenyl)-4-alkyl-6-(4,4,5,5-tetramethyl-l,3,2 - dioxaborolan-2-yl)pyridazin-3(2H)-one (Intermediates R22, R24). Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified using a method similar to that used in Example 47 utilizing the appropriate gradient eluent.

Table 5

\ n-3(2H)-one

[00787] Example 50

[00788]

[00789] 6-(3-amino-6-(l-(piperidin-4-vn-lH-pyrazol-4-vnpyrazin-2-vn- 2-(3.5- dimethoxyphenyl)-4-methylpyridazin-3(2H)-one dihydrochloride salt

[00790] Step 1 : Preparation of teit-butyl 4-(4-(5-amino-6-q-(3.5-dimethoxyphenvD-5- methyl-6-oxo- 1 ,6-dihydropyridazin-3 -yl)pyrazin-2-yl)- IH-pyrazol- 1 -vDpiperidine- 1 - carboxylate. A mixture of tert-butyl 4-(4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l- yl)piperidine-l-carboxylate (Intermediate L19; 398 mg, 0.940 mmol), 2-(3,5-dimethoxyphenyl)- 4-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyri dazin-3(2H)-one (Intermediate Rl 8; 350 mg, 0.940 mmol), Pd(PPh ₃ ) ₄ (109 mg, 0.0940 mmol), 2M Na ₂ C0 ₃ (aq) (1.41 mL, 0.940 mmol) was suspended in dioxane (1.88 mL). The resulting mixture was purged with N ₂ ( _g > for 6 min, then was sealed and stirred for 16 h at 90 °C. After cooling to ambient temperature, the reaction mixture was diluted with DCM (50 mL) and washed with water (2 x 15 mL). The organic extracts were dried over anhydrous MgS04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (1-55% acetone/hexanes as the gradient eluent) to afford the title compound (425 mg, 77% yield). MS (apci) m/z = 589.3 (M+H).

[00791] Step 2: Preparation of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-

2-yl)-2-(3,5-dimethoxyphenyl)-4-methylpyridazin-3(2H)-one dihydrochloride salt. The tert-butyl 4-(4-(5 -amino-6-( 1 -(3 , 5 -dimethoxyphenyl)-5 -methyl-6-oxo- 1 , 6-dihydropyridazin-3 -yl)pyrazin- 2-yl)-lH-pyrazol-l-yl)piperidine-l-carboxylate (420 mg, 0.713 mmol) was dissolved in TFA (2.0 mL) then stirred 2 h at ambient temperature. The reaction mixture was concentrated under vacuum then dissolved in DCM (2 mL) and treated with 2 N HC1 in dioxane (5 mL). The resulting suspension was filtered and the solids were rinsed with ACN and dried under vacuum to afford the title compound (325 mg, 81% yield). MS (apci) m/z = 489.2 (M+H). ¾ NMR (400 MHz, MeOH- d ₄ ) δ 8.59 (d, 1H), 8.44 (d, 1H), 8.31 (s, 1H), 8.14 (s, 1H), 6.80 (s, 1H), 6.79 (s, 1H), 6.61 (t, 1H), 4.68-4.61 (m, 1H), 3.82 (s, 6H), 3.6-3.56 (m, 2H), 3.25-3.2 (m, 2H), 2.3 (s, 3H), 2.35-2.32 (m, 4H).

[00792] Example 51

[00793]

[00794] 6-(3-amino-6-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazo l-4-yl)pyrazin-2- yl)-2-(3,5-dimethoxyphenyl)-4-methylpyridazin-3(2H)-one

[00795] A solution of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-y l)-2-

(3,5-dimethoxyphenyl)-4-methylpyridazin-3(2H)-one dihydrochloride salt (Example 50; 50 mg, 0.089 mmol) in DMF (1.8 mL) was treated with 1 -bromo-2-methoxy ethane (10 μΐ _^ , 0.11 mmol) and K2C0 ₃ (s) (49 mg, 0.36 mmol) under an atmosphere of N ₂ ( _g >. The resulting mixture was stirred overnight at ambient temperature, and then additional 1 -bromo-2-methoxyethane (20 μΐ _^ , 0.21 mmol) and K2C0 ₃ ( _S > (98 mg, 0.71 mmol) and the reaction was stirred for an additional period of 48 h at ambient temperature. The reaction mixture was diluted with 5% iPrOH/DCM (50 mL) and washed with water (10 mL) diluted. The organic extracts were dried over anhydrous MgS0 ₄ ( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (2-10% MeOH/DCM as the gradient eluent) to afford the title compound (33 mg, 68% yield). MS (apci) m/z = 547.3 (M+H). ¾ MR (400 MHz, CDC13-d) δ 8.44 (d, 1H), 8.25 (s, 1H), 7.91 (d, 2H), 6.79 (d, 2H), 6.51 (t, 1H), 6.48-6.3 (brs, 2H), 4.26-4.18 (m, 1H), 3.81 (s, 6H), 3.53 (t, 2H), 3.3 (s, 3H), 3.15-3.09 (m, 2H), 2.63 (d, 2H), 2.3 (s, 3H), 2.16-2.1 (m, 2H), 1.61-1.57 (m, 2H). 00796] Exam le 52

[00798] 3 -(3 -(3 -amino-6-( 1 -(piperidin-4-yl)- 1 H-pyrazol-4-vnpyrazin-2-vn-5 -methyl-6- oxopyridazin- 1 (6H)-yl)-N,4-dimethylbenzamide dihydrochloride salt

[00799] Step 1 : Preparation of tert-butyl 4-(4-(5-amino-6-(l-(5-(methoxycarbonvn-2- methylphenyl)-5-methyl-6-oxo-L6-dihydropyridazin-3-yl)pyrazi n-2-yl)-lH-pyrazol-l- vPpiperidine- 1 -carboxylate. A mixture of tert-butyl 4-(4-(5-amino-6-bromopyrazin-2-yl)-lH- pyrazol-l-yl)piperidine-l-carboxylate (Intermediate L19; 505 mg, 1.19 mmol), methyl 4-methyl- 3-(5-methyl-6-oxo-3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)pyridazin-l(6H)-yl)benzoate (Intermediate R19; 550 mg, 1.43 mmol), Pd(PPh ₃ ) ₄ (107 mg, 0.119 mmol), 2M Na ₂ C0 ₃ (aq) (1.79 mL, 3.58 mmol) was suspended in dioxane (2.39 mL). The resulting mixture was purged with N ₂ ( _g ) for 6 min, then was sealed and stirred overnight at 90 °C. After cooling to ambient temperature, the reaction mixture was diluted with 5% iPrOH/DCM (100 mL) and washed with water (2 x 20 mL) and brine (20 mL). The organic extracts were dried over anhydrous MgS0 ₄ ( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (with 2-60% acetone/DCM as the gradient eluent) to afford the title compound (782.5 mg, 98% yield). MS (apci) m/z = 601.3 (M+H).

[00800] Step 2: Preparation of 3 -(3 -(3 -amino-6-( 1 -( 1 -(tert-butoxycarbonyl)piperidin-4-yl)- lH-pyrazol-4-yl)pyrazin-2-yl)-5-methyl-6-oxopyridazin-l(6H)- yl)-4-methylbenzoic acid. A solution of tert-butyl 4-(4-(5-amino-6-(l-(5-(methoxycarbonyl)-2-methylphenyl)-5-me thyl-6- oxo-l,6-dihydropyridazin-3-yl)pyrazin-2-yl)-lH-pyrazol-l-yl) piperidine-l-carboxylate (780 mg, 1.30 mmol) in 4: 1 dioxane:MeOH (6.49 mL) was treated with a solution of LiOH»H ₂ 0 (136 mg, 3.25 mmol) in water (1.30 mL). The resulting mixture was stirred 4 h at ambient temperature then concentrated under vacuum. The resulting aqueous slurry was diluted with water (5 mL) then acidified (pH 2-3) with formic acid. The solid formed was filtered and dried in vacuo to provide the title compound (650 mg, 85% yield). MS (apci) m/z = 587.3 (M+H).

[00801] Step 3 : Preparation of tert-butyl 4-(4-(5-amino-6-(5-methyl-l-(2-methyl-5-

(methylcarbamoyl)phenyl)-6-oxo-L6-dihydropyridazin-3-yl)p yrazin-2-yl)-lH-pyrazol-l- yPpiperidine- 1 -carboxylate. A cold (0 °C) suspension of 3-(3-(3-amino-6-(l-(l-(tert- butoxycarbonyl)piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-yl) -5-methyl-6-oxopyridazin-l(6H)- yl)-4-methylbenzoic acid (650 mg, 1.11 mmol) in DMF (22.2 mL) was treated sequentially with HATU (632 mg, 1.66 mmol), 2M CH3 H2 in THF (1.11 mL, 2.22 mmol) and DIPEA (1.58 mL, 8.86 mmol). The resulting mixture was stirred 15 min at 0 °C then overnight at ambient temperature. The reaction mixture was poured into ice water and extracted with 5% iPrOH/DCM (3 x 50 mL). The combined organic extracts were dried over anhydrous Na2S04( _S ), filtered then concentrated under vacuum. The resulting residue was purified by silica chromatography (5-60% acetone/DCM as the gradient eluent) to afford the title compound (550 mg, 83% yield). MS (apci) m/z = 600.3 (M+H).

[00802] Step 4: Preparation of 3-(3-(3-amino-6-(l-(piperidin-4-vn-lH-pyrazol-4- yl)pyrazin-2-yl)-5-methyl-6-oxopyridazin-l(6H)-yl)-N,4-dimet hylbenzamide dihydrochloride salt. A ambient temperature solution of tert-butyl 4-(4-(5-amino-6-(5-methyl-l-(2-methyl-5- (methylcarbamoyl)phenyl)-6-oxo-l,6-dihydropyridazin-3-yl)pyr azin-2-yl)-lH-pyrazol-l- yl)piperidine-l -carboxylate (550 mg, 0.917 mmol) in DCM (1 mL) was treated with TFA (2 mL) then stirred 1 h at ambient temperature before concentrating to dryness under vacuum. The resulting residue was dissolved in DCM (2 mL), treated with 4 N HC1 in dioxane (2 mL), stirred for 10 min at ambient temperature, and then concentrated to dryness under vacuum. The resulting residue was resuspended in DCM and concentrated to dryness under vacuum twice then dried under high vacuum to afford the title compound (410 mg, 78% yield). MS (apci) m/z = 500.2 (M+H).

[00803] Example 53

[00804] [00805] 6-(2-amino-5-(l-methyl-lH-pyrazol-4-vnpyridin-3-vn-2-(3.5- dimethoxyphenyl)pyridazin-3(2H)-one

[00806] A solution of 3-bromo-5-(l-methyl-lH-pyrazol-4-yl)pyrazin-2-amine

(Intermediate L20; 204.8 mg, 0.8061 mmol) in 4: 1 dioxane:water (7.5 mL) was treated with 2- (3,5-dimethoxyphenyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaboro lan-2-yl)pyridazin-3(2H)-one (Intermediate R8; 293.4 mg, 0.8192 mmol), PdCl ₂ fdppf CH ₂ Cl2 (61.27 mg, 0.07448 mmol), K2C0 ₃ (s) (308.8 mg, 2.234 mmol). The resulting mixture was sparged with A%), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM: iPrOH (50 mL), and extracted with water (2 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by C18 reverse phase chromatography (5-95% water-ACN with 0.1%> TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (50 mL) and extracted with saturated NaHC0 _3(aq ) (1 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to afford the title compound along with impurities. The resulting residue was subjected to further purification by silica chromatography (40-100%) DCM- Acetone as the gradient eluent) to cleanly afford the title compound (40.1 mg, 13% yield). MS (apci) m/z = 405.1 (M+H). ¾ NMR (400 MHz, DMSO-de) δ 8.32-8.31 (d, 1H), 8.28-8.25 (d, 1H), 8.14-8.12 (m, 2H), 7.89 (s, 1H), 7.20- 7.18 (d, 1H), 6.89 (s, 2H), 6.82-6.81 (d, 2H), 6.61-6.60 (t, 1H), 3.85 (s, 3H), 3.78 (s, 6H).

[00807] Example 54

[00809] 6-(2-amino-5-(l-(piperidin-4-vn-lH-pyrazol-4-vnpyridin-3-ylV 2-(3.5- dimethoxyphenyl)pyridazin-3(2H)-one

[00810] Step 1 : Preparation of tert-butyl 4-(4-(6-amino-5-(l-(3,5-dimethoxyphenyl)-6- oxo-L6-dihvdropyridazin-3-yl)pyridin-3-yl)-lH-pyrazol-l-yl)p iperidine-l-carboxylate. A solution of tert-butyl 4-(4-(6-amino-5-bromopyridin-3-yl)-lH-pyrazol-l-yl)piperidin e-l- carboxylate (Intermediate L21; 622.4 mg, 1.474 mmol) in 4: 1 dioxane:water (15 mL) was treated with 2-(3,5-dimethoxyphenyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxabo rolan-2-yl)pyridazin-3(2H)- one (Intermediate R8; 580.7 mg, 1.621 mmol), PdCl ₂ dppf CH ₂ Cl ₂ (121.2 mg, 0.1474 mmol) and K ₂ C0 ₃ (s) (61 1.0 mg, 4.421 mmol). The resulting mixture was sparged with Α%), then sealed and stirred 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM:iPrOH (250 mL) and washed with water (2 x 50 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (5-95% DCM-Acetone as the gradient eluent) to afford the title compound which was immediately carried on to step 2. MS (apci) m/z = 574.2 (M+H).

[00811] Step 2: Preparation of 6-(2-amino-5-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyridin-

3 -yl)-2-(3 , 5 -dimethoxyphenyl)pyridazin-3 (2H)-one. tert-butyl 4-(4-(6-amino-5-(l-(3,5- dimethoxyphenyl)-6-oxo- 1 ,6-dihydropyridazin-3 -yl)pyridin-3 -yl)- lH-pyrazol- 1 -yl)piperidine- 1 - carboxylate was dissolved in 1 : 1 TFA:DCM (15.0 mL) then stirred 30 min at ambient temperature. The reaction mixture was concentrated under vacuum then purified by CI 8 reverse phase chromatography (5-95% ACN in H ₂ 0 with 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (50 mL) and extracted with saturated NaHC0 ₃ ( _aq ) (1 x 25 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to cleanly afford the title compound (415.9 mg, 60% yield). MS (apci) m/z = 474.1 (M+H).

[00812] Example 55

[00813]

[00814] 6-(2-amino-5-(l-(l-methylpiperidin-4-ylVlH-pyrazol-4-vnpyrid in-3-vn-2-(3.5- dimethoxyphenyl)pyridazin-3(2H)-one

[00815] A solution of 6-(2-amino-5-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyridin-3-y l)-2-

(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 54; 134.4 mg, 0.2838 mmol) in 1 : 1 DCM:MeOH (2.0 mL) was treated with formaldehyde (426.5 5.677 mmol) and sodium triacetoxyborohydride (300.8 mg, 1.419 mmol) and then stirred 60 h at ambient temperature. The reaction mixture was directly purified by silica chromatography (1-30% DCM-MeOH w/ 2% H4OH as the gradient eluent). The chromatographic fractions containing the title compound were combined then re-purified using CI 8 reverse phase chromatography (5-95% water- ACN w/ 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (50 mL) and extracted with saturated NaHC0 _3(aq ) (1 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to cleanly afford the title compound (46.9 mg, 34% yield). MS (apci) m/z = 488.2 (M+H). ¾ NMR (400 MHz, DMSO-de) δ 8.35-8.34 (d, 1H), 8.29 (s, 1H), 8.26 (s, 1H), 8.16-8.15 (d, 1H), 7.91 (s, 1H), 7.21-7.18 (d, 1H), 6.91 (s, 2H), 6.82-6.81 (d, 2H), 6.61-6.60 (t, 1H), 4.13-4.05 (m, 1H), 3.78 (s, 6H), 2.88-2.85 (m, 2H), 2.22 (s, 3H), 2.09-1.91 (m, 6H).

[00816] Example 56

[00817]

[00818] 6-(2-amino-5-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazo l-4-yl)pyridin-3- yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00819] A solution of 6-(2-amino-5-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyridin-3-y l)-2-

(3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 54; 54.1 mg, 0.114 mmol) in DMF (1.2 mL) was treated with l-bromo-2-methoxy ethane (21.5 μΐ _^ , 0.228 mmol) and K2C0 ₃ ( _S > (63.2 mg, 0.457 mmol). The resulting mixture was stirred 60 h at ambient temperature. The reaction mixture was diluted with EtOAc (25 mL) and washed with water (2 x 10 mL) and brine (10 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The crude residue was purified by silica chromatography (1-30% DCM-MeOH w/ 2% NH4OH as the gradient eluent) to afford the title compound (29.5 mg, 49% yield). MS (apci) m/z = 532.2 (M+H).

[00820] Example 57

[00821]

[00822] 6-(2-amino-5-(l-methyl-lH-pyrazol-4-vnpyridin-3-vn-2-(2.6-di chloro-3.5- dimethoxyphenyl)pyridazin-3(2H)-one

[00823] A solution of 6-(2-amino-5-bromopyridin-3-yl)-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyridazin-3(2H)-one (Intermediate M2; 14.4 mg, 0.0305 mmol) in 4: 1 dioxane:water (1.0 mL) was treated with l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-lH-pyrazole (6.98 mg, 0.0336 mmol), PdCl ₂ fdppf CH ₂ Cl ₂ (2.51 mg, 0.00305 mmol), K ₂ C0 ₃ ( _S ) (12.6 mg, 0.0915 mmol). The resulting mixture was sparged with A%), then sealed and stirred for 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with EtOAc (25 mL), and extracted with water (3 x 10 mL) and brine (10 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum. The resulting crude residue was purified by silica chromatography (5-95% DCM-Acetone as the gradient eluent) to afford the title compound (5.8 mg, 40% yield). MS (apci) m/z = 473.0 (M+H). ¾ MR (400 MHz, DMSO-d ₆ ) δ 8.39-8.37 (d, 1H), 8.34-8.33 (d, 1H), 8.19-8.18 (d, 1H), 8.12 (s, 1H), 7.89 (s, 1H), 7.33-7.30 (d, 1H), 7.12 (s, 1H), 6.72 (s, 2H), 4.01 (s, 6H), 3.85 (s, 3H).

[00824] Example 58

[00825]

[00826] 6-(2-amino-5-(l-(piperidin-4-vn-lH-pyrazol-4-vnpyridin-3-vn- 2-(2.6-dichloro- 3 , 5 -dimethoxyphenyl)pyridazin-3 (2H)-one

[00827] Step 1 : Preparation of teit-butyl 4-(4-(6-amino-5-(l-(2.6-dichloro-3.5- dimethoxyphenvD-6-oxo- 1 ,6-dihydropyridazin-3 -yl)pyridin-3 -yl)- IH-pyrazol- 1 -vDpiperidine- 1 - carboxylate. A solution of 6-(2-amino-5-bromopyridin-3-yl)-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyridazin-3(2H)-one (Intermediate M2; 215.0 mg, 0.4554 mmol) in 4: 1 dioxane:water (4.6 mL) was treated with tert-Butyl 4-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)pyrazol-l-yl]piperidine-l -carboxylate (180.4 mg, 0.4782 mmol), PdCl ₂ dppf CH ₂ Cl ₂ (37.46 mg, 0.04554 mmol) and K ₂ C0 ₃ ( _S > (188.8 mg, 1.366 mmol) was sparged with A%), then sealed and stirred 6 h at 90 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM:iPrOH (50 mL) and washed with water (2 x 25 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound in sufficient purity for immediate use in step 2. MS (apci) m/z = 646.2 [(M+H)+4], 644.2 [(M+H)+2], 642.2 (M+H) with diCl pattern.

[00828] Step 2: Preparation of 6-(2-amino-5-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyridin- 3-yl)-2-(2,6-dichloro-3,5-dimethoxyphenyl)pyridazin-3(2H)-on e. The tert-butyl 4-(4-(6-amino- 5-(l-(2,6-dichloro-3,5-dimethoxyphenyl)-6-oxo-l,6-dihydropyr idazin-3-yl)pyridin-3-yl)-lH- pyrazol-l-yl)piperidine-l-carboxylate was dissolved in 1 : 1 TFA:DCM (3.0 mL) then stirred 1 h at ambient temperature. The reaction mixture was concentrated under vacuum then purified by CI 8 reverse phase chromatography (2->75% water-ACN with 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (50 mL) and extracted with saturated NaHC0 ₃ ( _aq ) (1 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to cleanly afford the title compound (172.7 mg, 70% yield). MS (apci) m/z = 546.1 [(M+H)+4], 544.2 [(M+H)+2], 542.1 (M+H) with diCl pattern.

[00829] Example 59

[00830]

[00831] 6-(2-amino-5-(l-(l-methylpiperidin-4-ylVlH-pyrazol-4-vnpyrid in-3-vn-2-(2.6- dichloro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00832] A solution of 6-(2-amino-5-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyridin-3-y l)-2-

(2,6-dichloro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 58; 50.0 mg, 0.0922 mmol) in MeOH (1.8 mL) was treated with formaldehyde (139 μΐ _^ , 1.84 mmol) and stirred 15 min at ambient temperature. The resulting reaction mixture was treated with sodium triacetoxyborohydride (78.1 mg, 0.369 mmol) and stirred 16 h at ambient temperature. The reaction mixture was concentrated under vacuum then purified by C18 reverse phase chromatography (5-95% water-ACN w/ 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DGVLiPrOH (50 mL) and extracted with saturated NaHC0 ₃ ( _aq ) (1 x 25 mL). The organic extracts were dried over anhydrous Na2S04( _S ), filtered and concentrated under vacuum to cleanly afford the title compound (24.2 mg, 47% yield). MS (apci) m/z = 558.2 [(M+H)+2], 556.2 (M+H) with diCl pattern. H NMR (400 MHz, DMSO-d ₆ ) δ 8.39-8.35 (m, 2H), 8.26-8.24 (m, 1H), 8.21- 8.20 (m, 1H), 7.91 (s, 1H), 7.33-7.30 (d, 1H), 7.12 (s, 1H), 6.72 (s, 2H), 4.13-4.05 (m, 1H), 4.01 (s, 6H), 2.87-2.84 (m, 2H), 2.21 (s, 3H), 2.09-1.79 (m, 6H). [00833] Example 60

[00834]

[00835] 6-(2-amino-5-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazo l-4-yl)pyridin-3- yl)-2-(2,6-dichloro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00836] A solution of 6-(2-amino-5-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyridin-3-y l)-2-

(2,6-dichloro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Example 58; 17 mg, 0.031 mmol) in DMF (0.31 mL) was treated with l-bromo-2-methoxy ethane (3.8 μΐ., 0.041 mmol) and K ₂ C0 ₃ ( _S ) (6.1 mg, 0.045 mmol). The resulting mixture was stirred overnight at ambient temperature, then filtered through an acrodisc LC 25mm Syringe filter (with 0.45 μπι PVDF Membrane) and the filtrate was purified by C18 reverse phase chromatography (5-95% ACN in H ₂ 0 with 0.1% TFA as the gradient eluent) to afford the title compound as the TFA salt. The chromatographic fractions containing the TFA salt of the title compound were combined then neutralized with 1M NaOH( _aq ), and extracted with DCM. The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum. The resulting residue was purified further by silica chromatography (10-90% CHC1 ₃ /10% MeOH/1% NH ₄ OH in CHC1 ₃ as the gradient eluent) to afford the title compound (4.0 mg, 21% yield). MS (apci) m/z = 600.2 (M+H). H NMR (400 MHz, CD ₃ OD) δ 8.30-8.27 (d, 1H), 8.26 (d, 1H), 8.18 (d, 1H), 8.09 (d, 1H), 8.88-8.85 (m, 2H), 7.26-7.23 (d, 1H), 7.0 (s, 1H), 4.24-4.16 (m, 1H), 4.00 (s, 6H), 3.57-3.54 (t, 3H), 3.34 (s, 3H), 3.15-3.12 (m, 2H), 2.69-2.66 (t, 2H), 2.36-2.29 (m, 2H), 2.14-2.08 (m, 4H).

00837] Exam le 61

[00839] 3-(3-(2-amino-5-(l-(piperidin-4-vn-lH-pyrazol-4-vnpyridin-3- ylV6- oxopyridazin- 1 (6H)-yl)-N-methylbenzamide

[00840] Step 1 : Preparation of teit-butyl 4-(4-(6-amino-5-(l-(3-

(methylcarbamoyl)phenyl)-6-oxo- 1 ,6-dihydropyridazin-3 -yl)pyridin-3 -yl)- lH-pyrazol- 1 - vPpiperidine- 1 -carboxylate. A solution of 3-(3-(2-amino-5-bromopyridin-3-yl)-6-oxopyridazin- l(6H)-yl)-N-methylbenzamide (Intermediate Ml; 47.6 mg, 0.119 mmol) in 4: l dioxane:water (1.2 mL) was treated with tert-Butyl 4-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrazol-l- yl]piperidine-l-carboxylate (49.4 mg, 0.131 mmol), PdCl ₂ dppf CH ₂ Cl ₂ (9.78 _mgj 0.0119 mmol) and K ₂ C0 ₃ (s) (49.3 mg, 0.357 mmol). The resulting mixture was sparged with A%), then sealed and stirred 16 h at 100 °C. After cooling to ambient temperature, the reaction mixture was diluted with 4: 1 DCM:iPrOH (25 mL) and washed with water (2 x 10 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to afford the title compound which was immediately carried on to step 2. MS (apci) m/z = 571.3 (M+H).

[00841] Step 2: Preparation of 3-(3-(2-amino-5-(l-(piperidin-4-yl)-lH-pyrazol-4- yl)pyridin-3 -yl)-6-oxopyridazin- 1 (6H)-yl)-N-methylbenzamide. tert-Butyl 4-(4-(6-amino-5-(l- (3 -(methylcarbamoyl)phenyl)-6-oxo- 1 ,6-dihydropyridazin-3 -yl)pyridin-3 -yl)- 1 H-pyrazol- 1 - yl)piperidine-l-carboxylate was dissolved in 1 : 1 TFA:DCM (1.2 mL) then stirred 30 min at ambient temperature. The reaction mixture was concentrated under vacuum then purified by CI 8 reverse phase chromatography (5-95% ACN in H ₂ 0 with 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt. The TFA salt was dissolved in 4: 1 DCM:iPrOH (50 mL) and extracted with saturated NaHC0 ₃ ( _aq ) (1 x 25 mL). The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated under vacuum to cleanly afford the title compound (18.8 mg, 34% yield). MS (apci) m/z = 471.2 (M+H).

00842] Exam le 62

[00844] 3-(3-(2-amino-5-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyr azol-4-yl)pyridin- 3-yl)-6-oxopyridazin-l(6H)-yl)-N-methylbenzamide 2,2,2-trifluoroacetate salt

[00845] A mixture of 3-(3-(2-amino-5-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyridin- 3-yl)-6- oxopyridazin-l(6H)-yl)-N-methylbenzamide (Example 61; 9.88 mg, 0.0210 mmol), l-bromo-2- methoxyethane (2.17 \JL, 0.0231 mmol) and K ₂ C0 _3(S) (4.35 mg, 0.0315 mmol) in DMSO (0.21 mL) was stirred overnight at ambient temperature. The reaction mixture was diluted with DCM and washed with water and brine. The organic extracts were dried over anhydrous Na ₂ S04( _S ), filtered and concentrated in vacuo. The crude residue was purified by C18 reverse phase chromatography (5-95 % ACN:water with 0.1% TFA) to afford the title compound (4.8 mg, 37% yield). MS (apci) m/z = 444.1 (M+H).

[00846] Exam le 63

[00847] ^{Δ 1 rM}

[00848] 6-( 3 -amino-6-( 1 -( piped din-4-ylV lH-pyrazol-4-v0pyrazin-2-v0-2-( 3 - methylquinolin-7-yl)pyridazin-3(2H)-one bis(2,2,2-trifluoroacetate)

[00849] Step 1 : Preparation of tert-butyl 4-(4-(5-amino-6-(l -(3 -methyl quinolin-7-yl)-6- oxo- 1 , 6-dihydropyridazin-3 -yl)pyrazin-2-yl)- 1 H-pyrazol- 1 -yl)piperidine- 1 -carboxyl ate : A suspension of tert-butyl 4-(4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l-yl)piperidin e-l- carboxylate (Intermediate L19; 25.640 mg, 0.060570 mmol), 2-(3 -methyl quinolin-7-yl)-6- (4,4,5, 5-tetramethyl-l, 3, 2-dioxaborolan-2-yl)pyridazin-3(2H)-one (Intermediate R30; 33 mg, 0.1 mmol), Na ₂ C0 ₃ (90.855 μί, 0.18171 mmol), and Pd(PPh ₃ ) ₄ (7.0 mg, 0.006 mmol) in dioxane (605.70 μί, 0.060570 mmol) was sparged with Ar(g), then sealed and stirred 16 h at 90°C. After cooling to ambient temperature, the reaction mixture was partitioned between EtOAc and water. The organic extracts were washed with brine, dried over anhydrous Na ₂ S0 ₄ (s), filtered and concentrated. The residue was purified using silica gel chromatography 0-15%MeOH in EtOAc to afford the title compound (12 mg, 0.02 mmol, 34.2 % yield). MS (apci) m/z = 580.3 (M+H).

[00850] Step 2 : Preparation of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-

2 -yl)-2-(3 -methyl quinolin-7-yl)pyridazin-3(2H)-one bis(2,2,2-trifluoroacetate): tert-butyl 4-(4- (5-amino-6-(l-(3-methylquinolin-7-yl)-6-oxo-l,6-dihydropyrid azin-3-yl)pyrazin-2-yl)-lH- pyrazol-l-yl)piperidine-l-carboxylate (12 mg, 0.021 mmol) was dissolved in 1 : 1 TFA/DCM (2.0 mL) and stirred at ambient temperature for 6 h. The reaction mixture was concentrated under vacuum, and then treated with 2 mL MeOH. The mixture was concentrated under vacuum to afford the title compound as the TFA salt (9.1 mg, 0.019 mmol, 92 % yield) MS (apci) m/z = 480.2 (M+H).

[00851] Example 64

[00852] 6-(3-amino-6-(l-(l-(2-methoxyethyl)piperidin-4-yl)-l H-pyrazol -4-yl)pyrazin-2 - yl)-2-(3 -methyl quinolin-7-yl)pyridazin-3(2H)-one [00853] A solution 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-y l)-2-(3- methylquinolin-7-yl)pyridazin-3(2H)-one bis(2,2,2-trifluoroacetate) (Example 63; 8 mg, 0.02 mmol) in DMSO (556 μΐ.) was treated with K ₂ C03(s) (4.6 mg, 0.03 mmol). The mixture was cooled to 0°C in an ice water bath, and l-bromo-2-methoxy ethane (2 μΐ,, 0.02 mmol) was added. The resulting mixture was warmed to ambient temperature and stirred for 50 h. The reaction was diluted with water and extracted with DCM. The organic extracts were washed with brine, dried over anhydrous Na ₂ S0 ₄ (s), filtered and concentrated under vacuum. The crude residue was purified by silica gel chromatography (0-100% Acetone in DCM as the gradient eluent followed by 10% MeOH in DCM) to afford the title compound (1.8 mg, 20% yield). MS (apci) m/z = 538.2 (M+H).

[00854] Example 65

[00855]

[00856] (SV6-(3-amino-6-(l-((4.5.5-trimethylmorpholin-2-vnmethvn-lH- pyrazol-4- yl)pyrazin-2-yl)-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one 2,2,2-trifluoroacetate

[00857] A solution of (S)-6-(3-amino-6-(l-((5,5-dimethylmo holin-2-yl)methyl)-lH- pyrazol-4-yl)pyrazin-2-yl)-2-(3,5-dimethoxyphenyl)pyridazin- 3(2H)-one (29 mg, 0.0559 mmol) (Example 27; 29 mg, 0.06 mmol) in MeOH (0.5 mL) was treated with formaldehyde (12.6 μΐ., 0.168 mmol) and stirred for 15 min at ambient temperature. The resulting reaction mixture was treated with sodium triacetoxyborohydride (35.6 mg, 0.168 mmol) and stirred 30 minutes at ambient temperature. The reaction mixture was concentrated under vacuum and then purified by C18 reverse phase chromatography (5-95% water-ACN w/ 0.1% TFA as the gradient eluent) to afford the title compound as a TFA salt (22 mg, 74% yield). MS (apci) m/z = 533.2 (M+H). [00858] Example 66

[00859]

[00860] 6-(3-amino-6-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazo l-4-yl)pyrazin-2- yl)-2-(2,6-dichloro-3,5-dimethoxyphenyl)-4-methylpyridazin-3 (2H)-one

[00861] Step 1 : A mixture of tert-butyl 4-(4-(5-amino-6-bromopyrazin-2-yl)-lH-pyrazol-l- yl)piperidine-l-carboxylate (Intermediate L19; 0.225 g, 0.532 mmol), 2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxa borolan-2-yl)pyridazin-3(2H)-one (Intermediate R16; 0.234 g, 0.532 mmol), Pd(PPh ₃ ) ₄ (0.0461 g, 0.0399 mmol) and 2 M solution of Na ₂ C0 ₃ (0.558 mL, 1.12 mmol) in dioxane (3 mL) was stirred at 90 °C for 8 hours. The mixture was then filtered through filter paper and the filtrate was concentrated. The residue was purified on a silica column using Hexanes:EtOAc (10-90%) to give tert-butyl 4-(4-(5-amino-6-(l-(2,6- dichloro-3,5-dimethoxyphenyl)-5-methyl-6-oxo-l,6-dihydropyri dazin-3-yl)pyrazin-2-yl)-lH- pyrazol-l-yl)piperidine-l-carboxylate (0.213 g, 0.324 mmol, 60.9 % yield). MS (apci) m/z = 657.2 (M+H).

[00862] Step 2: A mixture of tert-butyl 4-(4-(5-amino-6-(l-(2,6-dichloro-3,5- dimethoxyphenyl)-5-methyl -6-oxo- l,6-dihydropyridazin-3-yl)pyrazin-2-yl)-lH-pyrazol-l- yl)piperidine-l-carboxylate (0.213 g, 0.324 mmol) in TFA (1.5 ml) and DCM (1.62 ml) was stirred at room temperature for 30 min and then concentrated. The residue was partitioned between DCM and aqueous saturated Na ₂ C0 ₃ . The combined organic extracts were washed with brine, dried over Na ₂ S0 ₄ and concentrated to give 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin- 2-yl)-2-(2,6-dichloro-3,5-dimethoxyphenyl)-4-methylpyridazin -3(2H)-one (0.157 g, 0.282 mmol, 86.9 % yield). MS (apci) m/z = 557.2 (M+H).

[00863] Step 3 : l-bromo-2-methoxy ethane (0.009365 ml, 0.09965 mmol) was added to 6-

(3 -amino-6-( 1 -(piperidin-4-yl)- lH-pyrazol-4-yl)pyrazin-2-yl)-2-(2,6-dichloro-3 , 5- dimethoxyphenyl)-4-methylpyridazin-3(2H)-one (0.0505 g, 0.09059 mmol) and K ₂ C0 ₃ (0.03756 g, 0.2718 mmol) in DMF (0.9059 ml) at room temperature. The reaction mixture was stirred for 3 days. The mixture was taken up in DCM and extracted with water. The combined organic extracts were washed with water and brine, dried over Na ₂ S04, filtered and concentrated. The residue was purified by C18 reverse phase chromatography (5-95% ACN: water with 0.1% TFA). The isolated product was taken up in DCM and washed with aqueous saturated Na ₂ C0 ₃ and brine, dried over Na ₂ S0 ₄ , filtered and concentrated to provide 6-(3-amino-6-(l-(l-(2- methoxyethyl)piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-yl)-2 -(2,6-dichloro-3,5- dimethoxyphenyl)-4-methylpyridazin-3(2H)-one (0.0145 g, 0.02356 mmol, 26.00 % yield). MS (apci) m/z = 615.2 (M+H).

[00864] Example 67

[00865]

[00866] 6-(3-amino-6-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazo l-4-yl)pyrazin-2- yl)-2-(3,5-dimethoxy-2-methylphenyl)pyridazin-3(2H)-one

[00867] Step 1 : To a solution of 6-chloro-2-(3,5-dimethoxyphenyl)pyridazin-3(2H)-one

(0.505 g, 1.89 mmol) in acetonitrile (18.9 mL, 1.89 mmol) was addedl-bromopyrrolidine-2,5- dione (0.337 g, 1.89 mmol) at 0°C. The reaction mixture was warmed to ambient temperature after 10 minutes and stirred for 2.5 hours. The mixture was partitioned between EtOAc and water. The combined organic phases were washed with water and brine, dried over Na ₂ S0 ₄ , filtered and concentrated in vacuo. The residue was purified by flash chromatography (10-90% EtOAc in hexanes) to yield 2-(2-bromo-3,5-dimethoxyphenyl)-6-chloropyridazin-3(2H)-one (0.61 lg, 1.77 mmol, 93.4% yield). MS (apci) m/z = 346.9 [(M+H)+2], 344.9 (M+H) with Br pattern.

[00868] Step 2: To a solution of 2-(2-bromo-3,5-dimethoxyphenyl)-6-chloropyridazin-

3(2H)-one (0.308 g, 0.891 mmol) in THF (5.94 ml, 0.891 mmol) was added methylzinc(II) chloride (0.446 mL, 0.891 mmol) and the mixture was sparged with Ar for 15 min. Bis(tri-t- butylphosphine) Pd(0) (0.0455 g, 0.0891 mmol) was added and the reaction mixture was heated to 60° C under N ₂ for 3 hours. The mixture was concentrated in vacuo and the concentrate was suspended in DCM, washed with water and brine, dried over Na ₂ S0 ₄ , filtered and concentrated in vacuo. The residue was purified by flash chromatography (10-90%) EtOAc in hexanes) to yield 6-chloro-2-(3,5-dimethoxy-2-methylphenyl)pyridazin-3(2H)-one (0.109 g, 0.388 mmol, 43.6 % yield). MS (apci) m/z = 281.0 (M+H). [00869] Step 3 : To a solution of 6-chloro-2-(3,5-dimethoxy-2-methylphenyl)pyridazin-

3(2H)-one (0.031 g, 0.1 1 mmol) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(l,3,2-dioxaborolane) (0.042 g, 0.17 mmol) in 1,4-dioxane (1.1 mL, 0.1 1 mmol) was added potassium acetate (0.033 g, 0.33 mmol) and the mixture was sparged with Ar for 5 mins. 2-(Dicyclohexylphosphino)-2,4,6- Triisopropylbiphenyl (0.0079 g, 0.017 mmol) and Palladium(II) acetate (0.0025 g, 0.01 1 mmol) were then added sequentially and the reaction mixture was sparged with Ar. The reaction vessel was sealed and the reaction mixture was heated to 100°C for 1 hr. The mixture was partitioned between DCM and water. The combined organic extracts were washed with water and brine, dried over Na ₂ S04, filtered and concentrated in vacuo to provide 2-(3,5-dimethoxy-2- methylphenyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl )pyridazin-3(2H)-one (0.041 g, 0.1 1 mmol, assumed quantitative yield).

[00870] Step 4: To a solution of 3-bromo-5-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH- pyrazol-4-yl)pyrazin-2-amine (Intermediate L22; 0.034 g, 0.089 mmol) and 2-(3,5-dimethoxy-2- methylphenyl)-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl )pyridazin-3(2H)-one (0.040 g, 0.1 1 mmol) in 1,4-dioxane (0.89 mL, 0.089 mmol) was added sodium carbonate (0.13 mL, 0.27 mmol) and the reaction mixture was sparged with Ar for 5 mins. Tetrakis(triphenylphosphine)Pd(0) (0.0082 g, 0.0071 mmol) was added and the reaction mixture was sparged with Ar. The mixture was sealed and heated to 100°C for 2 hours with stirring. The mixture was cooled to ambient temperature and purified by reverse phase chromatography (5- 95% ACN:water with 0.1% TFA) to provide the title compound (0.020 g, 0.037 mmol, 41% yield) as a yellow powder. MS (apci) m/z = 547.3 (M+H).

[00871] Example 68

[00872]

[00873] 6-( 3 -amino-6-( 1 -( 2-oxo-2-( piperidin- 1 -vDethvP- lH-pyrazol-4-v0pyrazin-2-vQ-

2-(2,6-dichloro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00874] To a solution of 6-(3-amino-6-bromopyrazin-2-yl)-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyridazin-3(2H)-one (Intermediate M3; 0.025 g, 0.053 mmol) in 1,4-dioxane (0.53 mL, 0.053 mmol) was added sodium carbonate (0.079 mL, 0.16 mmol) and 1 -(piperidin- 1 - yl)-2-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-py razol-l-yl)ethanone (0.020 g, 0.063 mmol) and the reaction mixture was sparged with Ar for 5 mins. Tetrakis(triphenylphosphine)palladium(0) (0.0049 g, 0.0042 mmol) was added and the reaction mixture was sparged with Ar. The reaction was sealed, heated to 100°C and stirred for 2.5 hrs. The reaction was cooled to ambient temperature and purified by reverse phase chromatography (5-95 % ACN:water with 0.1% TFA) to provide the title compound (0.020 g, 0.037 mmol, 41% yield) as a yellow powder. MS (apci) m/z = 589.2 [(M+H)+4], 587.2 [(M+H)+2], 585.1 (M+H) with di CI pattern.

[00875] Example 69

[00876]

[00877] 6-(3-amino-6-(l-(2-(dimethylamino)ethvn-lH-pyrazol-4-vnpyraz in-2-vn-2-(2.6- dichloro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00878] To a solution of 6-(3-amino-6-bromopyrazin-2-yl)-2-(2,6-dichloro-3,5- dimethoxyphenyl)pyridazin-3(2H)-one (Intermediate M3; 0.026 g, 0.055 mmol) in 1,4-dioxane (0.55 mL, 0.053 mmol) was added sodium carbonate (0.079 mL, 0.16 mmol) and N,N-dimethyl- 2-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazo l-l-yl)ethanamine (0.019 g, 0.071 mmol) and the reaction mixture was sparged with Ar for 5 mins. Tetrakis(triphenylphosphine)Palladium(0) (0.0051 g, 0.0044 mmol) was added and the reaction mixture was sparged with Ar. The reaction was sealed, heated to 100°C and stirred for 2.5 hrs. The mixture was cooled to ambient temperature and purified by flash chromatography (1 -9% MeOH in DCM) to yield the title compound (0.018 g, 0.034 mmol, 62% yield) as a yellow powder. MS (apci) m/z = 535.1 [(M+H)+4], 533.1 [(M+H)+2], 531.2 (M+H) with di CI pattern. ¾ MR (DM SO) δ 8.71 (d, 1H), 8.48 (s, 1H), 8.32 (d, 1H), 8.00 (d, 1H), 7.30 (d, 1H), 7.10 (s, 1H), 7.03 (br s, 2H, H ₂ ), 4.20 (t, 2H), 3.99 (s, 6H), 2.66 (t, 2H), 2.15 (s, 6H).

[00879] The following compounds shown in Table 6 were prepared according the method used for the synthesis of Example 69 using 6-(3-amino-6-bromopyrazin-2-yl)-2-(2,6-dichloro- 3,5-dimethoxyphenyl)pyridazin-3(2H)-one (Intermediate M3; 0.026 g, 0.055 mmol). Reaction progression in each was followed by LCMS and reaction time was adjusted as necessary. All compounds were purified using a method similar to that used in either Example 68 or Example utilizing the appropriate gradient eluent.

Table 6

in-3(2H)-one 6-(3-amino-6-(l- cy cl opropyl - 1 H-pyrazol -

74

4-yl)pyrazin-2-yl)-2-(2,6- 500.1 dichloro-3,5- (M+H) dimethoxyphenyl)pyridaz

in-3(2H)-one

6-(3-amino-6-(l-

75 (azetidin-3-yl)-lH- pyrazol-4-yl)pyrazin-2- 515.1 yl)-2-(2,6-dichloro-3,5- (M+H) dimethoxyphenyl)pyridaz

in-3(2H)-one

[00880] Example 76

[00881]

[00882] 6-(3-amino-6-(l-(2-(dimethylamino)ethvn-lH-pyrazol-4-vnpyraz in-2-vn-2-(2.6- dichloro-3,5-dimethoxyphenyl)-4-methylpyridazin-3(2H)-one

[00883] To a solution of 6-(3-amino-6-bromopyrazin-2-yl)-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-methylpyridazin-3(2H)-one (Intermediate M4; 0.069 g, 0.14 mmol) in 1,4- dioxane (1.42 ml, 0.142 mmol) was added sodium carbonate (0.21 mL, 0.43 mmol) and N,N- dimethyl-2-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- lH-pyrazol-l -yl)ethanamine (0.0488 g, 0.184 mmol) and the reaction mixture was sparged with Ar for 5 mins. Tetrakis(Triphenylphosphine)Palladium(0) (0.013 1 g, 0.01 13 mmol) was added and the reaction mixture was sparged with Ar. The reaction was sealed, heated to 100°C and stirred for 2 hrs. The mixture was cooled to ambient temperature and purified by flash chromatography (1 -9% MeOH in DCM) to yield the title compound (0.0256 g, 0.0469 mmol, 33.1% yield) as a yellow powder. MS (apci) m/z = 549.1 [(M+H)+4], 547.1 [(M+H)+2], 545.2 (M+H) with di Cl pattern. ¾ NMR (CDC ) δ 8.48 (m, 1H), 8.27 (s, 1H), 7.96 (d, 1H), 7.94 (d, 1H), 6.71 (s, 1H), 6.20 (br s, 2H, H ₂ ), 4.30 (t, 2H), 3.99 (s, 6H), 2.83 (t, 2H), 2.41 (d, 3H), 2.31 (s, 6H).

[00884] Example 77

[00885]

[00886] 6-(3-amino-6-(l-(azetidin-3-vn-lH-pyrazol-4-vnpyrazin-2-vn-2 -(2.6-dichloro- 3,5-dimethoxyphenyl)-4-methylpyridazin-3(2H)-one

[00887] Step 1 : To a solution of 6-(3-amino-6-bromopyrazin-2-yl)-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-methylpyridazin-3(2H)-one (Intermediate M4; 0.120 g, 0.246 mmol) in 1,4- dioxane (2.46 ml, 0.246 mmol) was added sodium carbonate (0.370 mL, 0.739 mmol) and tert- butyl 3-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazo l-l -yl)azetidine-l- carboxylate (0.103 g, 0.296 mmol) and the reaction mixture was sparged with Ar. tetrakis(triphenylphosphine)palladium(0) (0.0228 g, 0.0197 mmol) was added and the reaction mixture was sparged with Ar. The reaction was sealed, heated to 100°C and stirred for 2 hrs. The mixture was cooled to ambient temperature and purified by flash chromatography (1 -5% MeOH in DCM) to yield the title compound (0.0256 g, 0.0469 mmol, 33.1% yield) as a yellow powder. MS (apci) m/z = 633.2 [(M+H)+4], 63 1.2 [(M+H)+2], 629.2 (M+H) with di CI pattern.

[00888] Step 2: 2,2,2-Trifluoroacetic acid (1.0 ml, 0.10 mmol) was added to a solution of tert-butyl 3-(4-(5-amino-6-(l -(2,6-dichloro-3,5-dimethoxyphenyl)-5-methyl-6-oxo-l,6- dihydropyridazin-3-yl)pyrazin-2-yl)-lH-pyrazol-l-yl)azetidin e-l -carboxylate (0.065 g, 0.10 mmol) in dichloromethane (1.0 mL, 0.10 mmol) at ambient temperature for 3.5 hrs. The mixture was partitioned between DCM and aqueous saturated Na ₂ C0 ₃ . The combined organic extracts were washed with brine and concentrated to provide the title compound (0.045 g, 0.085 mmol, 82% yield) as a yellow solid. MS (apci) m/z = 533.1 [(M+H)+4], 531.1 [(M+H)+2], 529.2 (M+H) with di CI pattern. [00889] Example 78

[00890]

[00891] 6-(3 -amino-6-Π -Π -(2-methoxyethvOazetidin-3 -vO- 1 H-pyrazol-4- v0pyrazin-2- yl)-2-(2,6-dichloro-3,5-dimethoxyphenyl)-4-methylpyridazin-3 (2H)-one

[00892] l-Bromo-2-methoxy ethane (0.002915 mL, 0.03138 mmol) was added to a vial containing 6-(3-amino-6-(l-(azetidin-3-yl)-lH-pyrazol-4-yl)pyrazin-2-yl )-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-methylpyridazin-3(2H)-one (Example 77; 0.0151 g, 0.02852 mmol) and potassium carbonate (0.005913 g, 0.04279 mmol) in DMF (0.5705 mL, 0.02852 mmol) at ambient temperature. The mixture was stirred in sealed vial for 48 hrs. The mixture was partitioned between DCM and water. The combined organic extracts were washed with water and brine, dried over Na ₂ S04, and concentrated in vacuo. The residue was purified by reverse phase chromatography (5-95 % ACN:water with 0.1% TFA) to yield the title compound (0.0051 g, 0.008681 mmol, 30.44% yield) as a yellow solid. MS (apci) m/z = 591.1 [(M+H)+4], 589.1 [(M+H)+2], 587.1 (M+H) with di CI pattern.

[00893] Example 79

[00894]

[00895] 6-(3-amino-6-(l-(l-(2-ethoxyethvnazetidin-3-vn-lH-pyrazol-4- vnpyrazin-2-vn- 2-(2,6-dichloro-3,5-dimethoxyphenyl)-4-methylpyridazin-3(2H) -one

[00896] l-Bromo-2-ethoxy ethane (0.003632 mL, 0.03221 mmol) was added to a vial containing 6-(3-amino-6-(l-(azetidin-3-yl)-lH-pyrazol-4-yl)pyrazin-2-yl )-2-(2,6-dichloro-3,5- dimethoxyphenyl)-4-methylpyridazin-3(2H)-one (Example 77; 0.0155 g, 0.02928 mmol) and potassium carbonate (0.006070 g, 0.04392 mmol) in DMF (0.9760 mL, 0.02928 mmol) at ambient temperature. The reaction stirred in a sealed vial for 15 hrs. The mixture was partitioned between DCM and water. The combined organics were washed with water and brine, dried over Na ₂ S04, and concentrated in vacuo. The mixture was purified by reverse phase chromatography (5-95 % ACN:water with 0.1% TFA) to yield the title compound (0.0042 g, 0.006983 mmol, 23.85 % yield) as a yellow solid. MS (apci) m/z = 605.2 [(M+H)+4], 603.2 [(M+H)+2], 601.2 (M+H) with di CI pattern.

[00897] Example 80

[00898]

[00899] 3-(3-(3-amino-6-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyr azol-4-yl)pyrazin- 2-yl)-5-methyl-6-oxopyridazin-l(6H)-yl)-N,4-dimethylbenzamid e

[00900] To a solution of the 3-(3-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-

2-yl)-5-methyl-6-oxopyridazin-l(6H)-yl)-N,4-dimethylbenza mide dihydrochloride (50 mg, 0.087 mmol) in N,N-dimethylformamide (1747 μΐ _^ , 0.087 mmol) at 0°C under a nitrogen atmosphere was sequentially added K ₂ C0 ₃ (49 mg, 0.35 mmol) and l-bromo-2-methoxyethane (10 μΐ., 0.11 mmol). The mixture was stirred at RT overnight. The resulting mixture was diluted with 5% IPA/DCM (50 mL) and washed with water (10 mL). The organic layer was separated, dried (MgS0 ₄ ), filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (Redi Sep 24 g) eluting with 2-20% MeOH/DCM with 2% H ₄ OH to provide 3-(3- (3-amino-6-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazol- 4-yl)pyrazin-2-yl)-5-methyl-6- oxopyridazin-l(6H)-yl)-N,4-dimethylbenzamide (25 mg, 51 % yield) as a solid. LCMS (APCI+) m/z 558.2 (M+l), Retention time = 1.751 min.

00901] Exam le 81

[00903] 6-(2-amino-5-(l-(piperidin-4-vn-lH-pyrazol-4-vnpyridin-3-ylV 2-(3.5- dimethoxyphenyl)-4-methylpyridazin-3(2H)-one dihydrochloride

[00904] Step 1 : A glass pressure tube was charged with Intermediate R18 [crude 2-(3,5- dimethoxyphenyl)-4-methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxa borolan-2-yl)pyridazin-3(2H)- one] (660 mg, 1.77 mmol), Intermediate L21 [tert-butyl 4-(4-(6-amino-5-bromopyridin-3-yl)-lH- pyrazol-l-yl)piperidine-l-carboxylate] (749 mg, 1.77 mmol), Pd(Ph ₃ P) ₄ (205 mg, 0.177 mmol), sodium carbonate 2M in water (2660 μΐ _^ , 5.32 mmol) and 1,4-dioxane (3546 μΐ _^ , 1.77 mmol). The mixture was purged with N ₂ for 6 minutes. The tube was sealed with a Teflon screw cap and heated at 90 °C with vigorous stirring for 16 hours. The mixture was cooled to RT, diluted with DCM (100 mL) and washed with water. The organic phase was separated, dried (MgS0 ₄ ), filtered and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (Redi Sep 40 g) eluting with 1-55% acetone/hexanes (20 CV) to provide tert-butyl 4-(4-(6-amino-5-(l- (3,5-dimethoxyphenyl)-5-methyl-6-oxo-l,6-dihydropyridazin-3- yl)pyridin-3-yl)-lH-pyrazol-l- yl)piperidine-l-carboxylate (780 mg, 75 % yield) as a solid. LCMS (APC1+) m/z 588.2 (M+l), retention time = 2.528 min.

[00905] Step 2: Neat TFA (3 mL) was added to the tert-butyl 4-(4-(6-amino-5-(l-(3,5- dimethoxyphenyl)-5-methyl-6-oxo-l,6-dihydropyridazin-3-yl)py ridin-3-yl)-lH-pyrazol-l- yl)piperidine-l-carboxylate (600 mg, 1.02 mmol). The mixture was stirred at RT for 1 hour. The TFA was removed in vacuo and the residue was treated with 4N HC1 in dioxane (5 mL). The mixture was stirred at RT for 15 minutes and the solvent was removed in vacuo. The residue was evaporated from CH ₃ CN and dried under high vacuum to provide 6-(2-amino-5-(l-(piperidin-4- yl)-lH-pyrazol-4-yl)pyridin-3-yl)-2-(3,5-dimethoxyphenyl)-4- methylpyridazin-3(2H)-one dihydrochloride (425 mg, 74.3 % yield) as a solid. LCMS (APCI+) m/z 488.2 (M+l); Retention time = 2.261 min.

[00906] Example 82

[00907]

[00908] 6-(3-amino-6-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazo l-4-yl)pyrazin-2- yl)-2-(2,6-difluoro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one

[00909] Step 1 : A mixture of Intermediate L19 (228 mg, 0.538 mmol), Intermediate R29

(212 mg, 0.538 mmol), K ₂ C0 ₃ (2M, 807 μί, 1.61 mmol) and Pd(Ph ₃ P) ₄ (31.1 mg, 0.027 mmol) in dioxane (2.7 mL, 0.54 mmol) was sparged with nitrogen and heated at 80°C for 3 h. The reaction mixture was partitioned between ethyl acetate and water. The aqueous layer was extracted with EtOAc. The combined organic layers were dried and concentrated. The residue was purified by flash chromatography eluting with a hexanes/EtOAc gradient (0-100%) to provide tert-butyl 4-(4- (5 -amino-6-( 1 -(2, 6-difluoro-3 , 5 -dimethoxyphenyl)-6-oxo- 1 , 6-dihydropyri dazin-3 -yl)pyrazin-2- yl)-lH-pyrazol-l-yl)piperidine-l-carboxylate. LCMS (APCI+) m/z 611.2 (M+1); Retention time = 3.35 min.

[00910] Step 2: tert-butyl 4-(4-(5-amino-6-(l-(2,6-difluoro-3,5-dimethoxyphenyl)-6-oxo- l,6-dihydropyridazin-3-yl)pyrazin-2-yl)-lH-pyrazol-l-yl)pipe ridine-l-carboxylate was stirred in a solution of 1 : 1 DCM/TFA (10 mL) for 1 h. The mixture was concentrated at 50 °C. The residue was diluted with MeOH (5 mL) and 6N HCl/iPrOH (5 mL) was added. The mixture was concentrated to provide 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4-yl)pyrazin-2-y l)-2-(2,6- difluoro-3,5-dimethoxyphenyl)pyridazin-3(2H)-one hydrochloride salt as a white solid. LCMS (APCI+) m/z 511.2 (M+1); Retention time = 2.35 min.

[00911] Step 3 : To a suspension of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4- yl)pyrazin-2-yl)-2-(2,6-difluoro-3,5-dimethoxyphenyl)pyridaz in-3(2H)-one hydrochloride salt (31.8 mg, 0.062 mmol) and K2CO3 (43.0 mg, 0.312 mmol) in DMF (1246 μί, 0.062 mmol) was added 2-bromoethyl methyl ether (7.01 μL, 0.075 mmol) and the resulting mixture was stirred at RT for 1 d. The crude reaction mixture was loaded onto a silica column equilibrated with hexanes and eluted with hexanes > DCM > 20% MeOH/DCM to provide the title compound (18 mg, 0.031 mmol, 50.8%). LCMS (APCI+) m/z= 569.2; retention time 2.40 min.

00912] Exam le 83

[00914] 6-(3-amino-6-(l-(l-(2-methoxyethyl)piperidin-4-yl)-lH-pyrazo l-4-yl)pyrazin-2- yl)-2-(2-chloro-6-fluoro-3-methoxyphenyl)pyridazin-3(2H)-one

[00915] Step 1 : A mixture of Intermediate L19 (262 mg, 0.620 mmol), Intermediate R28

(236 mg, 0.620 mmol), K2CO3 (2 M, 930 μί, 1.86 mmol) and Pd(Ph ₃ P) ₄ (35.8 mg, 0.031 mmol) in dioxane (3.1 mL, 0.62 mmol) was sparged with nitrogen and heated at 80°C for 3 h. The reaction was partitioned between ethyl acetate and water. The combined organic layers were dried over Na ₂ S0 ₄ , filtered and concentrated. The residue was purified by flash chromatography eluting with a hexane/Ethyl acetate gradient of 0-100% to provide tert-butyl 4-(4-(5-amino-6-(l-(2-chloro-6- fluoro-3 -methoxyphenyl)-6-oxo- 1 , 6-dihydropyridazin-3 -yl)pyrazin-2-yl)- 1 H-pyrazol- 1 - yl)piperidine-l-carboxylate. LCMS (APCI+) m/z= 597.2 (100%), 599.2(40%); retention time 3.38 min.

[00916] Step 2: tert-butyl 4-(4-(5-amino-6-(l-(2-chloro-6-fluoro-3-methoxyphenyl)-6-oxo -

1 ,6-dihydropyridazin-3 -yl)pyrazin-2-yl)- lH-pyrazol- 1 -yl)piperidine- 1 -carboxylatewas treated with 1 : 1 DCM/TFA (20 mL) for 1 h. The solution was concentrated and 5 mL of 6N HCl/iPrOH and 5 mL of MeOH was added. The mixture was stirred for 1 h to form a white slurry and the suspension was concentrated. LCMS (APCI+) m/z= 497.0 (100%), 499.0 (40%); retention time 2.33 min.

[00917] Step 3 : To a suspension of 6-(3-amino-6-(l-(piperidin-4-yl)-lH-pyrazol-4- yl)pyrazin-2-yl)-2-(2-chloro-6-fluoro-3-methoxyphenyl)pyrida zin-3(2H)-one (25.3 mg, 0.051 mmol) and K2CO3 (35.2 mg, 0.255 mmol) in DMF (1.0 ml, 0.051 mmol) was added 2-bromoethyl methyl ether (5.74 μΐ, 0.06 mmol) and the resulting mixture was stirred at RT for Id. The crude reaction mixture was loaded onto a silica column equilibrated with hexanes and eluted with hexanes > DCM > 20% MeOH/DCM to provide the title compound (12 mg, 0.021 mmol, 42%). LCMS (APCI+) m/z= 555.2; retention time 2.388.

[00918] Biological Activity

Example A

Enzyme Assay

[00919] FGFR1, 2 and 3 kinase activity was measured by the Invitrogen LanthaScreen™

Assay technology which directly measures the amount of substrate phosphorylation by TR-FRET using a fluorescein-labeled peptide and Europium -labeled antibody.

[00920] To measure FGFR1 kinase activity, 200 pM His-tagged recombinant human

FGFR1 catalytic domain (amino acids 308-731) (Life Technologies Cat. No. PR4660A) was incubated with 100 nM Alexa Fluor® 647-Poly-GT Peptide Substrate (Life Technologies Cat. No. PV5836) and ATP in the presence of Mg ⁺⁺ , along with test compound in a buffer consisting of 250 mM HEPES, 25 mM MgCb, 0.05% TritonX-100, pH 7.5, and 2% DMSO. Compounds were typically prepared in a threefold serial dilution in DMSO and added to the assay to give the appropriate final concentration. After 20 minutes incubation at 22 °C, an equal volume of 2 nM LanthaScreen® Eu-PY20 Antibody (Life Technologies Cat. No. PV5691) and EDTA were added to quench the kinase reaction and start the detection reaction. After an additional 60 minute incubation at 22 °C, the reaction was measured using a PerkinElmer En Vision multimode plate reader via TR-FRET dual wavelength detection, and the percent of control (POC) calculated using a ratiometric emission factor. 100 POC is determined using no test compound and 0 POC is determined using no enzyme. The POC values were fit to a 4 parameter logistic curve and the IC50 value is point where the curve crosses 50 POC.

[00921] To measure FGFR2 kinase activity: 200 pM His-tagged recombinant human

FGFR2 cytoplasmic domain (amino acids 403-822), (Life Technologies Cat. No. PR5332A); 20 minutes incubation at 22 °C, 60 minute detection incubation at 22 °C.

[00922] To measure FGFR3 kinase activity: 750 pM N-terminal GST-HIS6 fusion protein with a 3C cleavage site recombinant human FGFR3 (amino acids R397-T806) (ProQinase Cat. No. 1068-0000-1); 10 minutes incubation at 22°C, 60 minute detection incubation at 22 °C.

[00923] The averaged IC50 values for the compounds tested in this assay are provided in Table F.

[00924] Table F. ICso's of compounds tested in the assay of Example A

Ex. # FGFRl Enz FRET FGFR2 Enz FRET FGFR3 Enz FRET IC50 (nM) IC50 (nM) IC50 (nM) [AVERAGE] [AVERAGE] [AVERAGE]

15 17.4 3.7 7.0

16 22.8 5.6 10.6

17 79.2 10.2 3.8

18 47.7 8.5 8.7

19 15.1 2.8 2.2

20 399.9 39.8 61.5

21 39.1 7.5 4.9

22 192.5 21.1 6.7

23 3.8 5.5 2.8

24 15.0 1.8 4.0

25 51.1 6.6 11.8

26 8.6 2.2 4.3

27 19.0 1.9 8.2

28 17.0 2.3 4.7

29 22.0 3.7 7.1

30 14.1 2.9 6.5

31 7.7 1.4 3.9

32 9.2 1.3 1.8

33 11.6 1.8 4.5

34 38.4 3.7 13.4

35 15.4 3.2 4.8

36 62.8 6.2 21.3

37 56.0 19.2 23.5

38 91.5 16.8 21.1

39 141.8 9.4 28.6

40 49.7 2.9 10.2

41 3.0 0.8 3.2

42 6.3 1.4 8.6 Ex. # FGFRl Enz FRET FGFR2 Enz FRET FGFR3 Enz FRET IC50 (nM) IC50 (nM) IC50 (nM) [AVERAGE] [AVERAGE] [AVERAGE]

43 7.0 1.6 1.7

44 7.1 1.4 6.2

45 1561.6 825.7 1086.6

46 3101.2 1231.5 3604.1

47 5.6 1.6 1.5

48 3.1 1.0 1.4

49 6.0 1.3 2.1

50 3.5 0.9 1.8

51 4.0 0.6 1.0

52 26.8 5.0 42.5

53 193.4 72.3 35.6

54 29.6 10.9 10.1

55 31.4 6.3 19.9

56 43.3 7.5 5.7

57 13.8 5.8 6.2

58 4.4 2.4 0.7

59 5.0 6.6 10.6

60 11.6 1.5 10.3

61 98.2 24.1 13.7

62 231.3 31.2 166.2

63 14.0 16.0 53.5

64 61.4 42.1 213.7

65 8.9 2.9 35.0

66 5.6 7.8 3.9

67 9.1 6.5 13.3

68 9.8 11.1 6.4

69 7.2 9.6 9.6

70 30.9 54.4 30.8 Ex. # FGFR1 Enz FRET FGFR2 Enz FRET FGFR3 Enz FRET

IC50 (nM) IC50 (nM) IC50 (nM)

[AVERAGE] [AVERAGE] [AVERAGE]

71 26.5 38.8 45.1

72 7.3 9.3 5.2

73 7.2 10.6 6.0

74 5.8 9.5 6.1

75 8.0 11.3 10.2

76 10.6 3.85 7.1

77 16.1 6.2 12.4

78 9.8 3.7 6.9

79 17.3 6.3 10.7

80 57.0 16.3 50.6

81 3.6 1.1 11.4

82 2.4 3.1 2.2

83 6.9 16.6 26.5

N/A = Not available

EQUIVALENTS

[00925] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

INCORPORATION BY REFERENCE

[00926] The entire contents of all patents, published patent applications, websites, and other references cited herein are hereby expressly incorporated herein in their entireties by reference.